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Chlamydia psittaci is the causative agent of ovine enzootic abortion (OEA), the single
most common cause of diagnosed infectious ovine abortion in the United Kingdom.
The immune effector mechanisms responsible for microbistatic and microbicidal
control of C. psittaci in ovine cells were investigated with a long term view to
improving the diagnosis and prophylactic control of OEA.
Characterisation of the immunological and pharmacological control of Chlamydia
spp is dependent of the accurate measurement of chlamydial growth in xritro.
Traditionally this has required manual enumeration of the replicating masses of
Chlamydiae or inclusion bodies that form within infected cells, which is both time
consuming and subjective. A novel technique for counting and measuring chlamydial
inclusions was developed using image analysis. A software solution, Inclusion
Counter, was developed using the public domain image analysis packages NIH
Image and Object Image. Results generated by Inclusion Counter were not only
accurate with respect to counting chlamydial inclusions but also provided
additional information about chlamydial growth that were previously unavailable or
impractical to measure.
Diagnosis and control ofOEA is complicated by the ability of C. psittaci to establish
a chronic low level or persistent infection in ewes infected out-with pregnancy.
Persistent C. psittaci infection was reproduced in vitro by maintaining infected ovine
fibroblastic ST.6 cells in the presence of recombinant ovine interferon gamma
(ROvIFN-y) at physiologically relevant concentrations for up to 63 days after
infection. ROvIFN-y restricted C. psittaci growth in a dose dependent manner;
concentrations of 25-100 units of biological activity per millilitre (U/ml) induced
and maintained persistence whereas concentrations of 250 U /ml or more eradicated
C. psittaci from infected cultures. Attempts to identify and characterise the source of
IFN-y in immune sheep using T-cell lines raised against recombinant C. psittaci
proteins were unsuccessful.
The mechanisms of ROvIFN-y mediated restriction of C. psittaci were investigated.
Pretreatment of ST.6 cells with recombinant interferon alpha or double stranded
RNA at concentrations matched with ROvIFN-y for anti-viral activity did not
restrict C. psittaci growth in ST.6 cells, indicating that the mechanism through which
ROvIFN-y restricts C. psittaci in ovine cells is independent from its anti-viral
activities. Nitric oxide was not detected in the supernates of infected ST.6 cells
pretreated with ROvIFN-y and addition of L-NMMA, a potent inhibitor of inducible
nitric oxide synthase, did not alter the anti-C. psittaci effects of ROvIFN-y in this cell
line. Furthermore, nitric oxide production could not be demonstrated in primary
ovine alveolar macrophages treated with combinations of ROvIFN-y, LPS, heat
XV
inactivated C. psittaci and/or live C. psittaci. Addition of exogenous L-tryptophan
partially reversed the anti-chlamydial effects of ROvIFN-y in ST.6 cells that had
been infected with C. psittaci over a 7 day period and also resulted in the recovery of
infectious Chlamydiae from persistently infected ST.6 cells maintained in 50 U/ml of
ROvIFN-y. These findings support a role for up-regulation of tryptophan catabolism







Chlamydia psittaciis a major cause of infectious ovine abortion. However, what
makes this pathogen interesting is its ability to survive for prolonged periods in
ewes infected outwith pregnancy without causing pathology or inducing protective
immunity. Thus, the interaction between the ovine immune system and C. psittaci
appears to strike a fine balance between restriction of pathology in the non-pregnant
ewe and maintenance of a chronic low level or persistent infection. When
persistently infected ewes become pregnant this balance is altered allowing C.
psittaci to invade the placenta and cause fetopathology.
Figure 1.1: C. psittaciinclusion bodies (arrow) in ovine ST.6 cells
Typical appearance of the inclusion bodies of the S26/3 ovine abortion strain of C.
psittaci after 48 hours growth in ovine ST.6 cells. Inclusion bodies are stained with




1.2.1. Developmental cycle of Chlamydia
Members of the genus Chlamydia are obligate intracellular gram-negative bacteria.
Chlamydiae are restricted in metabolic capacity and are thus dependent on a
eukaryotic host cell for the provision of a wide variety of metabolic intermediates
[Moulder, 1991], The developmental cycle of Chlamydia is unique and involves two
morphologically and functionally distinct stages (Figure 1.2), an infectious
metabolically inactive extracellular form, the elementary body (EB), and a non¬
infectious but metabolically active intracellular reticulate body (RB).
EB are non motile and rely on Brownian motion to instigate contact with potential
host cells [Moulder, 1991], Numerous mechanisms of attachment and uptake of
chlamydial EB have been proposed, including receptor-mediated endocytosis in
clathrin-coated pits, macropinocytosis in non coated pits, and parasite-specified
phagocytosis [Wyrick, 1998]. Following uptake, EB evade phagolysosomal fusion
and over the following 6-10 hours reorganise into RB which multiply by binary
fission within a membrane-bound vesicle that, at least in the case of C. trachomatis,
appears to share several characteristics with the recycling endosomes of the host cell
[Van Ooij et al, 1997]. RB start the process of differentiation back into infectious EB
at approximately 16-20 hrs after invasion. RB multiplication and differentiation
continues for a further 24-48 hours, by which point inclusion bodies (vesicles of
replicating chlamydiae) can be resolved in the host cell by light microscopy (Figure
1.1) [McClarty, 1994]. Infectious EB may be released into the extracellular milieu by
lysis of the host cell, fusion of the inclusion membrane with the cytoplasmic
membrane of the host cell or possibly through the breakdown of the inclusion
membrane and release of EB into the cytoplasm [Wyrick, 1998].
3
Figure 1.2: Developmental cycle of Chlamydia
16-20 hours: RB begin process
of differentiation into EB
The developmental cycle of Chlamydia begins with the attachment and absorption of
one or more chlamydial elementary bodies (EB) by a suitable host cell. EB
subsequently reorganise into reticulate bodies (RB) which multiply by binary fission.
RB differentiate into EB which are released into the extracellular milieu to complete the
cycle.
1.3.2.Taxonomy
There are currently four recognised species within the genus Chlamydia: C.
trachomatis, C. psittaci, C. pneumoniae, and C. pecorum. Historically, the genus was
originally divided into C. psittaci and C. trachomatis on the basis of inclusion body
morphology, glycogen content and sulphadiazine resistance [Page, 1968]. The
TWAR strain of C. psittaci was reclassified as C. pneumoniae in 1989 by Grayston et
al (1989), on the basis of DNA-DNA homology, EB ultrastructure and serology. The
fourth species, C. pecorum, was proposed in 1992 by Fukushi and Hirai (1992)
based on DNA-DNA homology analysis. The current taxonomic classification, host
specificity, range of diseases and morphological characteristics of the genus
Chlamydia are summarised in Table 1.1 (adapted from Fukushi and Hirai (1992),
Grayston et al (1989), Kaltenboeck et al (1993), Page (1968), Pudjiatmoko et al

























































































































































Of the four species of Chlamydia currently recognised, C. psittaci remains the most
heterogeneous in terms of host specificity, disease (Table 1.1) and intra-species
DNA-DNA homology (Table 1.2), although there are also significant differences
between the human, murine and swine biotypes of C. trachomatis [Kaltenboeck et al,
1993; Pudjiatmoko et al, 1997], Further reclassification of those strains of Chlamydia
currently classified as C. psittaci and C. trachomatis is supported by phylogenetic
analysis of the major outer membrane protein gene (ompl) [Kaltenboeck et al, 1993]
and the 16S ribosomal deoxyribonucleic acid (rDNA) [Pudjiatmoko et al, 1997].
Pudjiatmoko et al (1997) identified eight genetic groups of Chlamydia that might
form the basis for reclassification of the genus: (1) avian and ovine abortion strains
of C. psittaci; (2) the guinea pig inclusion conjunctivitis strain of C. psittaci (GPIC);
(3) feline strains of C. psittaci; (4) C. pecorum; (5) C. pneumoniae; (6) human
trachoma,urogenital and LGV strains of C. trachomatis; (7) swine strains of C.
trachomatis; and (8) the mouse pneumonitis strain of C. trachomatis (MoPn).
Table 1.2: DNA-DNA homology within the genus Chlamydia
Percentage homology with:
Species C. trachomatis C. psittaci C. pneumoniae C. pecorum
C. trachomatis 20-92 t 1-33 1-7 1-10
C. psittaci 1 4-95 1-8 1-19
C. pneumoniae 94-96 10
C. pecorum 88-1 00
This table was adapted from Fukushi and Hirai (1992) and is based on a DNA-DNA liquid
hybridisation assay adapted for chlamydiae [Cox et at 1988], t LGV and trachoma strains of
C. trachomatis show up to 92% homology with each other, a value of 20% homology was
obtained between the mouse pneumonitis strain of C. trachomatis and the LGV/trachoma
strains.
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1.3. Ovine Enzootic Abortion
Ovine Enzootic Abortion (OEA) occurs in most sheep-rearing countries [Buxton,
1994] and is a major problem in the sheep industry. OEA is the single most common
cause of diagnosed infectious ovine abortion in the United Kingdom (Figure 1.3)
[Veterinary Laboratories Agency, 1997]. Estimates place the economic burden of
this disease at £10 million - £20 million per annum for the British sheep industry
alone [Aitken et al, 1990 ].
Figure 1.3: Relative incidence of diagnosed ovine abortion in the United Kingdom






[Veterinary Laboratories Agency, 1997]
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1.3.1. Transmission of OEA
OEA was first described by Greig (1936) who named it enzootic abortion of ewes
and suggested, but did not present evidence, that it was due to a dietary deficiency.
Stamp et al (1950) later demonstrated that crude suspensions of material prepared
from aborted and premature lambs from suspected cases of enzootic abortion could
induce abortion when inoculated into naive ewes during pregnancy. In addition,
suspensions which had been passed through a 0.4 jum filter did not induce abortion,
supporting the involvement of an infectious agent rather than a soluble factor.
Whilst attempts to culture extracellular bacteria from infected ewes and aborted
lambs were unsuccessful, micro-organisms were observed within cells in the
chorionic villi of infected placentas and in large numbers in smears made from
infected placentas. The intracellular location, morphology and staining
characteristics of the organism led Stamp et al (1950) to speculate that it was
related to Rickettsia or to the psittacosis-lymphogranuloma group of infectious
agents, later classified as genus Chlamydia.
The discovery that OEA was caused by an infectious agent made understanding the
natural mode of transmission of OEA a priority. Transmission of OEA by sheep
ticks was discounted by Stamp et al (1950) because the epidemiology of the disease
was not consistent with tick distribution. In contrast, Ornithodoros coriaceus ticks
have been shown to transmit strains of C. psittaci which cause abortion in cattle
[Kimsey et al, 1983; McKercher et al, 1980], However, there is still no evidence in the
literature to suggest that ticks can transmit OEA strains of C. psittaci. The close
phylogenetic relationship of avian and OEA strains of C. psittaci is interesting
[Kaltenboeck et al, 1993; Pudjiatmoko et al, 1997] since it suggests that birds may
represent a possible reservoir for OEA. However, whilst it is possible that OEA
strains of C. psittaci are originally derived from avian strains it seems unlikely that
the most closely related avian strains, those isolated from parakeets [Takahashi et
al, 1997], could represent a reservoir ofOEA given the distribution of the disease.
The anatomical site of entry for C. psittaci in the ewe is likely to be a mucosal
surface. Experimental oral inoculation of pregnant ewes with OEA strains of C.
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psittaci has been shown to result in pathology similar to that seen in naturally
occurring OEA [Dawson et al, 1986; McEwen et al, 1951a; Wilsmore et al, 1984] and
tonsillar tissue has been identified as the most likely route of infection for C. psittaci
when delivered in this manner [Jones and Anderson, 1988]. Whilst it remains
unclear as to how C. psittaci disseminates to the reproductive tract in the ewe,
macrophages have been shown to play a role in the dissemination of C. pneumoniae
in mice [Moazed et al, 1998] and may play a similar role in OEA.
Early attempts to demonstrate sexual transmission of OEA did not induce
fetopathology [Appleyard et al, 1985; Wilsmore et al, 1984]. However, in a more
recent study, intravaginal inoculation of non-pregnant ewes with C. psittaci was
shown to result in abortion during the next pregnancy [Papp and Shewen, 1996a],
suggesting that venereal transmission is possible. In this case, infection could be
established directly in the urogenital tract. However, ingestion or inhalation of
contaminated material around the time of lambing remains the most likely mode of
transmission for OEA strains of C. psittaci, especially under intensive lambing
conditions [Aitken et al, 1990],
1.3.2. Pathology of OEA in non-pregnant sheep
There is little evidence to suggest that OEA strains of C. psittaci cause pathology in
ewes prior to pregnancy, although experimental infection of non-pregnant ewes is
associated with a brief febrile response at the time of infection [Amin and Wilsmore,
1995; Huang et al, 1990], Chronic infection of the vagina, uterus, and oviducts
[Papp and Shewen, 1996b], in conjunction with shedding of infectious chlamydiae
during estrus [Papp et al, 1994], has been described in ewes after pregnancy failure
due to experimental infection with an OEA strain of C. psittaci. These findings have
led to speculation that C. psittaci may cause chronic pathology in the reproductive
tract of post-OEA ewes, similar to that observed in women infected with C.
trachomatis [Papp and Shewen, 1997]. However, there is little evidence that post-
OEA ewes are in any way compromised in their ability to conceive or carry lambs to
full-term [Rodolakis et al, 1998].
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Despite the apparent absence of pathology in the non-pregnant ewe, the ability of C.
psittaci to infect ewes outwith pregnancy is critical for its survival and
dissemination. Latent or persistent subclinical infection of non-pregnant ewes with
the agent responsible for OEA was first reported in 1951 [McEwen et al, 1951b]. In
that study, significant numbers of ewes born in infected flocks and moved to clean
pasture two months prior to conception showed clinical symptoms of OEA in their
first pregnancy (7% aborted and a further 27% shed infectious material at the time
of lambing). Wilsmore et al (1984) later confirmed that ewes infected during the
perinatal period often go on to experience clinical disease during their first
pregnancy after infection.
Because C. psittaci has been difficult to isolate from naive ewes infected outwith
pregnancy, the phenotype and location of the host cell of persistent C. psittaci
infection has not been identified in vivo. C. psittaci antigen and DNA have been
detected in the draining lymph nodes of non-pregnant ewes for up to 18 days after
subcutaneous challenge with live C. psittaci [Buxton et al, 1996; Huang et al, 1990].
However, live chlamydiae were not recovered in either of these studies and the
presence of DNA and chlamydial antigens in draining lymphoid tissue shortly after
infection is not clearly demonstrative of a persistent infection. Similar studies
detected the presence of C. psittaci antigens in epithelial cells and lymphocytes in a
variety of tissues following nasopharyngeal or subcutaneous inoculation of naive
non-pregnant ewes with an OEA strain of C. psittaci, but as in the case described
above, the presence of live chlamydiae was not demonstrated [Amin and Wilsmore,
1995], Cells containing C. psittaci have been detected in vaginal and cervical samples
from chronically infected post-OEA ewes [Papp et al, 1998]. However, it remains to
be confirmed if the same is true for ewes persistently infected with C. psittaci prior
to abortion.
The ability of C. psittaci to enter a latent or persistent state in ewes infected prior to
pregnancy not only allows the pathogen to survive from one breeding season to the
next, but also severely complicates the diagnosis and management of OEA. This is
particularly problematic for farmers who wish to replace stock with ewes or lambs
purchased at market and it is not uncommon for flocks which were previously free
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from OEA to experience extremely high rates of abortion following the introduction
of infected replacement animals [Aitken et al, 1990].
1.3.3. Pathology of OEA in pregnant sheep
The timing of the events leading to fetopathology in OEA are remarkably consistent.
Regardless of when ewes are infected during pregnancy, C. psittaci is not found in
the placenta or fetus until day 60 of gestation [Buxton et al, 1990], This coincides
with the normal physiological invasion of the maternal caruncular stroma by
chorionic villi of the placenta and haemorrhage of maternal blood vessels. The
haematomas that result from this process may represent one less barrier for C.
psittaci to cross in order to infect the placenta. Despite the presence of C. psittaci in
the placenta from day 60 of gestation onward, pathological changes do not occur
until the later stages of pregnancy (around day 90 of gestation), resulting in
fetopathology and abortion at or just before the time of normal parturition (between
days 120-140 of gestation) [Buxton et al, 1990]. This pattern of pathology results in
the delivery of infectious material into the local environment at a time when there
are naive animals present that are susceptible to infection.
1.3.4. Zoonotic infection
In addition to its economic burden, OEA is also of potential zoonotic importance.
Infection in non-pregnant individuals is generally asymptomatic or results in mild
upper respiratory tract symptoms which may not always be diagnosed as C.
psittaci. However, a more severe influenza-like disease was reported in a group of
laboratory workers who were accidentally infected with the S26/3 strain of C.
psittaci while producing a vaccine for OEA [Baker and Cooper, 1983]. In contrast to
non-pregnant individuals, infection in pregnant women can be life threatening and
commonly involves abortion with severe systemic complications including, renal
dysfunction, hepatic dysfunction and disseminated intravascular coagulation
[Aitken, 1991; Hadley et al, 1992; Hyde and Benirschke, 1997; Jorgensen, 1997],
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Fortunately, zoonotic infection of pregnant women is rare [Sanghi et al, 1997] and
there is no evidence to support human to human transmission of the OEA strain of
C. psittaci [Hadley et al, 1992],
1.3.5. Diagnosis of OEA
Diagnosis of OEA is largely limited to retrospective identification of OEA as a
cause of abortion, rather than identifying persistently infected ewes which are at
risk of abortion. This is largely due to the absence of clinical disease, the poor
immune response induced by C. psittaci in ewes infected prior to pregnancy and
difficulties associated with detection of C. psittaci in the non-pregnant ewe. As a
result, diagnosis can only be used to determine whether OEA is present within a
given flock and to identify those ewes which are already immune to OEA but may
still shed infectious chlamydiae [Papp et al, 1994],
There are numerous options available for the diagnosis of OEA. Traditionally, vital
dyes such as modified Ziehl Nielsen's carbo fuchsin or Giemsa [Stamp et al, 1950]
have been used to identify chlamydial EB and inclusion bodies in smears or tissue
sections prepared from aborted material. However, vital dyes are nonspecific and
interpretation of the results requires an experienced pathologist. Genus- or
species-specific monoclonal antibodies, in conjunction with immuno-fluorescence or
immunohistochemistry, significantly increase the certainty with which OEA can be
diagnosed [Amin and Wilsmore, 1994], Advances in molecular biology have led to
routine use of the polymerase chain reaction (PCR) and ligase chain reaction (LCR)
to diagnose C. trachomatis infections in humans [Taylor-Robinson, 1997] and these
technologies may equally well be applied to the diagnosis of OEA [Hewinson et al,
1991; Rodolakis et al, 1998].
Serological diagnosis is complicated by the existence of non-pathogenic enteric
forms of C. pecorum which do not cause abortion but share antigenic markers with
OEA strains of C. psittaci. Attempts to develop more specific enzyme linked
immunosorbent assays (ELISA) [Anderson et al, 1995; Donn et al, 1997; Griffiths et
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al, 1996; Jones et al, 1997; Sting and Hafez, 1992] or indirect immuno-fluorescence
test (IFAT) [Markey et al, 1993] to distinguish between antibody raised against C.
psittaci and non-pathogenic C. pecorum strains have met with varying degrees of
success. More recently, a competitive ELISA based on monoclonal antibodies raised
against peptide sequences of the major outer membrane protein (MOMP) that are
specific to abortion strains of C. psittaci, was shown to be extremely sensitive and
specific and may provide a viable alternative to traditional laborious pathological
examination of aborted material [Salti-Montesanto et al, 1997]. The recent discovery
and characterisation of a family of 90 kilodalton (KDa) proteins from the outer
membrane of C. psittaci should also further improve diagnosis of OEA. These
proteins are recognised by the sera of post-OEA ewes and show little or no genetic
homology with C. pecorum strains [Longbottom et al, 1996; Longbottom et al, 1998a;
Longbottom et al, 1998b],
Despite advances in the diagnosis of OEA as the cause of abortion and the
identification of post-OEA ewes on the basis of serology, an effective approach to
the diagnosis of persistent infection in ewes remains elusive.
1.3.6. Vaccination strategies
Attempts to develop a vaccine for OEA were undertaken shortly after the discovery
that the disease was transmitted by an infectious agent [Stamp et al, 1950]. Initial
experiments demonstrated that formalin-inactivated vaccines, prepared from
aborted placental material or from C. psittaci grown in chicken egg yolk sacs,
protected ewes from subcutaneous challenge with live C. psittaci during pregnancy
and significantly reduced the overall rate of abortion in field studies [McEwen et al,
1951b]. These findings led to the development of a commercially available vaccine
composed of liquid paraffin and Falba-adjuvanted formalin-inactivated C. psittaci
(Strain A.22) [McEwen et al, 1955]. However, the inactivated vaccine did not
prevent shedding of chlamydiae at parturition [Rodolakis and Souriau, 1979] and
further field studies during the late 1970's indicated that the vaccine was either not
as effective as was initially thought or that widespread use of the vaccine had
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resulted in the selection of resistant strains of C. psittaci [Linklater and Dyson,
1979]. A second OEA strain of C. psittaci (S26/ 3) was added in 1981 [Aitken et al,
1981] but did not improve the efficacy of the vaccine, which was eventually
withdrawn in 1992. An experimental vaccine based on semi-purified formalin-
inactivated EB, derived from S26/3 and A.22 strains of C. psittaci grown to high
titres in tissue culture, has been shown to provide some degree of protection against
heterogeneous OEA strains of C. psittaci when delivered in conjunction with a
variety of adjuvants [Jones et al, 1995].
Live attenuated vaccines have a number of advantages over inactivated vaccines.
Live vaccines require a smaller initial dose to induce protection than inactivated
vaccines, thereby reducing production costs. In addition, it has become increasingly
apparent that the local tissue microenvironment and context in which antigen is
presented to T-cells can greatly influence the type of immune response elicited [Del
Prete, 1998]. Antigens derived from an inactivated vaccine, which is essentially
extracellular, are unlikely to be processed and presented in the same way that they
would in a natural chlamydial infection. This is supported by the finding that heat
inactivated chlamydiae induce different levels of pro-inflammatory cytokines
compared with live chlamydiae in human monocytic cells [Bianchi et al, 1997], ovine
alveolar macrophages [Entrican et al, 1999] and human umbilical vein endothelial
cells [Molestina et al, 1998], Furthermore, live vaccines may disseminate and induce
immune responses at more appropriate anatomical sites than inactivated vaccines
which typically result in a localised inflammatory response at the site of inoculation
[Buxton, 1994].
Rodolakis (1983) developed a live attenuated vaccine against OEA by using N-
methyl-N'nitro-N-nitrosoguanidine enhanced mutagenesis to generate temperature
sensitive mutants from a virulent OEA strain of C. psittaci (AB7). One of the
resultant mutants, designated IB, has been shown to induce protective immunity in
mice [Rodolakis, 1983] , ewes [Souriau et al, 1988; Rodolakis and Souriau, 1983]
and goats [Rodolakis and Souriau, 1986] without causing disease in pregnant
animals. The IB vaccine strain has also been shown to protect ewes against
challenge with heterogeneous OEA strains of C. psittaci and to prevent shedding of
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infectious chlamydiae at parturition [Chalmers et al, 1997; Rodolakis and Bernard,
1984], Following confirmation of the genetic stability of the IB vaccine strain
[Rodolakis and Souriau, 1989] and compliance with other safety criteria, it is now
fully licensed and commercially available within the UK, France and Spain
(Enzovax, Intervet, Chlamydia Vetoquinol) [Rodolakis et al, 1998].
A major drawback to vaccines based on inactivated or live attenuated C. psittaci is
that their use largely precludes serological diagnosis of OEA and severely
complicates epidemiological surveillance of the disease. As a result of this, and the
absence of long-term field data on the efficacy of the IB vaccine strain of C. psittaci,
there is still a great deal of interest in the development of a recombinant protein or
peptide vaccine for OEA.
Initial attempts to generate a vaccine based on the C. psittaci MOMP were
stimulated by the observation that an experimental vaccine prepared from the outer
membrane of C. psittaci, consisting predominantly (90%) of MOMP, protected ewes
against challenge with the S26/3 OEA strain of C. psittaci during pregnancy [Tan et
al, 1990]. Two monoclonal antibodies, which react with purified MOMP in its native
trimeric form [De Sa et al, 1995; Herring et al, 1994; McCafferty et al, 1995], have
been shown to reduce fetal and placental infection in mice [Buzoni-Gatel et al,
1990], However, vaccine trials with recombinant MOMP have been unsatisfactory
and the lack of protective immunity induced by recombinant MOMP has been
suggested to be due, at least in part, to its failure to adopt the natural tumeric
conformation of native MOMP [Herring et al, 1994, 1998].
Cevenini et al (1991) identified an 89 KDa protein in outer membrane complexes
derived from the A.22 OEA strain of C. psittaci which was recognised by sera from
post-OEA ewes. A family of four genes has since been identified, cloned and
characterised as encoding a group of proteins of approximately 90 KDa present in
the outer membrane of the S26/3 OEA strain of C. psittaci [Longbottom et al, 1996;
Longbottom, 1998a; Longbottom, 1998b]. This group of outer membrane proteins
(OMP90) appear, on the basis of immunoblotting of chlamydial outer membrane
complexes with sera from post-OEA ewes, to be immunogenic and in addition to
15
their potential value in diagnosis, described previously, may also be suitable vaccine
candidates.
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1.4. Murine models of in vivo chlamydial infection
Although OEA can be studied directly in vivo in the ewe, in vivo studies in inbred
strains ofmice offer a number of advantages over sheep. Experiments using mice are
generally cheaper, more rapid, permit adoptive transfer of cells between MHC-
matched animals and the use of congenitally immune deficient, transgenic and gene
knockout (KO) mouse strains allow detailed dissection of the immune response.
A mouse model of OEA does exist and is likely to be very useful in extending the
understanding of the immune response to C. psittaci in the ewe [Rodolakis et al,
1981]. However, at the time of writing, there have been few attempts to use this
model to dissect the immune response to OEA strains of C. psittaci. Consequently,
much of what is know about the in vivo immune response the C. psittaci in the ewe
must be extrapolated from experiments using strains of chlamydiae which induce
distinct pathology in the mouse from that seen in sheep infected with OEA strains
of C. psittaci. Whilst, these studies should not be taken out of context, they do
provide a useful insights into the interaction of the immune system with chlamydiae.
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1.5. The innate immune response to C. psittaci
1.5.1. Recruitment and activation of immune ceils
C. psittaci infection in the ewe appears to be established at a mucosal surface, either
in the epithelium of the vaginal [Papp and Shewen, 1996a] or nasopharyngeal /
gastrointestinal tract, possibly via lymphocytes and epithelial cells within mucosal-
associated lymphoid tissue (MALT) [Jones and Anderson, 1988]. Initial interaction
between C. psittaci and the immune system is therefore likely to involve the
recruitment and activation of immune cells from the underlying mucosa and local
vasculature by pro-inflammatory cytokines released from infected epithelial cells
and lymphocytes. The range of chemokines and pro-inflammatory cytokines
produced in vitro by cells infected with chlamydiae is consistent with the
recruitment and activation of a variety of immune cells involved in inflammatory
responses (Table 1.3) [Bianchi et al, 1997; Entrican et al, 1999; Entrican, unpublished
results; Heinemann et al, 1996; Ingalls et al, 1995; Kaukoranta-Tolvanen et al, 1996;
Manor et al, 1993; Molestina et al, 1998; Paguirigan et al, 1994; Rasmussen et al,
1997; Van Westreenen et al, 1998]. There is also evidence of both systemic
production of granulocyte-macrophage colony-stimulating factor (GM-CSF) [Magee
et al, 1991] and local production of Interleukin-la/(3 (IL-la/p) and Interleukin-6
(IL-6) by mice infected with MoPn [Magee et al, 1992].
The components of chlamydiae that mediate pro-inflammatory cytokine release
appear to be heat-labile and/or dependent on chlamydial replication in the host cell
[Bianchi et al, 1997; Entrican et al, 1999; Molestina et al, 1998; Ojcius et al, 1998a].
Ingalls et al (1995) were able to induce tumour necrosis factor-alpha (TNF-a)
production in ex vivo preparations of unfractionated human blood cells with both
live C. trachomatis EB and purified C. trachomatis LPS, albeit at much lower levels
than live Salmonella minnesota R595, S. minnesota R595 LPS or Neisseria gonorrhoea
LPS. Addition of LPS antagonists to cultures inhibited TNF-a release for










































































































































































































The lack of reagents currently available has limited the range of pro-inflammatory
cytokines that can be quantified in the supernatants of ovine cells infected with
OEA strains of C. psittaci to IL-1, interleukin-8 (IL-8) and GM-CSF [Entrican et al,
1999], However, given the central role played by IL-1 in the inflammatory response
[Dinarello, 1998], it seems plausible that OEA strains of C. psittaci could induce the
full spectrum of pro-inflammatory mediators that are released by human and
murine cells infected with other strains of chlamydiae (Table 1.3). In addition, IL-8
has been shown to up-regulate the production of other pro-inflammatory cytokines,
including IL-1|3, IL-6 and TNF-a in human mononuclear cells [Yu et al, 1994].
Precisely how C. psittaci manages to survive the ovine inflammatory response and
establish a persistent infection in the non-pregnant ewe or disseminate to the
placenta and cause fetopathology in the pregnant ewe remains unclear.
1.5.2. Interaction between C. psittaci and neutrophils
Recruitment and activation of neutrophils occurs rapidly following the induction of
inflammatory responses [Smith, 1994]. The presence of neutrophils has long been
recognised as a cytological indicator of the presence of chlamydiae [Yoneda et al,
1975] and their role in controlling chlamydial infections has been highlighted by in
vivo depletion studies [Barteneva et al, 1996]. Mice rendered neutrophil deficient by
monoclonal antibodies have been shown to suffer exacerbated and prolonged
infection compared to control mice following intravaginal infection with MoPn.
Furthermore, circumstantial evidence suggests that defects in neutrophil function
may play a role in host susceptibility to C. trachomatis in humans [Monno et al,
1991].
Neutrophil adherence to vascular endothelium and transendothelial migration to the
site of inflammation is mediated primarily through the action of IL-8 [Zhang et al,
1995] and related neutrophil chemoattractants, including the growth-related
oncogene (GRO) family of chemokines [Wu et al, 1994]. There is considerable
interplay between the pro-inflammatory cytokines, and the release of IL-8 and
related chemoattractants may be regulated by macrophage derived IL-1 and TNF-a
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[Wu et al, 1995; Zhang et al, 1995], However, an ovine fibroblastic cell line (ST.6)
has been shown to produce IL-8 in the absence of exogenous stimuli following
infection with the S26/3 strain of C. psittaci [Entrican, unpublished results],
suggesting that infection of epithelial cells alone may be sufficient to recruit
neutrophils to the site of C. psittaci infection in sheep. Neutrophils may also be
recruited to the site of chlamydial infections by chemotactic products of the
alternative complement pathway [Megran et al, 1985],
Neutrophils appear to be able to kill chlamydiae in the absence of exogenous
stimuli. Elementary bodies of trachoma and LGV strains of C. trachomatis do not
appear to be able to evade phagosome-granule fusion in human neutrophils and
have been shown to be rapidly degraded following uptake by these cells in the
absence of exogenous cytokines or opsonins [Register et al, 1986; Yong et al, 1982,
1986; Zvillich and Sarov, 1985]. However, Register et al (1986) showed that human
neutrophils are less efficient at killing C. psittaci EB than C. trachomatis EB. Similarly,
C. psittaci EB are more resistant to damage by the contents of human neutrophil
granules than C. trachomatis EB [Register et al, 1987].
In addition to their direct anti-microbial effects, neutrophils can cause host tissue
damage and are associated with immunopathology in a number of disease processes
[Smith, 1994]. Persistent neutrophil activation is associated with the chronic and/or
acute inflammation and pathology typical of chlamydial infections [Cvenkel and
Globocruk, 1997; Darville et al, 1995; Pizzichini et al, 1997; Rasmussen ei al, 1997;
Yang et al, 1994]. Although persistent infection in the non-pregnant ewe is not
associated with immunopathology or inflammation, accumulation of neutrophils at
the maternal-fetal interface has recently been described in the murine model of OEA
[Buendia et al, 1998],
Traditionally, neutrophils were thought to be largely incapable of protein synthesis
and their role in the immune response was considered to be restricted to
phagocytosis and the release of proteolytic and cytotoxic compounds. However,
studies in the late 1980s and early 1990s demonstrated that neutrophils can express
a variety of cytokines and surface receptors including: IFN-alpha (IFN-a); IL-1; IL-6;
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IL-8; interleukin-10 (IL-10); interleukin-12 (IL-12); TNF-a; platelet-activating factor
(PAF); major histocompatibility complex class I molecules (MHC I); complement
receptor 1 (CR1); and complement receptor 3 (CR3) [Cicco et al, 1990; Dubravec et
al, 1990; Jack and Fearon, 1988; Lord et al, 1991; Moore et al, 1992; Neuman et al,
1990; Romani et al, 1997]. Activation of neutrophils at the site of infection is
therefore likely to create a positive feedback loop leading to further recruitment and
activation of immune cells.
1.5.3. Interaction between C. psittaci and mononuclear cells
The interaction between chlamydiae and mononuclear cells is complex. Large
numbers of Chlamydial EB have been shown to induce an immediate cytotoxic
response in murine [Wyrick and Brownridge, 1978; Wyrick et al, 1978] and ovine
macrophages [Entrican et al, 1999]. This ability appears to be mediated by a
structural component of the EB outer membrane [Wyrick and Davis, 1984]. Heat
inactivation, but not UV inactivation, of EB prevents cytotoxicity [Su and Caldwell,
1995], suggesting that the mediator is heat-labile. At lower EB to macrophage ratios,
C. psittaci and C. trachomatis appear to be able to infect and multiply within
macrophages of human [Manor and Sarov, 1986], murine [Wyrick and Brownridge,
1978; Wyrick et al, 1978; Zhong and De La Maza, 1988] and ovine [Entrican et al,
1999] origin. In contrast, C. pneumoniae growth appears to be restricted in human
macrophages in vitro [Gaydos et al, 1996].
Peripheral blood monocytes are more resistant to chlamydial infection than mature
macrophages. However, during tissue culture, peripheral blood monocytes become
increasingly macrophage-like in phenotype and more susceptible to infection with
chlamydiae [Yong et al, 1987], Differences in the literature with regard to the
resistance of monocytes to identical strains of chlamydiae probably arise as a result
of variations in the time for which peripheral blood monocytes were cultured prior
to infection. It is therefore necessary to interpret the literature concerning in vitro
infection of peripheral blood mononuclear cells with some caution.
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Where direct comparisons have been made between macrophages and peripheral
blood derived monocytes, it appears that the ability of different strains of C. psittaci
and C. trachomatis to grow in monocytes correlates with their ability to cause
systemic infections in vivo. Human monocytes have been shown to inhibit the
growth of C. trachomatis serovar K but are less effective at restricting LGV strains of
C. trachomatis [Yong et al, 1987], which causes more invasive pathology in vivo
[Pitche et al, 1998], However, it has since been reported that C. trachomatis serovar
K can persist in human monocytes in a viable but non productive form [Koehler et al,
1996, 1997]. Similarly, human monocytes are more susceptible to infection with the
6BC avian strain of C. psittaci (which causes systemic disease [Pudjiatmoko et al,
1997; Vanrompay et al, 1995]) than they are to LGV strains of C. trachomatis [Manor
and Sarov, 1986]. Less is known about the interaction between monocytes and C.
pneumoniae. However, a recent clinical study found that C. pneumoniae DNA was
common in peripheral blood mononuclear cells of patients with coronary heart
disease and in middle-aged blood donors, suggesting that C. pneumoniae may infect
human monocytes in vivo [Boman et al, 1998].
In contrast to the ability of un-stimulated macrophages to support chlamydial
growth, activated macrophages are capable of restricting the growth and
development of chlamydiae. Peritoneal macrophages recovered from mice in
remission following a potentially lethal intraperitoneal challenge with the 6BC strain
of C. psittaci were shown to inhibit chlamydial growth when challenged in vitro
IHuebner and Byrne, 1988], The principal factor responsible for macrophage
activation has since been extensively characterised as T-cell or Natural killer (NK)
cell derived interferon-gamma (IFN-y) [Chen et al, 1996; Rothermel et al, 1983; Yong
et al, 1987; Zhong and De La Maza, 1988],
The interaction between chlamydiae and monocytes /macrophages is likely to act as
a double-edged sword, simultaneously exacerbating pathology whilst contributing to
the protective immune response. Infected mononuclear phagocytes may play a role
in the dissemination of chlamydiae from the initial site of infection [Moazed et al,
1998], They may also contribute to chronic inflammation and tissue damage through
the release of pro-inflammatory cytokines [Delannoy et al, 1993], which are at the
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same time critical for the recruitment and activation of immune effector cells and
lymphocytes.
Ovine macrophages infected with the S26/3 OEA strain of C. psittaci produce IL-8
in vitro [Entrican et al, 1999] and are likely to play a role in the recruitment and
activation of neutrophils to kill chlamydiae in vivo [Zhang et al, 1995]. Similarly,
production of IL-1 by infected ovine [Entrican et al, 1999] and human [Ingalls et al,
1995; Kaukoranta-Tolvanen et al, 1996; Paguirigan et al, 1994] macrophages
suggests that chlamydial infection of macrophages may be important in the
activation of lymphocytes and NK cells in vivo. In addition, IL-1 has multi
functional effects on a wide variety of cell types and can induce the production of
other pro-inflammatory cytokines by macrophages, including TNF-a [Dinarello,
1998] which can act synergistically with IL-12 to activate NK cells [Bancroft, 1993].
IL-12 is produced by human and murine mononuclear cells in response to challenge
with a variety of pathogens [Bancroft, 1993] and up-regulation of IL-12 expression
has been demonstrated by reverse transcriptase-PCR (RT-PCR) in conjunctival
samples from patients with ocular inflammation, but not scarring, associated with
trachoma caused by C. trachomatis [Bobo et al, 1996]. In addition to their pro¬
inflammatory role, some cytokines released by macrophages infected with
chlamydiae have been reported to have direct anti-chlamydial effects.
Macrophages have the potential to process and present chlamydial antigens to CD4
+ve T-cells in the context of MHC II. Murine bone marrow derived macrophages
(BMDM) have been demonstrated to process and present antigens from heat
inactivated chlamydiae to CD4 +ve T-cell, but are not as effective as mixed spleen
cells [Su and Caldwell, 1995]. MHC II expression is induced in the chlamydial
inclusion vacuole in a human monocytic cell line, THP1, following activation with
IFN-y [Ojcius et al, 1997], However, mononuclear phagocytes are not thought to be
the major APC involved in antigen presentation to CD4 +ve T-cells during the
primary immune response [Knight and Stagg, 1993] and the presence of dendritic
cells (DC) is required for presentation of chlamydial antigen to naive human T-cells
[Stagg et al, 1993a],
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1.5.4. Interaction between C. psittaciand dendritic cells
Dendritic cells are professional APCs and are thought to play a central role in
antigen presentation during primary immune responses. After acquiring antigen, DC
migrate to local lymphoid tissue via the afferent lymphatic system. Interdigitating
cells, located in the paracortex of lymph nodes, are thought to include DC which
have migrated into the lymph node following antigen acquisition in the periphery
[Knight and Stagg, 1993]. This may explain the appearance of chlamydial antigen in
"macrophage-like" cells associated with the cortex and medullary chords of
draining lymph nodes from ewes following primary subcutaneous challenge with C.
psittaci [Buxton et al, 1996].
Internalisation of chlamydiae by DC was originally observed using avidin
conjugated with fluorescein isothiocyanate (FITC) to probe permeabilised peripheral
blood derived DC previously incubated with biotinylated C. trachomatis EB.
Fluorescence activated cell sorter (FACS) analysis revealed significant amounts of
internalised biotinylated EB [Stagg et al, 1993b], refuting the previously held concept
that DC were incapable of internalising complex antigens. More recently, DC have
been shown to internalise live C. trachomatis and C. psittaci through nonspecific
macropinocytosis. Macropinosomes containing EB fuse with DC lysosomes
expressing MHC class II and the chlamydiae are subsequently killed and degraded,
allowing efficient antigen presentation to CD4 +ve T-cells [Ojcius et al, 1998b].
Differences in the duration and seventy of C. trachomatis (serovar-F) genital
infections observed between BALB/ c and C3H mouse strains, appear to correlate
with the ability of these mice to recruit a population of large, CD45 +ve, MHC II +ve
mononuclear cells into uterine tissue shortly after intravaginal challenge. FACS
analysis also revealed increased expression of CD40 and CD86, costimulatory
surface ligands involved in T-cell activation, indicative of an APC phenotype.
Furthermore, increased expression of CDlla, CDllb and CDllc was evident and
CDllc is preferentially, but not exclusively, expressed by DC. However, further
characterisation of these cells was confounded by their weak expression of both
F4/ 80, a mature macrophage surface marker, and DEC205, a DC antigen [Stagg et
al, 1998].
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DC may also contribute to the development of immunity through the production of
cytokines. Fixed Staphylococcus aureus and Escherichia coli LPS have been shown to
induce high levels of IL-12 p40 mRNA transcripts and secretion of active IL-12 in
murine and human DC [Heufler et al, 1996]. Human DC, generated in vitro by
culturing plastic-adherent PBMC in presence of IL-4 and GM-CSF, produce high
levels of TNF-a, IL-6, IL-8, IL-12, in response to E coli LPS [Verhasselt et al, 1997].
More recent studies, using single cell resolution intracellular cytokine staining in
epidermal Langerhans cells (LC) and ex two-derived CD14-, CDla+, CD83+,
CD40+ DC, also support a role for DC in the production of pro-inflammatory
cytokines following stimulation with LPS [Lore et al, 1998]. These finding suggest
that DC might also contribute, although perhaps to a lesser extent than
macrophages, to the production of pro-inflammatory cytokines and chemokines
following stimulation by chlamydial LPS.
In addition to producing cytokines and chemokines in responses to LPS, DC have
also been shown to produce IL-12 in response to antigen-specific interaction with T-
cells in the absence of exogenous stimuli [Heufler et al, 1996; Macatonia et al, 1995].
This characteristic of DC, which appears to be mediated through CD40-CD40L
ligation [Cella et al, 1996], has also been shown to profoundly influence the cytokine
profile of T-cells. Thus, DC appear to be able to drive naive CD4+ T-cells towards
a T-helper-l-like (Thl-like) cytokine profile [Macatonia et al, 1995]. Furthermore,
DC have been shown to induce Thl-like cytokine production by resting T-cells in
allogeneic mixed lymphocyte reactions without the need for any exogenous
cytokines or stimuli such as microorganisms [Heufler et al, 1996]. It would therefore
appear that DC and DC-derived IL-12 play an important role in skewing the
immune system towards a Thl-like response. These findings, when considered
together with what is known about the ability of DC to kill chlamydiae and present
their antigens to CD4 +ve T-cells [Ojcius et al, 1998b], suggest a significant role for
DC in the induction of the primary immune response to chlamydiae.
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1.5.5. Interaction between C. psittaci and NK cells
There is considerable evidence to support a critical role for NK cells during the
primary immune response to a variety of intracellular bacteria [Bancroft 1993].
Their principal role in this context appears to be the production of IFN-y at a time
when the host does not have a significant number of pathogen-specific T-cells
[Kaufmann, 1993]. Increased NK activity has been observed in the spleen and lung
of both naive athymic nude (nu/nu) mice and heterozygous (nu/+) mice during the
initial stages of pulmonary infection with MoPn. However, anti-asialo GM-1
antibody-mediated depletion of NK cells or stimulation of NK activity by
immunomodulators did not affect the outcome of MoPn infection in nu/nu mice
[Williams et al, 1987a]. In a later study, in vivo depletion of IFN-y was associated
with increased pathology in naive nu/nu mice infected with MoPn and depletion of
NK cells using anti-asialo GM1 antibody significantly reduced IFN-y production in
the lung suggesting a putative role for NK-derived IFN-y in this model [Williams et
al, 1993]. More recently, IFN-y and NK cells have been shown to appear
concomitantly in the genital tract of female BALB/c mice shortly after intravaginal
infection with MoPn. Furthermore, mice treated with anti-asialo GM1 antibodies
suffer prolonged MoPn infections compared to mice treated with control antibody,
lending further support for a role for NK cells in the primary immune response to
chlamydiae [Tseng and Rank, 1998].
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1.6. Acquired immunity to C. psittaci
It has long been recognised that ewes which abort or suffer fetopathology as a result
of placental infection with C. psittaci rarely experience repeated episodes of clinical
OEA [Stamp et al, 1950]. This suggests that events associated with infection of the
placenta or generalised chlamydaemia during pregnancy can induce immunological
memory. However, ewes do not develop sterile immunity C. psittaci and shed
chlamydiae during estrus for several years after developing protective immunity to
clinical OEA [Papp et al, 1994]. The immune response to OEA during secondary
challenge is therefore likely to be focused on prevention of fetopathology rather than
eradication of chlamydiae.
1.6.1. Immunity to C. psittaci in naive sheep infected outwith pregnancy
The question as to how C. psittaci persists in apparently immunocompetent sheep
without causing disease or inducing protective immunity to OEA remains largely
unresolved. Since C. psittaci does not appear to cause significant pathology in naive
ewes infected outwith pregnancy, it must be assumed that the immune response is
able to restrict the pathogen in a manner that does not confer protection to
fetopathology or abortion. Experimental infection of non-pregnant ewes is
associated with transient low level seroconversion as determined by complement
fixation test (CFT) [Dawson et al, 1986; Wilsmore et al, 1984] and more recently by
ELISA [Amin and Wilsmore, 1995]. However, serum antibody titres are not
indicative of protective immunity, since animals which seroconvert following
primary infection often abort during their next pregnancy [Dawson et al, 1986]. In
contrast, the ability of individual ewes to mount a strong cell mediated immune
(CMI) response, measured using a delayed type hypersensitivity (DTH) skin test to
semi-purified C. psittaci whole EB antigen, has been reported to correlate with
reduced fetopathology during the first pregnancy after infection [Dawson et al,
1986]. Although this is perhaps not unexpected for an intracellular pathogen, it
does not explain why the ewe fails to eradicate C. psittaci at the time of primary
infection or how persistent C. psittaci can be reactivated during pregnancy.
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1.6.2. The secondary ovine immune response to C. psittaci
The development of acquired immunity to OEA that follows abortion or
fetopathology has been shown to be associated with a prolonged increase in both
humoral and CMI responses. On the basis that CMI responses correlate better with
reduced susceptibility to abortion than seroconversion does, it has been suggested
that the high antibody titres observed in ewes that develop clinical disease are a
result of increased chlamydaemia during pregnancy. High antibody titres may be a
result of failure to mount an effective anti-chlamydial CMI response rather than an
absolute indicator of the development of acquired immunity [Dawson et al, 1986].
However, the possibility that antibody contributes to the immune response during
secondary7 challenge with C. psittaci in subsequent pregnancies can not be excluded.
1.6.3 Humoral immunity to chlamydiae
The current consensus of opinion on protective immunity to chlamydiae favours a
Thl-like immune response but does not preclude a role for antibody [Rasmussen,
1998], Passive transfer of immune sera has been shown to prolong survival in both
athymic nu/nu mice (BALB/c background) and their normal heterozygous nu/-
siblings following lethal challenge with MoPn. Delivery of immunoglobulin A (IgA) or
immunoglobulin G (IgG) monoclonal antibodies into the serum and vaginal secretions
of naive mice has been reported to reduce upper genital tract pathology in mice
infected with MoPn [Cotter et al, 1995], More recently, the ability of neutralising
anti-MOMP IgA monoclonal antibodies to protect mice infected with MoPn against
infertility has been confirmed in passive transfer experiments [Pal et al, 1997].
Similarly, and of more relevance to OEA, passive transfer of two different
monoclonal antibodies (which recognise the MOMP of B577 OEA strain of C.
psittaci [De Sa et al, 1995; McCafferty et al, 1995]) completely ablates fetopathology
in female Swiss mice challenged during pregnancy with the AB7 OEA strain of C.
psittaci [Buzoni-Gatel et al, 1990],
In addition to the ability of antibody to neutralise chlamydiae, certain IgG isotypes
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have been shown to enhance the in vitro infectivity of C. trachomatis in cells bearing
the low affinity receptor for antibody, Fc gamma RIII (CD16) [Su et al, 1991].
Furthermore, passive immunisation ofmice with IgG2b monoclonal antibodies raised
against EB surface antigens has been demonstrated to enhance the infectivity of a
serovar E strain of C. trachomatis in mice, suggesting that chlamydiae may be able to
take advantage of antibody to infect cells bearing CD16 [Peterson et al, 1997],
Despite the ability of passively transferred antibody to confer protection against
challenge with chlamydiae, experiments with B-cell deficient mice have suggested
that antibody is not a prerequisite for protection. Rendering BALB/c mice B-cell
deficient, by treatment from birth with goat or rabbit anti-mouse /j chain polyclonal
antibodies, was shown to have no effect on their susceptibility to primary intranasal
or intravaginal infection with MoPn [Ramsey et al, 1988; Williams et al, 1987b].
Furthermore, BALB/ c mice rendered B-cell deficient in this way were also shown to
be as resistant to secondary intravaginal challenge as normal BALB/c controls
[Ramsey et al, 1988].
Recent studies using immunoglobulin \i heavy chain KO mice (Igju -/-), which do not
develop functionally mature B-cells [Kitamura et al, 1991], have added further
weight to the argument that antibody and B-cells are not a critical component of the
immune response to chlamydiae [Johansson et al, 1997a; Su et al, 1997; Williams et
al, 1997]. Female Igiu -/- C57BL/6 mice do not differ significantly from female
C57BL/6 controls in their ability to resolve primary genital tract infections with
human serovar D or MoPn strains of C. trachomatis [Johansson et al, 1997a; Su et al,
1997]. Furthermore, Igfi -/- C57BL/6 mice and control C57BL/6 mice mounted
equally effective memory responses during secondary challenge with the serovar D
strain of C. trachomatis [Johansson et al, 1997a].
Whilst the induction of immunological memory and the ability to mount a more
effective immune response during secondary challenge does not appear to be
compromised in Igju -/- mice, they have been shown to be marginally more
susceptible to reinfection of the genital tract [Su et al, 1997] and lung [Williams et al,
1997] with MoPn when compared to normal control mice. Flowever, Williams et al
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(1997) reported anomalies in Thl-like cytokine production by Igg -/- mice during
secondary infection with MoPn which may have contributed to the differences in
susceptibility of these mice to reinfection. IFN-y production was slightly suppressed
and TNF-a production was greatly enhanced in Igju -/- mice during secondary
infection compared to control mice. The anti-chlamydial effects of TNF-a may
compensate for the absence of antibody, masking its role in the secondary immune
response. Alternatively a reduction in IFN-y production by IgjU -/- mice may
contribute to the slight increase in their susceptibility to C. trachomatis. The later of
these two possibilities seems less plausible given that in the same study IFN-y
deficient mice (IFN-y -/-) actually appeared to be less susceptible to reinfection
than control mice and like Igg -/- mice, produced almost twice as much TNF-a
compared to the controls [Williams et al, 1997].
Regardless of whether relative changes in IFN-y and TNF-a expression in B-cell
deficient mice compensate for the absence of a functional humoral response, there
does not appear to be an absolute requirement for B-cells or antibody in the
resolution of primary C. trachomatis infection or acquired immunity to C. trachomatis
in the mouse. At the same time the increased susceptibility of IgjU -/- mice, albeit
marginal, to secondary infection with C. trachomatis suggests that chlamydiae-
specific B-cells may contribute to the secondary immune response, either directly
through the production of neutralising antibody [Buzoni-Gatel et al, 1990; Cotter et
al, 1995; Pal et al, 1997; Williams et al, 1982] or by acting as C. trachomatis-specific
APCs. However, until similar experiments are repeated in the context of the murine
model of OEA [Rodolakis et al, 1981] it can only be speculated upon as to whether
the same is true for pregnant mice, or sheep, infected with OEA strains of C. psittaci.
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1.6.4 CD4 +ve a|3 T-cells and immunity to chlamydiae
Studies involving the experimental infection of B-cell deficient mice with Serovar D
and MoPn strains of C. trachomatis have been unanimous in concluding that CMI
plays a more dominant role than antibody in the protective immune response to
chlamydiae [Johansson et al, 1997a; Ramsey et al, 1988; Su et al, 1997; Williams et al,
1987b; Williams et al, 1997].
In contrast to B-cell deficient mice, athymic nu/ nu mice are much more susceptible
to infection with MoPn than functionally intact heterozygous nu/+ controls
[Williams et al, 1981], However, in addition to being largely devoid of functionally
mature a[3 T-cells, nu/nu mice fail to mount a humoral response to chlamydiae
[Coalson et al, 1987]. Reconstitution of nu/nu BALB/c mice with thymuses
explanted from neonatal +/+ BALB/c mice restores their ability to produce
functionally mature a[3 T-cells and affords significantly more protection against
intranasal challenge with MoPn than passive transfer of immune sera. Reconstituted
nu/nu mice also produce antibody in response to MoPn, suggesting that both CMI
and humoral immunity to chlamydiae are a(3 T-cell dependent [Williams et al, 1982].
Severe combined immunodeficiency (SCID) mice, which do not produce functional
B-cells, a[3 T-cells or y5 T-cells [Yancopoulos and Alt, 1988], are more susceptible to
pneumonia caused by MoPn than nu/nu mice [Magee et al, 1993], possibly as a
result of the presence of subpopulations of y5 T-cells in nu/nu mice [Williams et al,
1987a, 1996], SCID mice have been shown to be partially protected from challenge
with MoPn by passive transfer of a MoPn-specific Thl-like CD4 +ve a[3 T-cell clone
lending further support to the role for CMI in immunity to chlamydiae [Magee et al,
1993].
More recent studies have concentrated on the use of KO mice and antibody targeted
depletion to dissect the primary and secondary immune responses to chlamydiae.
Antibody mediated depletion of CD4 +ve or CD8 +ve T-cells has been shown to
significantly increase chlamydial burden in C57BL/6 mice infected intranasally with
MoPn during the primary immune response. However, mortality was significantly
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higher in mice after CD4 targeted depletion, when compared to CD8 depleted mice
which did not differ significantly from control mice. Depletion of CD 4 +ve T-cells
(but not CD8 +ve T-cells) was also associated with a significant reduction in both
serum IgG and the ability of spleen cells to produce IFN-y in response to UV-
inactivated MoPn EB [Magee et al, 1995].
CD4 KO (CD4 -/-) C57BL/6 mice experience increased chlamydial burdens and
prolonged infection with MoPn compared to control C57BL/6 mice or beta 2-
microglobulin KO (fl-2m -/-) C57BL/6 mice. Although antibody mediated depletion
of CD8 +ve T-cells did not result in significantly increased mortality, a significant
increase in mortality has been reported in |3-2m -/- mice relative to normal control
mice [Magee et al, 1995], In a parallel experiment, Morrison et al (1995) showed that
whilst CD4 -/- C57BL/6 mice suffered significantly prolonged infection compared
to controls and p~2m -/- mice, they were able to resolve primary genital tract
infection with MoPn. In the same study, both |T2m -/- and CD4 -/- mice mounted
an effective memory response to secondary challenge. In contrast to the findings of
Magee et al (1995), there was no evidence that IgG production was significantly
affected in CD4 -/- mice during genital tract infection with MoPn, although IgA
production was delayed in CD4 -/- mice compared to p-2m -/- and control mice.
However, MHC II KO (MHC II -/-) C57BL/6 mice produce significantly reduced
amounts of antibody, fail to resolve primary infection and do not develop
immunological memory following intravaginal challenge with MoPn [Morrison et al,
1995], The discrepancy between the outcome of infection in CD4 -/- and MHC II -
/- mice is surprising since both models are thought to be completely CD4 +ve a|3 T-
cell deficient [Grusby et al, 1991; Killeen et al, 1993; Rahemtulla et al, 1991].
Like MHC II -/- C57BL/6 mice, MHC II -/- BALB/c mice have been shown to be
very susceptible to secondary infection in the lung with MoPn when compared to
normal BALB/c controls, fT2m -/-, Igfi-/- or interleukin-4 KO (IL4-/-) BALB/c
mice [Williams et al, 1997]. On the basis of these findings, CD4 +ve T-cells appear
to play the pivotal role in both the primary and secondary immune response to C.
trachomatis in the mouse.
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The ability of different inbred strains of mice to resist primary infection with MoPn
has been shown to correlate with quantitative differences in cytokine expression.
C57BL/6 mice are more resistant than BALB/c mice to both intravaginal and
intranasal challenge with MoPn [Stagg et al, 1998; Yang et al, 1996]. Whilst both
mouse strains have an apparently functionally intact immune system, BALB/ c mice
were shown to express higher levels of IL-10, more IgGl antibody, weaker DTH
responses and less IFN-y than C57BL/6 mice [Yang et al, 1996].
The protective immune response to primary infection with MoPn is profoundly
compromised in IL-12 depleted and IFN-y KO (IFN-y -/-) C57BL/6 mice [Perry et
al, 1997], IL-12 depleted mice were shown to have decreased numbers of infiltrating
CD4 +ve T-cells in infected tissues and took almost twice as long to clear
chlamydiae from the reproductive tract when compared to mice treated with a
control antibody. Neutralisation of IL-12 also caused qualitative and quantitative
changes in immunoglobulin isotype expression, including expression of IgGl which is
associated with a Th2-like response. Furthermore, spleen cells from IL-12 depleted
mice produced significantly less IFN-y in response to heat-inactivated chlamydiae,
indicating that the Thl-like immune response was suppressed in these mice. IFN-y -
/- mice initially appeared to control genital tract infection with MoPn but went on
to develop systemic infections often resulting in mortality. These mice also showed
abnormalities in cytokine and immunoglobulin isotype expression, including failure
to produce IgG2a and significantly depressed IL-6 production during the initial
stages of infection. However, IL-10 production was shown to be depressed in IFN-y
-/- mice when compared to control mice, suggesting that suppression of IFN-y
production does not necessarily skew the immune response toward Th2-like
cytokine production. In contrast to IL-12 depleted and IFN-y -/- mice, IL-4 depleted
mice were indistinguishable from control mice with respect to time taken to resolve
infection, cytokine production and immunoglobulin isotype production [Perry et al,
1997]. These findings lend substantial support to earlier studies which demonstrate
that antibody mediated depletion of IFN-y can induce exacerbated and prolonged
disease in naive mice challenged with C. trachomatis [Rank et al, 1992; Williams et al,
1988] or with the S26/3 OEA strain of C. psittaci [McCafferty et al, 1994].
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Whilst IFN-y has been shown to play a significant role in the primary immune
response to MoPn [Perry et al, 1997; Yang et al, 1996], its role appears to be less
important during the secondary immune response to chlamydiae. Although, there
appears to be an absolute requirement for CD4 +ve T-cells for the generation of
immunologicalmemory to chlamydiae, IFN-y -/- mice have been shown to be equally
resistant to reinfection as normal mice of the same genetic background [Cotter et al,
1997; Williams et al, 1997]. IFN-y -/- mice were reported to produce significantly
elevated levels of TNF-a during the secondary response to MoPn and it has been
suggested that additional CMI mechanisms may operate during the secondary
response to MoPn [Williams et al, 1997], In contrast, experimental infection of IFN-y
receptor deficient mice (IFN-yR -/-) does not result in the development of
immunological memory and these mice develop significantly increased pathology
compared to control mice following secondary intravaginal challenge with MoPn
[Johansson et al, 1997b].
1.6.5 CD8 +ve ap T-cells and immunity to chlamydiae
Whilst studies using p-2m -/- mice suggest that CD8 -i-ve a|3 T-cells are not an
essential component of the primary or secondary immune response to MoPn [Magee
et al, 1995; Morrison et al, 1995; Williams et al, 1997] there is considerable evidence
that CD8 +ve T-cells contribute to the resolution of chlamydial infections. Adoptive
transfer of cfilaniyciiae-specific CD8+ T-csll clones lias lieen sliown to increase tiie
frequency with which nu/nu mice eliminate MoPn, although the ability of individual
clones to contribute to protection was shown to be dependent on their capacity to
produce IFN-y and TNF-a [Igietseme et al, 1994]. Similarly, adoptive transfer of a
CD8 +ve cytotoxic T-cell line, derived from a mouse infected with a LGV strain of
C. trachomatis, was also shown to partially protect normal female BALB/c mice
from infection with an LGV strain of C. trachomatis through an IFN-y dependent
mechanism [Starnbach et al, 1994], Furthermore, epidemiological studies have also
implicated C. trachomatis-specific CD8 +ve T-cells in the resolution of trachoma in
humans [Holland et al, 1997; Reacher et al, 1991].
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1.6.6 y6 T-cells and immunity to chlamydiae
Little is known about the contribution of y5 T-cells to the protective immune
response to chlamydiae and even less about their role in the ovine immune response
to OEA. The presence of y5 T-cells in nu/nu mice has been cited as a potential
source of IFN-y and may be the reason why nu/nu mice are more resistant to
chlamydial infections than SCID mice [Williams et al, 1987a]. However,
experimental infection of y8 T-cell deficient (y5 -/-) mice with MoPn has shown that
whilst y8 T-cells may play a positive role in protection during the initial stages of
infection, their role in the later stages of infection is less clear and they may even
contribute to pathology [Williams et al, 1996],
1.6.7 Cytokines and immunity to chlamydiae
The anti-chlamydial properties of cytokines have been extensively scrutinised in
vitro. Early studies showed that a cocktail of cytokines, derived in this case from
concanavalin A (ConA) stimulated spleen cells of immune mice, could activate
murine macrophages to restrict the growth of the 6BC avian strain of C. psittaci
[Byrne and Faubion, 1982]. IFN-y was subsequently identified as the component
responsible for restricting the growth of C. psittaci in human macrophages [Rothermel
et al, 1983] and murine fibroblasts [Byrne and Krueger, 1983 ]. IFN-y has since been
reported to restrict the growth of C. psittaci, C. trachomatis and more recently C.
pneumoniae in a variety of different cells of human, murine and ovine origin [Chen et
al, 1996; De La Maza et al, 1987a, 1987b; Graham et al, 1995; Kane and Byrne,
1998; Mehta et al, 1998; Rapoza et al, 1991; Yong et al, 1987; Zhong and De La
Maza, 1988],
IFN-y is not the only cytokine that can restrict the growth of chlamydiae directly.
TNF-a has been shown to inhibit the growth of a LGV strain of C. trachomatis in
human HEp-2 cells (derived from a carcinoma of the larynx) through a mechanism
that was dependent on endogenous Interferon-beta (IFN-|3) production by HEp-2
cells [Shemer-Avni et al, 1988; 1989], IFN-p has also been shown to restrict the
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growth of C. trachomatis in the absence of TNF-a [Shemer-Avni et al, 1989], TNF-a
may act synergistically with IFN-y to restrict C. -pneumoniae growth in human FIEp-2
cells [Summersgill et al, 1995] and IL-1 has been demonstrated to act synergistically
with IFN-y in restricting the growth of C. psittaci in human monocyte derived
macrophages [Carlin and Weller, 1995],
1.6.8. IFN-y mediated persistence of chlamydiae in vitro
Chlamydial diseases are commonly characterised by long-term persistent infections.
Persistent subclinical C. psittaci infection is well documented in the context of OEA
in the non-pregnant ewe [Rodolakis et al, 1998]. Similarly, chlamydial persistence is
thought to be involved in both long-term asymptomatic infections and chronic
inflammatory pathology, characteristic of genital and ocular C. trachomatis infections
in humans [Ward, 1995]. Furthermore, there is mounting evidence of an association
between persistent C. pneumoniae infection and cardiovascular disease [Gibbs et al,
1998], Consequently, there has been considerable interest in the mechanisms through
which chlamydial persistence is mediated.
Penicillin was the first anti-microbial agent shown to induce chlamydial persistence
in vitro [Matsumoto and Manire, 1970], The presence of penicillin in cultures of
murine L-cells infected with C. psittaci resulted in the formation of aberrant RB
which did not undergo binary fission or develop into infectious EB. However,
penicillin did not eradicate RB from infected cultures and C. psittaci resumed its
normal cytolytic growth cycle when persistently infected cells were transferred into
penicillin-free culture conditions. Similar results have also been reported in murine
McCoy cells infected with C. psittaci or C. trachomatis under amino acid-free or -
depleted culture conditions [Coles et al, 1993].
At the same time that Coles et al (1993) were investigating the role of amino acid
deprivation in chlamydial persistence, it became clear that IFN-y could induce a
persistent C. trachomatis infection in human cells that shared several characteristics
with penicillin mediated persistence. The effect of IFN-y on C. trachomatis growth in
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the human epithelial HeLa 229 cell line was shown to be dose dependent and at
relatively low concentrations resulted in the formation of morphologically aberrant
chlamydiae that did not mature into infectious EB [Beatty et al, 1993]. C. trachomatis
development and production of infectious EB was restored when IFN-y was
removed from the culture conditions [Beatty et al, 1993]. Further characterisation of
this model revealed that C. trachomatis could be maintained in a non-productive
persistent state for over 30 days when infected cells were maintained in the
presence of IFN-y and that persistence was mediated by host cell tryptophan
catabolism [Beatty et al, 1994a, 1995]. IFN-y has since been reported to mediate
chlamydial persistence in human in polarised human epithelial cells infected with C.
trachomatis [Kane and Byrne, 1998] and human HEp-2 cells infected with C.
pneumoniae [Mehta et al, 1998].
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1.7. Aims of the study
The ability of C. psittaci to cause a persistent infection in the non-pregnant ewe
without inducing protective immunity to OEA severely confounds both diagnosis
and vaccine strategies. The mechanisms through which persistent C. psittaci infection
is mediated in sheep have not been previously defined. The main purpose of this
work was to investigate whether the ovine immune response can contribute to the
induction and maintenance of C. psittaci persistence. To which end the following
studies were pursued:
• An image analysis software solution was developed with a view to automating
the otherwise laborious and error prone task of measuring chlamydial growth in
vitro.
• The mechanisms responsible for ovine IFN-y mediated restriction of C. psittaci
growth in ovine cells were investigated.
• The ability of ovine IFN-y to induce and mediate persistent C. psittaci infection
of an ovine cell line was investigated.
• The mechanisms responsible for IFN-y mediated C. psittaci persistence were
investigated.
• Attempts were made to generated and characterise ex vivo T-cell lines, raised
against the predominant C. psittaci surface antigen MOMP, with a view to





2.1. Cell culture and C. psittaci
2.1.1. General culture conditions
All aspects of cell culture, handling of C. psittaci and Semliki Forest Virus (SFV)
were performed under biosafety level two conditions. All cell lines and primary
cultures were propagated and maintained in antibiotic free media (unless stated
otherwise) in a 37°C humidified 5% C02 environment. Cell viability was determined
by nigrosine exclusion (BDH Chemicals, Poole, UK).
Unless stated otherwise, reagents were obtained from Moredun Research Institute
(MRI) scientific services.
2.1.2. Fetal bovine sera
Fetal bovine serum (FBS: Boehringer Mannheim, Lewes, UK) was screened at MRI
and shown to be free of C. psittaci-speciiic antibodies [Jones et al, 1997], In addition,
each batch of FBS was tested to ensure that it did not influence C. psittaci infectivity
or inclusion formation. FBS was also screened for bovine virus diarrhoea virus
(BVDV) specific antibodies and infectious BVDV. BVDV can establish persistent
infections in ruminant cell lines and has the potential to alter cell function [Nettleton
and Entrican, 1995], The ruminant cell lines used throughout these experiments were
routinely screened for BVDV by IFAT. In addition, cell lines were tested every 6
months for the presence of mycoplasmas using a commercially available ELISA
(Boehringer Mannheim).
2.1.3. Cryopreservation
Cells were cryopreserved at a density of 5xl06 - lxlO7 viable cells/ml in freezing
medium: 50% of the appropriate culture medium, 40% FBS and 10% dimethyl-
sulfoxide (DMSO; Sigma-Aldrich Poole, UK). Cell suspensions were aliquoted into
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1 ml Nunc Cryotubes (GIBCO BRL, Paisley, UK), cooled to -70°C at a rate of
approximately 1°C/minute, using a Nalgene Cryo freezing vessel containing
isopropanol (GIBCO BRL), then transferred to long-term storage in liquid nitrogen.
2.1.4. ST.6 cells
The ovine fibroblastic cell line, ST.6, was originally derived from a metastatic
tumour explanted from the posterior mediastinal lymph node of an adult ewe
identified as having a naturally occurring adenocarcinoma of the small intestine
[Norval et al, 1981].
ST.6 cells were maintained in Iscove's modified Dulbecco's medium (IMDM; GIBCO
BRL) supplemented with 5% FBS (IMDM+5% FBS). ST.6 cultures were routinely
maintained in IMDM + 5% FBS in 225 cm2 vented tissue culture flasks (Corning
Costar, Fligh Wycombe, UK). Cultures were passaged 1 in 3 every 3-4 days or when
the cell monolayers became confluent. Cell monolayers were washed twice with
sterile pH 7.4 phosphate buffered saline (PBS; Appendix 1.1), detached with 2 ml
of trypsin/versene (Appendix 1.2) and resuspended to 9 ml in IMDM+5% FBS.
Fresh 225 cm2 flasks were seeded with 3 ml of cell suspension and made up to 25 ml
with IMDM+5% FBS.
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The murine macrophage cell line RAW 264.7 [Raschke et al, 1978] was obtained
from the European Collection of Animal Cell Cultures.
Raw 264.7 cells were maintained in IMDM+5% FBS in 75 cm2 vented tissue culture
flasks (Corning Costar). Cultures were passaged 1 in 10 every 3-4 days or when the
cell monolayers became confluent. The monolayer was mechanically disrupted using
a sterile plastic cell scraper (Corning Costar), the cell suspension was centrifuged at
400 g for 5 minutes and the pellet was resuspended in 10 ml of IMDM+5% FBS.
Fresh flasks were seeded with 1 ml of cell suspension and made up to 10 ml with
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IMDM+5% FBS.
2.1.6. Collection of bronchoalveolar lavage cells
Bronchoalveolar Lavage (BAL) cells were collected using a modified version of the
protocol described by Burrells (1985). Conventionally reared adult ewes and
specific pathogen free (SPF) ewe lambs were euthanized by intravenous injection
with sodium pentobarbital (Euthetal; Rhone Mereux, Harlow, UK). The lungs were
excised with the trachea clamped shut to avoid contaminating the interior of the
lung with blood. Approximately one litre of PBS was poured into the trachea, after
which lungs were briefly massaged and the resultant suspension of BAL cells was
decanted into a sterile container through sterile gauze. At this stage, any BAL
suspensions contaminated with blood were discarded. Cells were washed three
times by centrifugation at 500 g for 30 minutes in cold (4°C) Hanks Balance Salt
Solution (HBSS; GIBCO BRL), supplemented with 2% FBS, 100 (Ug/ml gentamicin
sulphate (Sigma-Aldrich), 200 international units/ml (IU/ml) of penicillin
(Britannia Pharmaceuticals, Redhill, UK), 100 jug/ml of streptomycin (GIBCO BRL),
4 fig/ml Amphotericin B (Sigma-Aldrich), 10 IU/ml Heparin (Sigma-Aldrich). The
cells were washed a final time in cold (4°C) antibiotic-free IMDM + 10% FBS and
cryopreserved in 1 ml aliquots of freezing medium at a density of 1X107 viable
cells/ml.
2.1.7. Collection of ovine peripheral blood mononuclear cells
Adult ewes which had previously aborted as a result of experimental infection with
the S26 / 3 EAE strain of C. psittaci during pregnancy [Jones et al, 1995] were isolated
and kept at the MRI animal facilities. Adult ewes which were seronegative by CFT
for C. psittaci S26/3 and had no previous record of EAE were also isolated and
kept at MRI animal facilities for use as controls.
Whole peripheral blood, drawn from the jugular vein, was collected in 20 ml
vacutainers coated with preservative-free heparin (Becton Dickinson, Oxnard,
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USA). The blood was transferred into sterile 25 ml universal tube (Bibby Sterilin,
Stone, UK) and centrifuged at 800 g for 20 minutes at 10°C with the centrifuge brake
mechanism disabled. The resultant buffycoats, containing the peripheral blood
mononuclear cells (PBM), were removed and diluted in cold (4°C) PBM wash
medium (HBSS supplemented with 2% FBS, 100 jug/ml gentamicin sulphate and 10
IU/ml Heparin). The buffycoat suspension was layered onto Lymphoprep: specific
gravity 1.077 g/1 (Nycorned, Oslo, Norway) and centrifuged at 800 g for 30
minutes at 10°C with the centrifuge brake mechanism disabled. The interface was
collected, washed three times with PBM wash medium and counted using a
haematocytometer before resuspending the cells at 2X106 viable cells/ml in
IMDM supplemented with 10% FBS, 25 jug/ml gentamicin sulphate (PBM Culture
medium).
2.1.8. C. psittaci S26/3
Tissue culture-derived stocks of the S26/3 ovine abortion strain of C. psittaci
[McClenaghan et al, 1984] were obtained by incubating confluent ST.6 cultures in
225 cm2 vented tissue culture flasks for 6 hours with 8 ml of IMDM+5% FBS
containing 2xl07 inclusion forming units (IFU) of C. psittaci grown in chicken egg yolk
sacs [Stamp et al, 1950]. Chlamydiae were harvested after 5 days by disrupting the
ST.6 cells with 3 mm diameter sterile glass beads. The resultant suspension was
centrifuged at 500 g for 10 minutes to remove debris. Supernatants were collected
and centrifuged at 10000 g for 10 minutes to pellet chlamydiae which were then
resuspended in chlamydial transport medium (Appendix 1.3) and stored at -70°C
[Graham et al, 1995].
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2.2. Phenotypic analysis of primary ovine cells
2.2.1. Flow cytometry
Surface marker expression on ovine BAL cells was characterised using flow
cytometry. Single cell suspensions containing approximately 2x10" cells/ml were
prepared in cold (4°C) fluorescent activated cells sorter medium ( FACS medium;
HBSS supplemented with 0.01% sodium azide (Sigma-Aldrich) and 2% FBS). 50 jul
aliquots of the resultant cell suspensions were added to Nunc V-bottomed 96-well
microtitre plates (GIBCO BRL) and centrifuged for 10 minutes at at 500 g (4 °C).
The supernatant was discarded and the cell pellets were resuspended by gentle
agitation using a benchtop vortex (Fisher Scientific, Loughburgh, UK). Non-specific
antibody binding was blocked by incubating the cells at 4 °C for 20 minutes in FACS
medium supplemented with 2% normal rabbit serum, after which the cells were
centrifuged and washed twice with FACS medium as described before. The cells
were then incubated for 30 minutes at 4 °C with primary antibodies diluted
appropriately in FACS medium. After three washes in FACS medium, cells were
incubated at 4 °C for 30 minutes in 50 fd of rabbit anti-mouse immunoglobulin
conjugated with fluorescein isothiocyanate (rabbit anti-mouse-FITC; DAKO A/S,
Denmark) diluted 1 / 50 in FACS medium. Cells were then washed three more times
with FACS medium, fixed in FACS medium supplemented with 1%
paraformaldehyde (Sigma-Aldrich) and stored in the dark at at 4 °C. Analysis was
performed a using flow cytometer (Facscan; Becton Dickinson, California, USA)
with linear amplification for forward/side scatter and logarithmic amplification for
FITC green fluorescence. Events were gated to exclude erythrocytes and dead cells
on the basis of forward and side scatter.
2.2.2. Non-specific esterase staining of adherent BAL cells
Ovine BAL cells were adjusted to 2xl06 cells/ml in IMDM supplemented with 10 %
FBS and 25 jug/ml gentamicin sulphate. 300 iul aliquots of the resultant cell
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suspension were seeded into 8-well Permanox chamber-slides (Fisher Scientific) and
incubated for 6 hours under standard cell culture conditions. Non-adherent cells
were discarded and the adherent cells were washed once in IMDM+10% FBS. Non¬
specific esterase activity was determined using a commercially available kit
following the procedure described by the manufacturer (a-napthyl acetate esterase
assay; Sigma-Aldrich). The percentage of a-napthyl acetate esterase positive cells
was determined using image analysis.
2.2.3. Phagocytic characterisation of adherent BAL cells
Ovine BAL cells were adjusted to 1x10° cells/ml in IMDM supplemented with 10 %
FBS and 25 Mg/ml gentamicin sulphate. 300 |ul aliquots of the resultant cell
suspension were seeded into 8-well Permanox chamber-slides and incubated for 6
hours under standard cell culture conditions. Non-adherent cells were discarded
and the culture medium was replaced with 300 jul of IMDM+10% FBS containing
lXlO7 latex beads/ml (3 jum diameter; Sigma-Aldrich). After a further 12 hours
chamber-slides were fixed in absolute methanol (Fisher Scientific) and stained with
0.5% Methyl blue (Sigma-Aldrich) in deionised water for 2 minutes and the
percentage of cells containing latex beads was determined using image analysis.
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2.3. Recombinant ruminant cytokines
2.3.1. Recombinant ovine IFN-y
Ovine IFN-y cDNA was originally cloned using the polymerase chain reaction
[Mclnnes et al, 1990]. Chinese Hamster Ovary (CHO) cells which had been stably
transfected with OvIFN-y cDNA inserted into the pEE14 mammalian expression
plasmid vector (Celltech, Slough, UK) were maintained in antibiotic-free Glasgow's
Modified Eagle's Medium without glutamine (GMEM; GIBCO BRL) supplemented
with 7.5% dialysed FBS and 100 fiM methionine sulphoxamine (MSX; Sigma-
Aldrich). The pEE14 expression vector contains a glutamine synthase gene as a
selection marker which allows transfected clones to grow in glutamine free medium
in the presence of low levels of MSX.
Recombinant OvIFN-y (ROvIFN-y) was produced by, washing the transfected CHO
cell monolayers with PBS to remove MSX and FBS, then incubating cultures in
serum-free GMEM in the absence of MSX for 4 days. Culture supernatants were
harvested, centrifuged for 10 minutes at 500 g to remove cell debris and passed
through a sterile low protein binding 0.22 |um filter unit (Millipore, Bedford, USA).
Supernatants were aliquoted into 1 ml volumes and stored in sterile 1.5 ml
microcentrifuge tubes (Coming Costar) at -70°C before being assayed for biological
activity.
2.3.2. Recombinant bovine IFN-a
Recombinant bovine interferon-alpha (RBovIFN-a) was kindly donated by CIBA-
GEIGY (CIBA-GEIGY, Switzerland).
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2.3.3. Ovine anti-viral interferon bioassay
The biological activity of rOvIFN-y and RBovIFN-a were measured using an ovine
interferon bioassay [Entrican et al, 1989, 1992]. ST.6 cells were suspended in IMDM
+ 5% FBS at a density of 5X104 cells/ml, seeded in volumes of 100 gl into 96-well
flat-bottomed microtitre plates (Corning Costar) and allowed to grow for two days.
Log2 serial dilutions of samples to be tested were prepared in IMDM + 2% FBS.
Plates were incubated for 12 hours with triplicate 100 jul aliquots of each dilution.
Culture supernatants were discarded from the plates and replaced with 200 gl of
IMDM + 2% FBS containing 100 TCID50 of SFV (a kind gift from Dr Alan Morris,
Warwick, UK). After a further 48 hour incubation the plates were examined for
cytopathic effect (CPE) induced by SFV. One unit of interferon biological activity
was defined as the maximum dilution of sample capable of inhibiting the CPE of
SFV by 50%. The activity of the original samples were extrapolated from the
dilution corresponding to 1 U/ml.
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2.4. Histology and imaging
2.4.1. Cytospins
100 jul aliquots of cell suspensions, adjusted to a density of between 1X105 and
2X105 cells/ml, were centrifuged onto glass slides at 90 g for 5 minutes using a
Cytospin 3 cytocentrifuge (Shandon Scientific, Runcorn, UK) after which the slides
were allowed to air dry before fixation and staining.
2.4.2. Modified Ziehl Neelsen's (MZN) Stain
ST.6 cultures were fixed in absolute methanol for 15 minutes, air dried and
incubated at 60°C with 2% Ziehl Neelsen's carbo fuchsin (Pro-Lab Diagnostics,
Neston, UK) for 1 hour, washed thoroughly in tap water, and destained in 1%
acetic acid for 4 seconds. Cells were then counter-stained with 0.5% Methyl blue in
1% acetic acid (Fisher Scientific) in deionised water, washed thoroughly in tap
water and allowed to air dry.
2.4.3. Giemsa Stain
ST.6 cultures and cytocentrifuge preparations were fixed in absolute methanol for
15 minutes, air dried and incubated in a solution of 10% Giemsa's improved R66
stain (BDH Chemicals) in deionised water for 45 minutes at room temperature (RT).
Cultures that had been maintained in 96-well flat-bottomed microtitre plates were
washed in tap water and air dried. Slides were washed in tap water, dehydrated in
graded ethanol, cleared in xylene and mounted with coverslips using Shandon's
synthetic mountant (Shandon Scientific).
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2.4.4. C. psittacispecific immunoperoxidase (IPX) staining
Ovine bronchoalveolar macrophages which had previously been maintained in 8-
well Permanox chamber slides were fixed for 15 minutes in absolute methanol and
allowed to air dry. Non-specific antibody binding was blocked by incubating wells
at 37 °C for 60 minutes with 200 jul of normal rabbit serum diluted 1/50 in PBST-
BSA (PBS containing 0.05% Tween 20 (Sigma-Aldrich, UK) and 3% bovine serum
albumin (BSA; Sigma-Aldrich)). The wells were then washed three times in PBST-
BSA and incubated at 37 °C for 60 minutes with 200 /ul of anti-C. psittaci MOMP
monoclonal antibody (Mab) 4/11 (MRI) diluted appropriately in PBST-BSA. The
optimal working concentration of Mab 4/11 ascites (typically 1/50) was
determined by titration on ST.6 cells infected with C. psittaci prior to use. Wells were
washed a further three times in PBST-BSA and incubated at RT for 10 minutes in
PBST-BSA containing 3% hydrogen peroxide (H202; Sigma-Aldrich) to block
endogenous peroxidase activity. After three more washes with PBST-BSA, wells
were incubated at 37 °C for 60 minutes in the presence of 200 jul of goat anti-mouse
Mab conjugated to horse radish peroxidase (goat anti-mouse-HRP; DAKO A/S)
diluted 1/500 in PBST-BSA. Wells were washed a final three times with PBST-BSA
and then incubated for 30 minutes at 37 °C with 180 pi of 3, 3'-Diaminobenzidine
Tetrahydrochloride (DAB) substrate prepared using SIGMA FAST tablets as
instructed by the manufacturer (Sigma-Aldrich). At this stage, the chamber slide
well housings and gaskets were discarded and the slides were washed thoroughly in
tap water. Slides were then counterstained for 2 minutes in Meyer's hematoxylin
(Sigma-Aldrich), washed in tap water, dehydrated in graded ethanol and cleared in
xylene. Permanox slides were not mounted with coverslips.
2.4.5. Image Acquisition and Storage
Images were acquired with a JVC KY-F30 3 charge coupled device (CCD) camera
module attached to a Olympus BH2-RFCA conventional compound microscope
(Olympus Optical CO, London, UK). Live 24-bit red, green and blue (RGB)
European television standard (PAL) video was digitised using a Video Desk HR-24
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NuBus card mounted in a Power Macintosh 7100/ 66 fitted with 16 megabytes (MB)
of random access memory (RAM), running System 7.5.3 (Apple Computer,
California, USA) and ColourVision 1.5 (Improvision, University ofWarwick Science
Park, UK). Colour images were captured in ColourVision at a resolution of 700 x
572 pixels and stored as 24-bit colour Tag Image File Format (TIFF) files on one
gigabyte (1GB) Jaz Disks (Iomega Corporation, Utah, USA).
Images were also acquired with a JVC TK-1280E single CCD colour camera module
attached to a Olympus BX-50 conventional compound microscope (Olympus
Optical CO). Live 24-bit super-VHS colour PAL video was digitised using the
standard AV digitiser mounted in a Power Macintosh 7100/80 AV (Apple
Computer) fitted with 80 MB RAM, running Mac OS 8.1 (Apple Computer) and
NIH Image 1.61 [Rasband and Bright, 1995], NIH Image is a public domain software
package developed at the U.S. National Institute of Health and is available from
the internet by anonymous FTP from zippy.nimh.nih.gov/pub/NIH Image/ or on
floppy disk from the national Technical Information Service, Springfield, Virginia,
part number PB95-500195GEI. Colour images were captured in NIH Image 1.61
using Plug-in Digitiser vl.2.4 (Cyrus Daboo, Cambridge, UK) at a resolution of 752
x 576 pixels and stored as 24-bit colour TIFF files on 1GB Jaz Disks.
2.4.6. Image Processing
Images were processed on a Power Macintosh Performa 6320 fitted with 48 MB
RAM running Mac OS 8.1 (Apple Computer) or a Power Macintosh 7100/80 AV
fitted with 80 MB RAM, running Mac OS 8.1. Standard image analysis procedures
such as cell counting and scoring were performed using Object Image 1.62n6 [Vischer
et al, 1994]. Object Image is a public domain software package, based on NIH
Image, developed by Norbert Vischer (Universiteit van Amsterdam, Amsterdam,
The Netherlands) and is available from the internet by anonymous FTP from
ftp: / / simon.bio.uva.nl/object-Image.html.
Software for the automated measurement of chlamydial inclusion bodies, Inclusion
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Counter vl.O , was developed using NIH Image 1.61 [Rasband and Bright, 1995]
(ftp: / /codon.nih.gov/pub/nih-image/user-macros/inclusion_counter.hqx).
Updated versions, Inclusion Counter v2.0 (ftp:/ / codon.nih.gov/pub/nih-
image/user-macros/inclusion_counterv2.sit.hqx), were developed in Object Image
1.62n6 [Vischer et al, 1994].
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2.5. Measurement of C. psittacimultiplication
2.5.1. Chlamydial LPS-ELISA
The concentration of lipopolysaccharide (LPS) in experimental culture supernatants
was determined using an ELISA. The anti-LPS Mab 13/4 was produced as ascites
and titrated to determine the optimal concentration for use in the ELISA. Flat-
bottomed F-type 96-well ELISA plates (Dynatech, UK) were coated over night at
4°C with 100 iul of Mab 13/4 diluted in pH 9.6 carbonate coating buffer (Appendix
1.4). Plates were emptied, washed three times with PBST (PBS containing 0.05%
Tween 20) and blotted dry. Plates were blocked with 200 ^1/well of donor horse
serum (Northumbria Biologicals, Cramlington, UK) diluted 1/5 in pH 9.6 carbonate
coating buffer for one hour at 37°C. Plates were washed three times with PBST,
after which 100 ^1 aliquots of samples were added to each well in triplicate.
Duplicate log2 serial dilutions of S. minnesota RE-595 LPS (Sigma-Aldrich) were
used as standards. Plates were incubated at 37°C for one hour and then washed
three times in PBST and blotted dry as before. 100 jiri of affinity purified 13/4 Mab
conjugated to horse radish peroxidase (13/4-HRP) diluted in PBST to
approximately 50 jug/ml, was added to each well after which the plates were
incubated for one hour at 37°C. Plates were washed and blotted dry as before after
which substrate was added. Two different substrates were used:
1; Plates were incubated for 10 minutes at RT in the presence of 100 jul/well of
Sigma Fast o-phenylenediamine dihydrochloride substrate (OPD; Sigma-Aldrich).
The reaction was stopped using 50 u\/well of 2.5 M sulphuric acid (Fisher
Scientific). Optical density (OD) was measured with a Titretec Multiscan ELISA
Reader (Flow, HighWycombe, UK) using an absorbance filter of 492 nm.
2; Plates were incubated at RT in the presence of 100 ^1/well of
Tetramethylbenzidine (TMB; Kirkegaard & Perry Laboratories, Maryland, USA)
and the reaction was stopped using 0.1 M Hydrochloric acid (Fisher Scientific). OD
was measured with a Titretec Multiscan ELISA Reader using an absorbance filter of
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450 nm.
2.5.2. Titration of chlamydial infectivity
The infectivity of C. psittaci stocks and experimental culture supernatants was
determined by titration on confluent monolayers of ST.6 cells in 96-well flat-
bottomed microtitre plates. Culture supernatants were discarded from plates and
100 jul of serial dilutions (log2 or log10) in IMDM+2% FBS, were added in triplicate.
The plates were incubated for two days, after which the cell monolayers were fixed
and stained using the Giemsa or Modified Ziehl Neelsen's methods. The total
number of inclusion bodies in each well was counted by eye with the aid of an 16
mm eye-piece graticule (Graticules, Tonebridge, UK) over a range of dilutions and
the number of inclusion-forming units/ml (IFU/ml) was determined by
extrapolation for each sample.
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2.6. Recombinant MOMP
2.6.1. Production of recombinant MOMP in Escherichia coli
The MOMP gene of the S26/3 strain of C. psittaci was originally cloned and
sequenced by Herring et al (1989). The coding region for the C-terminal 351 amino
acids of S26/3 MOMP was transfected into E. coli using the pET-22b vector
(Novangen: Calbiochem-Novabiochem UK Ltd, Nottingham, UK). On induction
with Isopropyl-(3-thiogalactopyranoside (IPTG; Bioline, London, UK), the construct
produces large quantities of a truncated protein lacking the first 16 amino acids of
S26/3 MOMP (TMOMP) which accumulate as inclusion bodies inside transfected
E. coli [Herring et al, 1998].
Stably transfected E. coli were stored at -70°C in L-broth (Appendix 1.5)
supplemented with 30% glycerol (Fisher Scientific) in 1 ml Nunc Cryo Tubes. A
sample of E. coli was removed from storage and streaked onto solid L-agar gel
(Appendix 1.6) to form single colony isolates using a nichrome wire inoculating loop
(Fisher Scientific). After incubation overnight at 37°C, a single colony was removed
using a nichrome wire inoculating loop and suspended in 20 ml of L-broth
supplemented with 100 gg/ml of ampicillin (Sigma-Aldrich) in a glass conical flask.
The flask was then incubated in an Aerotron shaking incubator (Fisher Scientific) at
37°C. After 6 hours, the flask was removed and stored at 4°C over night. The flask
was removed from storage and mixed by gentle agitation. 16 ml of the E. coli
suspension were withdraw and centrifuged at 5000 g for 15 minutes. The pellet was
resuspend in 2 ml of L-Broth and 0.8 ml of cell suspension was added to each of
two 400 ml of prewarmed L-Broth supplemented with 100|Ug/ml of ampicillin in 2
litre conical flasks in the Aerotron at 37°C. Samples were periodically removed and
the OD of the E. coli suspension was measured using a spectrophotometer (Fisher
Scientific). When the £. coli suspension reached an OD of 0.6, IPTG was added to
each flask to give a final concentration of 1 mM. The cultures were grown for a
further 3 hrs, after which they were centrifuged at 5000 g for 15 minutes,
resuspended in 100 ml of PBS, centrifuged for a further 15 minutes at 5000 g and
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stored as a pellet over night at 4°C. The pellet was resuspended and incubated for
30 minutes at RT in 100 ml of pH 8.0 Tris (Hydroxymethyl) aminomethane/HCL
buffer (Tris-HCL; Sigma-Aldrich) supplemented with 0.5 mM EDTA (Sigma-
Aldrich), 1 M sucrose (Sigma-Aldrich) and 120 ug/ml of chicken egg white lysozyme
(Calbiochem, Nottingham, UK). The suspension was then centrifuged at 25 000 g for
10 minutes. The pellet was resuspended in 50 ml of pH 8.0 Tris buffer containing
with 0.5 mM EDTA and 1 M sucrose and centrifuged at 25 000 g for a further 10
minutes. The cells were resuspended in 50 ml Tris supplemented with 0.5 mM
EDTA and sonicated with an W385 ultrasonic processor (Jencons Scientific,
Leighton Buzzard, UK) 6 times for 15 seconds on ice with one minute standing in
between. The product was centrifuged at 6000 g for 15 minutes and resuspended in
40 ml of sterile PBS three times, after which the pellet was resuspended in 8 ml of
sterile PBS.
The presence of TMOMP in the sample was confirmed by using a direct dot-
immunobinding technique. The concentration and purity of TMOMP in the product
was determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and ID gel densitometery. The product was adjusted to 10 mg /ml of
TMOMP in PBS and stored at -20°C in 200 jul aliquots.
2.6.2. Direct dot-immunobinding assay for TMOMP
TMOMP samples were spotted directly onto a nitrocellulose membrane in duplicate
and allowed to air dry. Non-specific antibody binding was blocked by incubating
the nitrocellulose membrane at 37 °C for 60 minutes with normal rabbit serum
diluted 1/50 in PBST-BSA. The nitrocellulose membrane was then washed three
times in PBST-BSA. One of the duplicate spots was incubated at 37 °C for 30
minutes with the Mab 4/11. The nitrocellulose membrane was washed three more
times in PBST-BSA, after which both duplicates were incubated for 30 minutes at
37 °C in the presence of goat anti-mouse-HRP diluted 1/1000 in PBST-BSA. The
nitrocellulose membrane was washed three more times with PBST-BSA and then
incubated for 10 minutes at 37 °C with DAB substrate. Specific binding of Mab
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4/11 to TMOMP in the sample was confirmed by macroscopic examination.
2.6.3. Polyacrylamide gel chromatography
TMOMP was purified for use in cell culture using a conventional adjustable bed
column (Isco, Nebraska, USA) filled with Bio-Gel P-60 polyacrylamide gel: 45-90
jum hydrated particle size; with an exclusion limit of 3 - 60 KDa (Bio-Gel P-60, Bio-
Rad Laboratories Laboratories, Hemel Hempstead, UK). 18 g of anhydrous Bio-Gel
P-60 was weighed out into a 2.5 1 Conical Buchner flask. 360 ml of degassed
deionised water was added to the flask gradually with continuous mixing to ensure
that a uniform suspension of was formed. The gel was allowed to hydrate and settle
out of suspension overnight. Approximately half the supernatant was decanted off
and the side arm of the flask attached to a vacuum pump. The flask was sealed and
the contents degassed under 100 mBars of pressure for 20 minutes at RT. A further
360 ml of degassed deionised water was added and mixed with the gel. The flask
was allowed to stand at RT for 2 hours or until >95% of the gel particles had settled
out of suspension, at which point, approximately 80% of the supernatant was was
decanted off and discarded. This process was repeated three times to remove all
the fine particles. A 250 ml reservoir was attached to top of the column. In order to
void any air bubbles from the lower outlet tubbing, the column was filled with
degassed deionised water and the lower column outlet opened until the water fell to
approximately 20% of the column height. Hydrated gel was then added until it
filled the column and over half the reservoir. Degassed distilled water was layered
on top of the gel, the lower outlet was opened and the column was left overnight to
pack. A P-3 peristaltic pump (Fisher Scientific) was attached to the lower outlet of
the column and run in reverse for a few seconds to void any air bubbles, after which
the lower outlet was closed. The upper reservoir was removed and a flow adapter
(Isco) was inserted into the top of the column down to the level of the flow bed. A
one litre reservoir of column buffer (degassed 40 mM Phosphate buffer (Appendix
1.7) containing 0.1% sodium dodecyl sulfate-polyacrylamide (SDS; Sigma-Aldrich))
was prepared and attached to to lower outlet of the column. 360 ml of column
buffer was passed through the column over 96 hours at a operating flow rate of 3.8
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ml/hour. After this period, the reservoir was replenished with column buffer.
2.6.4. Purification of Recombinant TMOMP
Two mg of TMOMP suspended in 200 /ft of PBS were diluted with 800/ul of 40 mM
Phosphate Buffer containing 2% SDS and 5% 2-mercaptoethanol (ICN Biomedicals,
Basingstoke, Hampshire, UK) in a 1.5 ml micro centrifuge tube. A small perforation
was made in the cap of the micro centrifuge tube before it was closed and incubated
in a water bath at 100°C for 5 minutes to dissolve the TMOMP. The resultant
solution was allowed to cool to RT before it was loaded onto the Bio-Gel P-60
column. The peristaltic pump attached to the column was stopped and the lower
column outlet removed from the column buffer reservoir. The pump was reversed for
a few seconds to void air bubbles and the lower outlet tubing was carefully placed
into the micro centrifuge tube containing the TMOMP solution. The pump was
allowed to draw up the TMOMP solution until the first air bubble appeared in the
tubing. At this point the pump was stopped and the end of the lower outlet tubing
which had been in contact with the TMOMP solution was gently washed with
column buffer to avoid contamination of the buffer reservoir. The outlet was then
placed into a second microfuge tube containing column buffer, reversed briefly to
void air bubbles and allowed to draw up approximately 0.5 ml of column buffer.
The pump was then stopped and inserted into the buffer reservoir, again briefly
reversing the pump to void any air bubbles. The pump was switched to forward
and the lower outlet tubing securely fixed in the buffer reservoir. The upper outlet of
the column was attached to a fraction collector (Isco) set to collect one fraction ever
hour in 5 ml sample tubes (Corning Costar). The flow rate of the pump was set to
3.4 ml /hour and the column was run for 36 hours.
The protein content of the fractions was estimated using a Beckman DU 650
Spectrophotometer (Beckman Instruments, California, USA) at an absorbance of
260 nm. The two fractions with the highest absorbance values were mixed and
concentrated by centrifugation at 5000 g for 20 minutes in Centricon-30
concentrators: <30 KDa exclusion limit (Amicon, Stonehouse, UK). This was done
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repeatedly with 2 ml aliquots until the TMOMP had been concentrated to a volume
of approximately 500 jul. The concentration of TMOMP was estimated by SDS-
PAGE and ID gel densitometery.
2.6.5. SDS-PAGE
SDS-PAGE was used to confirm the molecular weight and amount of TMOMP
present in samples prepared using the E. coli system outlined above. SDS-PAGE
was performed using the Mini-PROTEAN® II electrophoresis system (Bio-Rad
Laboratories Laboratories). Gels were hand cast as follows. Approximately 4 ml of
12% acrylamide resolving gel (Appendix 1.8) was added to each cast and 75 %
ethanol (Fisher Scientific) was then layered on top of the resolving gel to void any
air bubbles. Once the resolving gel had set, the ethanol was decanted off and
allowed to evaporate. The cast was then topped up with 4% acrylamide stacking
gel (Appendix 1.9), and a Teflon comb (Bio-Rad Laboratories) was used to make
the loading wells and the gel allowed to polymerise.
After polymerisation, gels were transferred into a Mini-PROTEAN® II
electrophoresis tank and electrode buffer (Appendix 1.10) was added to the inner
and outer cells. TMOMP samples and standards (2.5 jug, 7.5, jug and 15 jug) were
heated to 100°C for five minutes diluted 1:1 in sample buffer (Appendix 1.11)
before loading onto gels along with medium range molecular weight markers (Sigma-
Aldrich) diluted 1:1 in sample buffer. Gels were electrophoresed at 200 mV and 70
rnA for 45 minutes or until the bromophenol blue in the sample buffer passed the
end of the gel matrix. The gels were carefully removed and stained with Coomassie
Blue (Sigma-Aldrich) for five minutes, after which they were destained over night in
acid-alcohol (Appendix 1.12) and imaged using a flatbed gel-scanner (Bio-Rad
Laboratories).
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2.6.6. ID gel densitometery
The protein concentration in SDS-PAGE bands was estimated by densitometery
using the software package Molecular Analyst/PC (Bio-Rad Laboratories). Briefly,
the OD of the TMOMP standards were used to generate a standard curve from
which the amount of TMOMP present in the samples was extrapolated. TMOMP
samples were then diluted to 2 mg/ml in column buffer, filter sterilised and stored
in 200jul aliquots at -70°C. The molecular weight of the product was compared
against the molecular weight standards.
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2.7. Lymphocyte stimulation assay
Antigens and mitogens were added to the central 60 wells of Nunc 96-well round
bottomed microtitre plates (GIBCO BRL) diluted in 100 jul volumes of PBM culture
medium. In the case of TMOMP, which was insoluble at the low concentrations of
SDS required for cell culture, volumes of 0.5 - 2 jd of 1 mg/ml TMOMP in 40 mM
Phosphate buffer + 0.1% SDS were added directly to the bottom of empty wells
before being made up to 100 jul with PBM culture medium. 100 jul/well of ovine
PBM at a density of 2X106 viable cells/ml in PBM culture medium were then added
to plates and cultured for 3 days. 50 /ul of PBM culture medium containing 100 nmol
of 3H-thymidine with a specific activity of 185Gbq/mmol (Amersham Pharmacia
Biotech UK, Little Chalfont, UK) were added to each well and the culture incubated
for a further 16 hours. Cultures were then harvested onto glass fibre filters (Packard
Instruments B. V. Chemical Operations, Groningen, The Netherlands) using a
Micromate 196 Harvester (Packard Instruments, Pangbourne, UK). Wells were then
washed with deionised water and harvested a further three times. The filters were
allowed to dry before the cell associated radioactivity (Counts per minute: CPM)
was measured using a MATRIX Direct (1 Counter 96 (Packard Instruments).
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Chapter 3.0
Initial feasibility studies and development of an
automated image analysis solution for measuring
chlamydial growth in vitro
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3.1. Introduction
Much of the work published on anti-chlamydial pharmaceuticals and immune
mechanisms has been heavily dependent on the accurate measurement of chlamydial
growth in vitro. Traditionally, enumeration of chlamydial inclusion bodies by eye
has been the most common method ofmeasuring chlamydial growth in vitro and it is
still widely used today [Kane and Byrne, 1998; Mehta et al, 1998; Pudjiatmoko et al,
1998; Roblin and Hammerschlag, 1998; Ramsey et al, 1998; Su and Caldwell, 1998].
However, there are several drawbacks to measuring chlamydial growth in this way.
Considerable amounts of time must be set aside for counting inclusions, and without
the implementation of double blind counting systems, results are open to subjective
error. In addition, measurement of secondary parameters of chlamydial growth such
as host cell lysis and inclusion size are so time consuming that they are usually
ignored or only speculated upon.
Procedures for staining inclusions vary widely, but cultures are typically fixed at 48-
72 hours after infection to ensure that any inclusion bodies present can be resolved
by light microscopy. Chlamydiae can be differentiated from cellular background
using a number of vital dyes. These include: Giemsa [Johnson, 1975]; Ziehl Neelsen's
Carbo fuchsin [Stamp et al, 1950]; methylene blue [Johnson et al, 1978]; and
toluidine blue [Mohammed and Hillary, 1984]. Alternatively, infected cells can be
probed with anti-chlamydial monoclonal or polyclonal antibodies which in turn can
be labelled by antibodies conjugated to fluorochromes or enzymes allowing
inclusions to be differentiated from cellular background on the basis of deposition of
insoluble coloured product or fluorescence.
Whilst the technology to automate the measurement and enumeration of chlamydial
inclusion bodies has existed for some time, it has not as yet been implemented. The
requirement for an rapid, easy to use and accurate replacement for counting and
measurement of chlamydial inclusion bodies by eye, precipitated the development
of a suite of NIH Image based macros, Inclusion Counter vl.O. This chapter
describes the development and evaluation of Inclusion Counter vl.O.
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3.2. Materials and Methods
3.2.1 Preparation of cells and chlamydiae for imaging
100 nl aliquots of ST.6 cells were seeded into a 96-well flat-bottomed microtitre
plate at a concentration of 5xl04 cells/ml in IMDM+5% FBS and propagated under
standard conditions (Chapter 2.1.1.). C. psittaci (ovine abortion strain S26/3) was
removed from storage at -70°C (Chapter 2.1.8.) and diluted in IMDM+2% FBS to
give a final concentration of 2xl05 IFU/ml. The resultant suspension of chlamydiae
was diluted a further 8 times at a ratio of 1:1 in IMDM+2% FBS to give a total of 9
Log2 serial dilutions of S26/3 C. psittaci (Table 3.1).











After 48 hours the supernatants of the ST.6 cultures were discarded. 100 p\ aliquots
of IMDM+2% FBS were added to the outermost wells of the plate and to all the
wells in column 11. Six replicates of 100 p\ of each dilution of S26/ 3 C. psittaci were
added to the remaining wells. Cultures were incubated under standard conditions
(Chapter 2.1.1.) for 6 hours, after which the supernatants were discarded and
replaced with 200 p\ of IMDM+2% FBS. The cultures were then incubated for a
further 66 hours, after which they were fixed and stained with MZN by the




200 24-bit RGB colour images were acquired at a magnification of Xl25 following
the procedure described in Chapter 2.4.5. During acquisition the images were
automatically saved with a sequentially numbered suffix in the following format:
image.0001; image.0002 .... image.0200.
3.2.3 Manual image analysis of C. psittaci inclusion bodies
Five images were selected for preliminary image analysis to determine which of the
morphological features of chlamydial inclusion bodies could be used as the basis of
an automated system for their enumeration and measurement. Each 24-bit colour
TIFF image was opened in NIH Image 1.61 [Rasband and Bright, 1995] as a stack of
three greyscale images (RGB stack), each image in the stack representing one of the
Red (Figure 3.1B), Green (Figure 3.1C) and Blue colour (Figure 3.1D) channels. An
indexed colour image was then automatically created from the RGB stack using NIH
Image's custom 256 colour palette. The entire image was outlined using the
rectangular selection tool to create a region of interest (ROI) that excluded any
spurious data produced by the frame grabber along edges of the image. Using NIH
Image's histogram function, pixel greylevel values were plotted against frequency for
each colour channel of all five images.
In the Indexed colour image, inclusion bodies were manually outlined using the
freehand selection tool. After outlining each inclusion body, the outline was
transposed to the RGB stack using the Restore Selection command. The area, mean
greylevel value, Standard deviation from the mean greylevel value and roundness of
each inclusion was then measured for each channel in the RGB stack. The results of
these measurements were used as the basis for the design of Inclusion Counter vl.0.
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3.2.4 Automated enumeration and measurement of inclusions
Inclusion Counter vl.O, a suite of macros written for NIH Image 1.61, was designed
and developed for counting and measuring chlamydial inclusion bodies in cell
culture. The result generated by Inclusion Counter vl.O were compared for accuracy
against results generated by manually measuring inclusions in 200 images.
3.2.5 Semi-automated measurement of C. psittaci inclusion bodies
A semi-automated system was designed and used to assign definitive and verifiable
values for the number of inclusions, mean inclusion area and total area occupied by
inclusions to each of the 200 digital images.
3.2.6 Statistical Analysis




3.3.1 Chlamydial growth and image acquisition
S26/3 C. psittaci EBs were titrated onto ST.6 cultures previously grown to
confluence in a 96-well flat-bottomed microtitre plate. The concentration range of
EBs used to infect the ST.6 cultures resulted in a logarithmic (Log2) distribution of
inclusion bodies across the plate, allowing acquisition of images containing a broad
range of inclusion numbers. After the cultures had been stained and air dried, the
96-well flat-bottomed microtitre plate was inverted and imaged at a magnification
of xl25 using a conventional compound microscope. In general the specificity of the
MZN stain was acceptable, although there were some notable exceptions. Some of
the smaller inclusions stained poorly (Figure 3.1A; inclusion bodies #9 and #10) and
in some cases cellular debris stained positively with MZN (Figure 3.1A: arrow).
Images were digitised at a resolution of 700x572 pixels and 24-bit colour depth
using a 3-CCD Camera module and a frame grabber mounted in a Power Macintosh
desktop computer. The resultant images were of a high enough quality to be used for
image analysis (Figure 3.1A), despite the fact that they were acquired through
plastic with a conventional objective lens designed for imaging through glass
coverslips.
Cells which had been infected with the highest concentration of EBs were heavily
lysed by 72 hours and were not used for imaging. Four non-overlapping images were
acquired from each well of the remaining infected cultures giving a total of 192
images of cells infected with various numbers of chlamydiae. A further 8 images
were acquired from wells containing uninfected cultures to provide negative
controls.
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Inclusion Bodies are outlined and numbered, artefacts are highighted (arrow).





Figure3.1C: The green channel component of Figure 3.1 A
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3.3.2 Preliminary image analysis
Images of ST.6 cells infected with 26/3 C. were selected for preliminary
analysis on the basis of the following criteria: the intensity and specificity of
staining in selected images should be representative of the entire batch of images;
variations in inclusion body size should also be representative; each image should
contain enough infected cells to allow morphology studies to be performed on a
significant number of inclusion bodies; but the number of inclusion bodies in a
selected image should not be high enough to significantly influence the overall pixel
frequency/greylevel value histogram in any of the colour channels of the image. A
typical example image is shown in Figure 3.1.
Table 3.2
Inclusion AREA Roundness MEAN Standard MEAN Standard MEAN Standard
Body # /pixels Greylevel deviation Greylevel deviation Greylevel deviation













1 1103 0.2375 135 25 185 28 132 32
2 563 0.2251 110 22 150 25 94 19
3 535 0.2913 124 14 191 15 141 14
4 601 0.2908 152 12 193 10 146 14
5 1221 0.1679 122 22 173 28 130 26
6 253 0.2252 108 17 153 23 114 16
7 117 0.5871 125 17 176 19 130 18
8 121 0.5141 133 15 181 16 130 25
9 13 0.7786 99 7 123 9 81 9
10 88 0.2851 95 10 127 13 87 11
Mean
Value 462 0.3603 120 16 165 19 118 18
Std. Dev.
from mean 427 0.1983 18 6 26 7 23 7
Minimum
Threshold N.A. N.A. 85 5 114 5 72 4
Maximum
Threshold N.A. N.A. 156 27 216 33 165 33
Minimum
Value 13 0.1679 95 7 123 9 81 9
Maximum
Value 1221 0.7786 152 25 193 28 146 32
Table 3.2: Results generated by manually outlining and measuring the individual inclusion
bodies in Figure 3.1. Inclusion body number correlates directly to the number assigned to
inclusion bodies in figure 3.1 A.
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Area was calculated using the standard procedure employed by NIH Image. The
number of pixels within a selection, the outline of each inclusion body, were counted
and the results were then converted into real units using a predetermined scaling
factor for the image. In this case assigning real units to the area measurement was
not of interest and the area of inclusion bodies was expressed in pixels, using a
scaling factor of 1. The perimeter of each inclusion body was also measured using
the standard procedure applied by NIH image (data not shown). A number of
approaches to perimeter measurement exist in the literature [Russ, 1998]. NIH image
uses the following approach, perimeter pixels of an object or those pixels which
make up the outline selection of the object are recorded. Corner and non-corner
pixels are defined and the perimeter is then calculated using the following equation:
Perimeter = Pixels Cor„er+ 2 Pixels No-come,
Roundness was then calculated from the area and perimeter values using the
following equation:
4 x tc x Area
Roundness = —
Perimeter
This is one of the most commonly used equations for defining the roundness or
circularity of an object, usually referred to as Formfactor [Russ, 1998], and
produces a value between 0 and 1, where a perfect circle has a value of 1. In this
case, roundness was calculated in NIH image using a custom designed macro.
Alternatively, it can be calculated in a separate spreadsheet application.
The mean greylevel values of the pixels and the standard deviation from the mean
greylevel value within each inclusion body image were calculated for all three colour
channels for each inclusion body. Area values for inclusion bodies varied
significantly, standard deviation from the mean area was almost as large as the
mean area value itself, and the smallest inclusions had area values close to the
resolution of the CCD camera at this level of magnification. Roundness values for
inclusion bodies varied widely. The standard deviation from the mean greylevel
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values within each inclusion body were generally quite low, approximately 10% of
the mean greylevel value of each inclusion body.
The mean and standard deviation from the mean of the mean greylevel values of
each inclusion body was then calculated for the image as a whole. These values were
used to calculate a threshold for the image in each colour channel as follows:
Minimum Threshold = Mean Greylevel Value - 2(Standard Deviations)
and
Maximum Threshold = Mean Greylevel Value + 2(Standard Deviations)
Defining a threshold for the greylevel values of the pixels within an image instructs
the computer to ignore any pixels which fall outside the range of the threshold. The
results of applying the calculated threshold ranges to the images in Figure 3.1 are
shown as insets in Figure 3.2.
Histograms of pixel frequency plotted against the pixel greylevel values were
generated for each colour channel using NIH Images built in histogram function
(Figure 3.2). The overall profile of the histograms did not differ significantly from
the histograms produced for images of uninfected cells (Figures 3.3A and 3.4) and
there was no evidence of a second population of pixels with higher greylevel values
as seen in images of heavily infected cells (Figure 3.3B and 3.5). The calculated
values for the threshold ranges in the green and blue channels produced relatively
crnnd cpompnfafinn rvf inrliicirvn frryrn cellular baclcPTOlirsd fOITlDSr^d to the red
^w w M 1VVL VAV JL A V A AA L^A VAV^AV/A A V V/VIAVU XX VXX 1 WXXAAXtAX KS V U.1 LVi Wll LL/til VVi tV 11 IV X VVI
channel. This was expected since the threshold range in the red channel intruded
into the main peak of the histogram in that channel. However, some components of
the cellular background were segmented with inclusion bodies in both the green and
blue channels. This was particularly obvious when similar threshold ranges
calculated from all five of the images selected for preliminary analysis (Table 3.3)
were applied to images of uninfected cells (Figure 3.4B and Figure 3.4C).
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Table 3.3: Results generated by manually outlining and measuring C. psittaci
inclusion bodies from 5 different images
Inclusion AREA Roundness MEAN Standard MEAN Standard MEAN Standard
Body # /pixels Greylevel deviation Greylevel deviation Greylevel deviation













1 3 0.5890 140 18 187 21 57 14
2 12 0.8507 139 9 197 11 98 14
3 13 0.7786 99 7 123 9 80 8
4 26 0.3620 107 12 119 17 65 14
5 26 0.6325 110 13 141 12 97 8
6 37 0.7457 109 9 128 8 66 16
7 40 0.6239 128 17 159 11 99 14
8 40 0.7089 157 10 194 9 129 10
9 41 0.5493 115 13 158 14 99 8
1 0 44 0.9680 136 14 190 18 99 25
1 1 77 0.3669 101 13 129 17 80 12
1 2 80 0.4437 93 9 119 14 68 10
1 3 87 0.3434 69 7 112 14 68 12
1 4 88 0.2851 95 10 127 13 83 10
1 5 101 0.3615 150 14 186 11 113 12
1 6 115 0.8652 104 15 166 24 97 20
1 7 117 0.5871 125 17 176 19 130 16
1 8 121 0.5141 133 15 181 16 130 24
1 9 128 0.5939 97 12 155 15 81 16
20 142 0.8208 111 15 170 16 99 14
2 1 211 0.4211 118 16 177 17 98 24
22 237 0.4010 113 23 163 31 129 14
23 244 0.4508 117 13 189 21 132 16
24 253 0.2252 108 17 153 23 114 16
25 295 0.3350 140 16 185 16 131 14
26 299 0.1958 131 17 159 21 100 16
27 309 0.6018 117 15 186 13 97 16
28 396 0.3355 123 10 164 12 98 10
29 428 0.3244 116 12 176 20 114 16
30 439 0.4680 106 11 145 23 112 16
31 471 0.6196 161 13 198 14 128 17
32 486 0.3346 97 13 126 17 82 10
33 527 0.4131 135 19 175 24 115 16
34 528 0.5201 123 17 179 25 115 21
35 535 0.2913 124 14 191 15 133 12
36 563 0.2251 110 22 150 25 82 17
37 565 0.3969 146 19 188 19 135 14
38 601 0.2908 152 12 193 10 130 12
39 603 0.2996 134 16 195 18 134 16
40 721 0.2652 126 15 167 21 98 17
41 743 0.5061 119 14 189 10 130 14
42 773 0.2587 102 15 141 18 83 12
43 783 0.4398 123 11 180 16 116 12
44 811 0.2538 81 13 128 24 64 21
45 842 0.5355 147 12 196 13 131 16
46 958 0.2689 124 15 164 26 113 20
47 1037 0.3563 87 12 157 25 98 21
48 1103 0.2375 135 25 185 28 132 29
49 1167 0.4024 159 16 197 14 133 17
50 1221 0.1679 122 22 173 28 130 25
51 1297 0.3747 153 14 192 17 134 16
Mean
Value 408 0.4550 121 14 166 18 105 16
Std. Dev.
from mean 367 0.1924 21 4 25 6 23 5
Minimum
Threshold N.A. N.A. 79 7 116 6 59 7
Maximum
Threshold N.A. N.A. 162 22 217 29 152 25
Minimum
Value 3 0.1679 69 7 112 8 57 8
Maximum
Value 1297 0.9680 161 25 198 31 135 29
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Figure32
A: Pixel frequency plotted against pixel greylevel value for the Red channel of
the image in Figure 3.1 A. The cursor bar represents the threshold range
calculated from the measurements in Table 3.2. The result of applying this
threshold to the image in Figure 3.1B are displayed as a binary image inset in
the top right of the figure.
B: Pixel frequency plotted against pixel greylevel value for the green channel of
the image in Figure 3.1 A. The cursor bar represents the threshold range
calculated from the measurements in Table 3.2. The result of applying this
threshold to the image in Figure 3.1C are displayed as a binary image inset in
the top right of the figure.
C: Pixel frequency plotted against pixel greylevel value for the green channel of
the image in Figure 3.1 A. The cursor bar represents the threshold range
calculated from the measurements in Table 3.2. The result of applying this
threshold to the image in Figure 3.1D are displayed as a binary image inset in
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Figurea3A: Uninfected ST.6 cells
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Figure3.3B: Heavily infected ST.6 cells
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Figure 3.4
A: Pixel frequency plotted against pixel greylevel value for the Red channel of
the image of uninfected cells in Figure 3.3A. The cursor bar represents the
threshold range calculated from the measurements in Table 3.3. The result of
applying this threshold to the red channel component of the image in Figure
3.3A are displayed as a binary image inset in the top right of the figure.
B: Pixel frequency plotted against pixel greylevel value for the green channel of
the image of uninfected cells in Figure 3.3A. The cursor bar represents the
threshold range calculated from the measurements in Table 3.3. The result of
applying this threshold to the green channel component of the image in Figure
3.3A are displayed as a binary image inset in the top right of the figure.
C: Pixel frequency plotted against pixel greylevel value for the blue channel of
the image of uninfected cells in Figure 3.3A. The cursor bar represents the
threshold range calculated from the measurements in Table 3.3. The result of
applying this threshold to the blue channel component of the image in Figure
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A: Pixel frequency plotted against pixel greylevel value for the Red channel of
the image of heavily infected cells in Figure 3.3B. The cursor bar represents the
threshold range calculated from the measurements in Table 3.3. The result of
applying this threshold to the red channel component of the image in Figure
3.3B are displayed as a binary image inset in the top right of the figure.
B: Pixel frequency plotted against pixel greylevel value for the green channel of
the image of heavily infected cells in Figure 3.3B. The cursor bar represents the
threshold range calculated from the measurements in Table 3.3. The result of
applying this threshold to the green channel component of the image in Figure
3.3B are displayed as a binary image inset in the top right of the figure.
C: Pixel frequency plotted against pixel greylevel value for the blue channel of
the image of heavily infected cells in Figure 3.3B. The cursor bar represents the
threshold range calculated from the measurements in Table 3.3. The result of
applying this threshold to the blue channel component of the image in Figure
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It was obvious from the preliminary analysis that further processing of the images
was required to achieve optimal segmentation of inclusion bodies from cellular
background. A number of approaches were pursued to this end. The first was to
further examine the colour channel distribution of the inclusion bodies and the
cellular background. Dissection of a standard colour wheel into its red, green and
blue components is shown in figure 3.6. In the case of the MZN stain used here, the
colour of the inclusion bodies was best described by their green channel component
(Figure 3.6B). The purple-blue colour of the cellular back ground showed up best in
the the red channel (Figure 3.6A) but also contained a significant green channel
(Figure 3.6B) component. It was necessary to strike a balance between the channel in
which the greylevel value of the inclusion bodies was highest and the channel in
which the greylevel value of the cellular background lowest.
Figure 3.6A: Red channel component of figure 3.6D. B: Green channel component of figure
3.6D. C: Blue channel component of figure 3.6D. D: The original RGB image
Figure 3.6: A standard colour wheel
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The highest contrast between inclusion bodies and the cellular back ground (Figure
3.7) was achieved by averaging the green (Figure 3.IB) and blue channels (Figure
3.1C).
Figure3.7: The result of averaging the green and blue channels of the image in
Figure 3.1 A
A number of different background subtraction techniques were examined with
respect to improving the segmentation of inclusion bodies from the cellular
background. The standard approach to correcting images for a variation in light
levels resulting from defects in the optical quality of the microscope or CCD camera
used for acquisition of the images is simply to subtract an image of the background,
in this case an empty well from a 96-well flat-bottomed microtitre plate, from the
images which require correction [Russ, 1998], The problems associated with
segmenting inclusion bodies from cellular background, encountered here, arose from
irregularities in the optical quality of individual wells and from differences in the
growth and arrangement of the ST.6 cell monolayers. Whilst the above approach is
very useful for removing constant background irregularities, due for example to a
misaligned condenser, it was not used here since the variations in cellular
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background differed from image to image.
Rank levelling, another approach to background subtraction, is more useful when
dealing with local variations in background and is strictly dependent on the content
of the image to which it is applied. The procedure for rank levelling is fairly
straightforward. Briefly, a copy was made of the original image (Figure 3.7), the
copy was then subjected to 7 iterations of NIH image's built-in 3x3 neighbourhood
minimum rank filter (see Russ (1998) for a full description of rank and kernel based
filters) and the result (Figure 3.8A) was subtracted from the original image to
produce the final background corrected image (Figure 3.8B).
The problem with this approach is that the number of applications of the minimum
rank filter applied to an image must be balanced between removing the objects of
interest and preserving variations in background greylevel values. In this case, a
relatively large number of iterations was required to remove the largest inclusion
bodies from the image in figure 3.8A. As a result, much of the background variation
remained unaltered (figure 3.8B) and segmentation of inclusion bodies was not
greatly improved by this technique. In addition, rank levelling altered the greylevel
values of the pixels in the inclusion bodies as well as the cellular background.
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Figurea8A: The result of applying 7 iterations of a 3x3 minimum rank filter to the
image in Figure 3.7
Figurea8B: The result of subtracting the image in Figure 3.8A from the image in
Figure 3.7
85
Another form of background subtraction that was investigated was a 2-D rolling
ball algorithm. The 2D rolling ball algorithm was originally designed for removing
variations in background staining from 2-D electrophoretic gels whilst at the same
time maintaining the integrity of bands in the gels [Sternberg, 1983]. The 2-D rolling
ball algorithm was originally implemented in the source code of NIH Image by M.
Castle and J. Keller (University of Michigan Mental Health Research Institute, East
Lansing, USA).
The 2-D rolling ball algorithm is best visualised as a 3-D ball or sphere which rolls
along the X-axis and then the Y-axis of the image. Where the diameter of the ball is
larger than an object, in this case an inclusion body, it does not enter that part of the
image. If the diameter of 2D rolling ball algorithm was set above the length of the
largest inclusion body in the image it selectively reduced variations in the cellular
background greylevel value without affecting the greylevel values of the inclusion
bodies (Figure 3.9A). As a result much better segmentation of inclusion bodies from
cellular background was achieved when a threshold was applied to the resultant
image (Figure 3.9B). Most importantly it normalised the pixel frequency / greylevel
value histograms of the images to which it was applied (Figure 3.10) making and
made it much easier to segment inclusion bodies from cellular background in a large
number of images by applying the same threshold range to all of the images.
Despite the improvements made in the segmentation of inclusion bodies from
cellular background errors in segmentation still occurred. Inclusion bodies #9 and
#10 (Figure 3.1A) were not segmented and the cellular debris (Figure 3.1A; arrow)
was segmented with the inclusion bodies.
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Figure3.9A: Result of applying a 100 pixel diameter 2-D rolling ball algorithm to
figure 3.7
Figure3l9B: A binary image of Figure 3.9A produced by applying the threshold
values calculated for the green channel in Table 3.3
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Figure3.1OA: Pixel frequency / greylevel value histograms of the average of the
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Figure3.10B: Pixel frequency / greylevel value histograms of the average of the
green and blue channels of images from Figures 3.1 A(—), 3.3A(—) and




3.3.3 Development of an automated image analysis system for the enumeration
and measurement of Chlamydial inclusion bodies
The results of the preliminary image analysis of C. psittaci inclusions stained with
MZN in ST.6 cells were used as the basis for the design of Inclusion Counter vl.O, an
automated image analysis solution for counting and measuring chlamydial inclusion
bodies in cell culture based on NIH Image.
3.3.3.1 Universal colour segmentation
The first problem addressed during the design of Inclusion Counter vl.O was the
need for a universal method of colour segmentation that performed equally well
with different staining protocols. Inclusion Counter vl.O was designed not only to
allow the operator to choose between a variety of different colour segmentation
options but also to prompt the operator into selecting the correct version. A menu
option called Choose a Colour Channel was developed which produced a range of
greyscale images, 3-D surface plots and line profiles of selected inclusion bodies and
cellular background in all of the colour channel combinations available. This allowed
the operator to see how well inclusion bodies would be differentiated from cellular
background using the options available in Inclusion Counter vl.O. The range of
colour segmentation options available in Inclusion Counter vl.O are listed in Table
3.4 in conjunction with suitability for segmenting different hues of stain in both
bright field and dark field applications.
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3.3.3.2 Guard frame design
The resolution at which digital images can be acquired varies widely. Images
acquired using analogue CCD cameras, like the one used here, vary depending on
both the video signal (usually PAL or NTSC standard) and the resolution of the
frame grabber mounted in the computer. In addition, the wide range of digital
cameras that are now available for this kind of application do not adhere to any
form of standard with respect to resolution. Another problem that commonly arises
during image acquisition is the appearance of spurious information along one or
more of the edges of images digitised by a frame grabber (Figure 3.11A). Such
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spurious information varies in its location between different cameras and frame
grabber boards. It was therefore necessary to design a customisable counting or
guard frame that could be adjusted to suit any resolution of image and to exclude
areas of the images containing spurious information.
Whilst NIH Image provided a variety of ROI tools which could be used to restrict
the area of the images that was measured, it does not implement a true guard frame.
Correct implementation of a guard frame is an absolute requirement for accurate
counting and measurement of objects within a specified ROI. Figure 3.11A shows a
thresholded image and the ROI that was used as a guard frame for processing the
image. When NIH Image was instructed to count and measure the thresholded
objects within the ROI, it did so regardless of whether they touched the edges of the
ROI or not. As a result the number of objects in the ROI was overestimated, since
objects were counted when touching all four edges of the image, and the area and
morphological measurements were miscalculated because some of the objects
touching the edges of the ROI were either truncated by the edge of the image or
touched other objects outside the ROI. A customisable guard frame was designed to
correct this error. The thresholded image (Figure 3.11A) was converted into a binary
image (Figure 3.11B). Objects touching the top and left edges of the guard frame
were deleted (Figure 3.11C). NIH Image was then used to return the corrected
number of objects within the ROI. The guard frame was then applied to the image
for a second time and objects that touched any edge of the guard frame were
deleted (Figure 3.11D).
91
Figure3.11A: Thresholded image with visible region of interest (dashed line) and
spurious information generated by the frame grabber (arrows).
Figure3.11B: Binary image of thresholded objects in figure 3.11A with visible
region of interest (dashed line).
92
Figure3.11C: Binary image with visible region of interest (dashed line), objects
touching top and left edges were not included in the count (Red)
Figure3.11D: Binary image with visible region of interest (dashed line), objects
touching edges were not measured (RED)
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NIH Image was then instructed to perform an analyse particles routine and returned
the corrected values for the mean area, standard deviation from the mean area and
total area occupied by the objects in the ROI. Table 3.5 illustrates the level of error
that occurred when the guard frame was not used.
Table 3.5: Errors incurred by incorrect implementation of the guard frame
Standard ROI Guard frame % Error
Inclusion bodies / ROI 114 105 7.90
Mean Area (Pixels) 395.91 327.01 17.40
Standard deviation (Pixels) 750.55 259.56 65.41
Total area (Pixels) 45134 32047 28.99
The guard frame was implemented in the macro language of NIH Image, allowing the
operator to set and record an appropriate guard frame by choosing Set ROI from the
Special menu. Inclusion Counter vl.O would only analyse images if a guard frame
had been set prior to image processing and returned an error message if there was no
guard frame available. In addition, the area of the guard frame itself was also
measured providing a precise value for the area of the cell monolayer sampled by
each image. This approach also allowed a backup copy of the ROT file which
specified the guard frame to be saved for later use.
3.3.3.3 Calculation of the 2-D rolling ball
Correct estimation of the diameter of the background subtraction algorithm was
critical. If the Diameter was set too low the greyscale values of the inclusion bodies
were adversely effected. If the diameter was set too high the background correction
was ineffective and computation time was increased. A routine for calculating the
diameter of the 2-D rolling ball was adapted from a macro written by Mark Vivino
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[Vivino, 1992]. Inclusion Counter vl.O prompted the operator to measure the length
of the largest inclusion body present in the images and returned an estimate of the
diameter of the 2-D rolling ball required. In addition it generated a circular ROI
which could be moved around each image to ensure that the diameter was correct
(Figure 3.12).
Figure3.12: The interface provided for calculating of the 2-D rolling ball diameter
, File Edit Options Process Analyze Special Stacks Windows Objects Help
Tools Indexed Color
Move the ROI across the image, ifat
any point an inclusion does not fit in











3.3.3.4 Automation of the 2-D rolling ball background subtraction
The operator selected the appropriate menu command from the special menu (Figure
3.13) defining the combination of colour channels to be analysed and entered a
value for the diameter of the 2-D rolling ball background subtraction algorithm when
prompted. Inclusion Counter vl.O then automatically preprocessed the images.
Automation was achieved through the implementation of a Boolean argument that
made use of the numerical suffix of the images.
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For n:= 1 to 1000 do begin;
OpenCimage.'.q^);
The Boolean argument above instructed Inclusion Counter vl.O to sequentially open
and process all of the images with names conforming to the format Image.OOOn,
where the maximum number of images that can be processed is 999. The results
were saved as greyscale images with names in the format of
Figure3.13: The menu commands available for the automated 2-D rolling ball
background subtraction algorithm
r Grey Scale. Background Subtraction
^
24 bit TIFF to Grey Scale. Background Subtraction
Red Channel. Background Subtraction
Green Channel. Background Subtraction
Blue Channel. Background Subtraction
Red and Green Channels. Background Subtraction
Red and Blue Channels. Background Subtraction
Green and Blue Channels. Background Subtraction
3.3.3.5 Calculation of the scaling factor of the images
Values obtained using Inclusion Counter vl.O for mean inclusion area, standard
deviation from the mean inclusion area and total area occupied by inclusion bodies
within the ROI were converted into real units using a scaling factor. Once the images
had been preprocessed with the 2-D rolling ball algorithm, the operator calculated
the scale of the images using an image of a graticule slide (Graticules LTD, UK)
acquired at the same magnification as the images. This process was facilitated by
two macro implemented menu commands, Scale Part 1 and Set Scale Part 2. The
operator was then prompted to record the scaling factor of the images for future
reference.
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3.3.3.6 Automation of enumeration and measurement of Inclusion Bodies
Two separate methods of counting and measuring inclusion bodies were
implemented. The first employed fixed value for the upper and lower greyscale
value thresholds. These values were calculated by the operator as described in
section 3.3.2. The second approach allowed the operator to rapidly set the
thresholds for each image individually. This was achieved by developing two
separate macro files, Batch Count Inclusions vl.O and Manual Density Slice vl.O. Both
included identical components for selecting colour channels, setting and applying
the guard frame, 2-D rolling ball background subtraction and scaling the images.
They differed only in that the way the images were thresholded.
In Batch Count Inclusions vl.O, the images were analysed automatically by selecting
the menu command, Background Subtracted Images Automated Inclusion Enumeration.
The operator was prompted to enter the values for the scale of the images, the
upper and lower threshold values and the values for the minimum and maximum
area of the inclusion bodies. The operator opened the first image in the series of
background subtracted grey scale images with names with the format
Subtracted.OOOn, the guard frame was applied and its area was measured. Inclusion
Counter vl.O then used the threshold values previously specified by the operator to
convert the greyscale image into a binary image. Inclusion bodies were counted and
measured using the guard frame as described previously and the results were saved
in a text file. Inclusion Counter vl.O repeated this process for all of the image in the
series Subtracted.0001 - Subtracted.OOOn using the Boolean argument below.
For n:= 1 to 1000 do begin;
Open('Subtracted.',q:4);
In Manual Density Slice vl.O, a threshold was assigned to each image by the
operator. Inclusion Counter vl.O prompted the operator to open the first image in
the series Subtracted.0001 - Subtracted.OOOn. The upper threshold was set at a
greylevel value of 254 and the operator adjusted the lower threshold limit manually
as directed. Inclusion Counter vl.O converted the thresholded image into a binary
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image and saved it with the name in the format Binary.0001. Inclusion Counter vl.O
then automatically opened the next image in the series and allowed the operator to
repeat the thresholding process. This was repeated for all of the images in the series
for up to a maximum of 999 images. After all of the greyscale images had been
converted into binary images the operator selected Binary Images. Automated
Inclusion Enumeration from the Special menu. Inclusion Counter vl.O prompted the
operator to enter the scale of the images and the minimum and maximum values for
the areas of the inclusion bodies, it then applied the guard frame and counted and
measured the inclusion bodies in each of the images in the series, saving the results
in a text file.
Text files generated by Inclusion Counter vl.O can be opened in any spreadsheet
software package allowing further data analysis.
3.3.4 Computer aided manual enumeration and measurement of inclusion
bodies
A new layer was added to each image in Adobe Photoshop 4.0. Working in the new
layer, the outline of each inclusion was traced and filled with black (Figure 3.14B).
The background layer of cells and inclusions was then discarded, and the remaining
layer flattened and saved in a separate folder as a binary image in Macintosh
Picture (PICT) format (Figure 3.14C).
A macro was designed in NIH Image 1.61 to automatically count and measure the
binary images of inclusion bodies generated manually in Photoshop (Photoshop
Helper vl.O. The operator selected Process Photoshop Images from the Special menu in
NIH Image 1.61. Inclusion Counter vl.O prompted the operator to enter the scale of
the images and to opened the first image in the series. A guard frame was then
applied to the images as described previously, the number of inclusion bodies, the
mean area of the inclusion bodies, standard deviation from the mean area of the
inclusion bodies and total area occupied by inclusion bodies. The binary images of
inclusions were replaced by numbered outlines and a text file was produced
98
containing the measurements. The image of outlined and numbered inclusion bodies
was then pasted into a further layer of the original image in Photoshop 4.0 and the
resultant image saved in Photoshop format. The final images produced by this
technique consisted of the original cell monolayers with outlines and numbers
superimposed over each inclusion in a separate layer (Figure 3.14D). This allowed a
second user to verify the count and kept the original image intact enabling
automated image analysis to be performed on the same image.
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Figure3.14A: 24-bit colour image of ST.6 cells and inclusion bodies
Figure3.14B: The image from figure 3.14A with inclusion bodies traced and filled
with black in a second layer in Photoshop 4.0
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Figure3.14C: The binary image of inclusion bodies produced by the layer
containing the original image in Photoshop 4.0
Figuie3.14D: The final composite image with inclusion bodies outlined and
numbered by Inclusion Counter v1.0
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3.3.5 Statistical comparison of the results generated by automated image
analysis and manual image analysis.
The number and area of inclusion bodies were measured in 200 digital images of
ST.6 cells infected with C. psittaci by manually outlining, measuring and counting
inclusions using Photoshop 4.0 and NIH Image 1.61 as described previously. The
results generated by this system were then verified by a second user and definitive
values for the numbers of inclusions, mean inclusion body area, standard deviation
from the mean inclusion body area and total area occupied by inclusion bodies
within the guard frame were assigned to each image.
Figure3.15: Values generated by Inclusion Counter v1.0 for inclusion bodies/field
plotted against definitive values for inclusion bodies/field















0 50 100 150 200
Definitive Values for Inclusion / field
I ' ' 1 1 ! 1 ' ' 1 I ' ' ' ' I 1 ' 1 1 I
0 50 100 150 200
Definitive Values for Inclusion / field
Batch Count Inclusions vl.O and Manual Density Slice vl.O were evaluated for their
accuracy in counting and measuring inclusion bodies. The relationship between the
number of inclusions in each field obtained by manual counting and the values
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generated by Inclusion Counter vl.O are displayed in (Figure 3.15). Analysis of the
results generated by both components of Inclusion Counter vl.O by simple linear
regression showed a significant positive correlation with the definitive values
assigned to the images, Batch Count Inclusions vl.O (Correlation Coefficient = 0.9654;
Slope = 0.8288; Intercept = 5.1173; P< 0.0001) and Manual Density Slice vl.O
(Correlation Coefficient = 0.9699; Slope = 0.7134; Intercept = 3.1742; P< 0.0001).
A significant positive correlation was found between mean inclusion area values
generated by Inclusion Counter vl.O and the definitive values assigned to the images
(Figure 3.16). There was a significant positive correlation between manual
measurement and Batch Count Inclusions vl.O (Correlation Coefficient = 0.5691;
Slope = 0.2783; Intercept = 171.7268; P< 0.0001) and between Manual Density Slice
vl.O and manual measurement (Correlation Coefficient = 0.6609; Slope = 0.3665;
Intercept = 147.4130; P< 0.0001).
Figure 3/16: Values generated by Inclusion Counter vl.O for mean inclusion body
area plotted against definitive values for mean inclusion body area
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A significant positive correlation was found between the standard deviation from
the mean inclusion area returned by Inclusion Counter vl.O and the definitive values
assigned to the images (Figure 3.17). There was a significant positive correlation
between Batch Count Inclusions vl.O and manual measurement (Correlation
Coefficient = 0.7028; Slope = 0.4646; Intercept = 147.4719; P< 0.0001) and between
Manual Density Slice vl.O and manual measurement (Correlation Coefficient =
0.7367; Slope = 0.5392; Intercept = 86.5118; P< 0.0001).
Figure3.17: Values generated by Inclusion Counter v1.0 for standard deviation
from the mean inclusion body area plotted against definitive values for standard
deviation from the mean inclusion body area
Batch Count Inclusions vt.O
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The relationship between values generated for the total area occupied by inclusion
bodies within each field of view was also investigated. The Results are shown in
Figure 3.18. Values for the total area occupied by inclusions obtained using Inclusion
Counter vl.O showed significant positive correlation with the definitive values
assigned to the images, Batch Count Inclusions vl.O with manual measurement
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(Correlation Coefficient = 0.9689; Slope = 1.0176; Intercept = -257.9802; P< 0.0001)
and Manual Density Slice vl.O with manual measurement (Correlation Coefficient =
0.9639; Slope = 0.7308; Intercept = 270.1981; P< 0.0001).
Figure3.18: Values generated by Inclusion Counter vl.O for total inclusion body
area plotted against definitive values for total inclusion body area
Batch Count Inclusions vl.O
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The range of inclusion numbers was not uniformly dispersed throughout the images,
and the majority of fields of view contained less than 50 inclusions. Further
statistical analysis was therefore performed to ensure that the statistics were not
being skewed by the higher values obtained for some images. Table 3.6 shows the
results of simple linear regression correlations between definitive values and
Inclusion Counter vl.O generated values over this range of images. All results
generated by Inclusion Counter vl.O over this range showed significant positive










Batch Count Inclusions v1.0
Manual Density Slice v1.0
0.8651 0.8991 4.2655 0.0001
0.8992 0.7857 2.1587 0.0001
Mean Inclusion
area (pm 2 )
Batch Count Inclusions vt.O
Manual Density Slice v1.0
0.5771 0.2956 157.5905 0.0001
0.4409 0.2489 200.8251 0.0001
Standard deviation Batch Count Inclusions v1.0
from the mean area Manual Density Slice v1.0
0.7066 0.4634 148.7181 0.0001
0.5500 0.3986 127.4296 0.0001
Total Inclusion Area Batch Count Inclusions v1.0
/Field of view (pm 2) Manual Density Slice v1.0
0.9632 0.9012 294.6179 0.0001
0.9054 0.7426 283.6222 0.0001
Simple linear correlations between the definitive values assigned to each image and values
generated by Inclusion Counter. The range of images has been restricted to images
containing 50 or fewer inclusion bodies (n=152) to ensure that the results of the correlations
were not skewed by images with extreme values for inclusion number.
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3.4 Discussion
In contrast to the in vitro setting where counting inclusion bodies by eye remains the
method of choice for measuring chlamydial growth, clinical diagnosis of chlamydial
infections has largely moved on from isolation and culture of live chlamydiae to the
development and use of more automated techniques [Taylor-Robinson, 1997]. These
include: antigen-specific ELISAs [Pugh et al, 1985; Souriau and Rodolakis, 1986;
Mohanty et al, 1996]; anti-chlamydial antibody-specific ELISAs [Evans and Taylor-
Robinson, 1982; Salti-Montesanto et al, 1997]; PCR [Corkish and Bevan, 1991;
Palmer et al, 1991; Rasmussen et al, 1992]; and LCR [Dille et al, 1993]. Whilst these
approaches have proved useful to varying degrees in the setting of clinical diagnosis
[Taylor-Robinson, 1997], remarkable few of these techniques have been applied to
the problem of measuring chlamydial growth in vitro. This is largely because these
techniques were originally designed for qualitative rather than quantitative analysis
or as in the case of anti-chlamydial antibody ELISAs cannot be applied to the
situation in vitro. Despite this, a number of semi-automated techniques have been
applied to the quantification of chlamydial growth in vitro. These include: a
chlamydial-LPS specific ELISA that was used to measure the effects of ROvIFN-y
on C. psittaci growth in ovine ST.6 cells [Graham et al, 1995]; an RT-PCR based
assay for evaluation of the in vitro antibiotic susceptibility of C. pneumoniae [Khan
et al, 1996]; and most recently the use of flow cytometry to evaluate the antibiotic
susceptibility of C. trachomatis in <?zfro[Dessus-Babus et al, 1998]. However, whilst
the ELISA [Graham et al, 1995] and RT-PCR [Khan et al, 1996] assays are less time
consuming than counting inclusion bodies by eye, they only provide an indirect
measure of chlamydial growth and neither of these techniques have been widely
adopted outside their original laboratories. In contrast, the flow cytometry based
solution developed by Dessus-Babus et al (1998) provides a direct measure of the
percentage of infected cells. It is too early to say if this technique will gain wide
acceptance and counting inclusion bodies by eye remains the method of choice for
measuring chlamydial growth in vitro.
The aim of the experiments detailed here was to assess the feasibility of using image
107
analysis for the measurement of chlamydial growth in vitro and if possible generate
an automated system that would overcome the disadvantages of counting inclusions
by eye without reducing sensitivity and add functionality that was previously
unavailable. The image analysis software package, NIH Image, was chosen for this
purpose on the grounds of its power, flexibility and public domain status. In
addition, because it has attracted such a large number of users, the level of peer-
based technical support for NIH Image remains largely unequalled.
Initial studies based on manual measurement of inclusion bodies (Tables 3.2 and
3.3) and pixel frequency/greylevel value histogram analysis of images (Figures 3.2,
3.4 and 3.5) indicated that segmentation of inclusion bodies was possible on the
basis of differences between the greylevel values of inclusion bodies and the cellular
background. When dealing with colour images, as was the case here, segmentation
could be enhanced by selecting the combination of the red, green and blue colour
channels in which there was maximum contrast between the greylevel values of
inclusion bodies and the cellular background. In the case of inclusion bodies stained
with MZN and cellular background counter stained with methyl blue this was
achieved by averaging the greylevel values of the green and blue colour channels of
the images. A threshold greylevel value was then applied to the images instructing
the computer to exclude any pixels falling out with the range of greylevel values
specified. In this way, the majority of the cellular background was excluded from
the measurements. However, greylevel value alone was not sufficient to allow
satisfactory segmentation of inclusion bodies since some components of the cellular
background were included in the thresholded image. The second parameter by which
objects in the thresholded image were defined as inclusion bodies was size. Objects
were counted as inclusion bodies if the value returned for their area fell within the
specified range. Superficially, the perimeter of the C. psittaci inclusion bodies
appeared to be relatively smooth, suggesting that formfactor or roundness might
have been used to further define objects as chlamydial inclusion bodies. However,
roundness values obtained for inclusion bodies (Table 3.3) varied too widely to be
used for this purpose and this approach was not pursued further.
In the experiments detailed here, the images were captured under variable lighting
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conditions from plastic 96-well flat-bottomed microtitre plates, which are relatively
poor in terms of optical quality compared to glass. Attempts to facilitate greylevel
based segmentation of inclusion bodies by adjusting the background greylevel values
were varied in their success. Standard procedures for background correction were
inappropriate or adversely effected the greylevel values of the inclusion bodies.
However, the implementation of the 2-D rolling ball background subtraction
algorithm [Sternberg, 1983] greatly improved segmentation of chlamydial inclusion
bodies. In addition the 2-D rolling ball algorithm normalised the light levels through
out the entire batch of images (Figure 3.10) allowing a single threshold range to be
applied to all of images in a given series. Images acquired using more sophisticated
image capture systems which are capable of automated focusing and light level
adjustment do not necessarily require preprocessing with the 2-D rolling ball
background subtraction algorithm. Since computation of the 2-D rolling ball
algorithm is relatively time consuming this process was made optional so that
images captured with microscopes equipped with these features could be processed
more rapidly.
The final version of Inclusion Counter vl.O consisted of four main components:
Batch count Inclusions vl.O; Manual Density Slice vl.O; No Background Subtraction
vl.O; and Photoshop Helper vl.O. These allowed automated enumeration and
measurement of chlamydial inclusion bodies to be performed on images
independently of the type of the staining and microscopy used. In addition,
Photoshop Helper vl.O and a separate Photoshop 4.0 actions file, Help with Inclusion
Counter, provided a system for manual measurement of chlamydial inclusion bodies
that could be used to verify the results obtained with the automated components of
Inclusion Counter vl.O.
In order to assess the accuracy of Inclusion Counter vl.O, it was first necessary to
assign a definitive value for inclusion body areas and number to each image. A
number of approaches were considered. The system detailed in chapter 3.3.4 was
chosen primarily because it was open to secondary verification and allowed
measurement of inclusion bodies by eye to be performed on the same image that was
processed automatically by Inclusion Counter vl.O, removing the requirement for
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assumptions to be made about sample size and the spatial distribution of inclusion
bodies. This approach, whilst extremely time consuming, was by far the most
accurate available and allowed definitive values for inclusion body size and number
to be assigned to each image.
In general, the results generated by Inclusion Counter vl.O showed close correlation
with values obtained using the method for manual measurement of inclusions
described in section 3.3.4. In particular, the values for the number of inclusions and
total area occupied by inclusions per field of view returned by Inclusion Counter
vl.O correlated closely with the definitive values assigned to each image (Figures
3.15 and 3.18). The correlation between the values generated by Inclusion Counter
vl.O for mean inclusion body area and those obtained by manually outlining
inclusion bodies (Figure 3.16) was significant but were not as good as correlations
obtained for inclusion body number (Figures 3.15). It is notable that in contrast to
this, results obtained for the total area occupied by inclusion bodies were more
accurate (Figure 3.18). This discrepancy was largely due to the lack of variability of
mean inclusion body area between the images used in this study. Values obtained
for the standard deviation from the mean area within images describe the
population heterogeneity for inclusion body area (figure 3.17). The correlation
between standard deviation from the mean area values generated by Inclusion
Counter vl.O and manual measurements was reasonably good. This measurement
parameter may be useful when examining the effects of anti-chlamydial
pharmaceuticals of immune effector mechanisms.
Whilst the results generated by Batch count Inclusions vl.O and Manual Density Slice
vl.O were generally similar, the results generated by Batch count Inclusions vl.O were
more accurate when analysis was restricted to images of cell monolayers containing
50 or fewer inclusion bodies (Table 3.6). This was most notable for the values
returned for the total area occupied by inclusion bodies where the correlation
coefficient, slope and intercept values were more precise for Batch count Inclusions
vl.O.
There were a number of drawbacks to allowing the operator to set the threshold for
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each image individually. Firstly, because the threshold was set by the operator in a
greyscale image rather than a colour image accurate discrimination between
artifacts/artefacts and inclusion bodies was difficult. A typical example of
common artefacts of MZN staining is shown in figure 3.1A. In the colour image it
was possible to discriminate between the artefacts and the inclusion bodies on the
basis of their position in the focal plane and slight differences in saturation.
However, it was much harder to discriminate between these artefacts and the
inclusion bodies in the greyscale image which was used to set the threshold for the
image (Figure 3.7). Secondly, allowing the operator to set the threshold of each
image independently opened up Inclusion Counter vl.O to subjective decision
making by the operator, one of the key features that it was designed to avoid. This
is particularly problematic in the case of uninfected controls where an operator will
nearly always ensure that none of the cellular background is counted. This
effectively nullifies the value of including uninfected controls and means that they
cannot be used as measure of the level of error inherent in the system. It also means
that the level of error is variable, as is apparent from the more scattered distribution
of values for images with large numbers of inclusion bodies (Figures 3.16 and 3.18).
By forcing the operator to calculate the threshold using the technique detailed in
section 3.2.3, Batch count Inclusions vl.O avoids these problems entirely. In addition,
whilst setting the threshold individually only take a few seconds for each of the
images, this process become extremely time consuming when large numbers of
images require processing.
The most useful feature of Inclusion Counter vl.O was its ability to provide not only
accurate values for the number of inclusion bodies in a given field of view but also
the total area occupied by the inclusion bodies. The same approach can be easily
implemented to calculate the area of the cell monolayer which was lysed due to
chlamydial growth. This allows the progression of the infectious process to be
measure after the first cycle of chlamydial growth and host cell lysis, providing
useful information about the effects of anti-chlamydial agents beyond the initial
phase of infection. Inclusion Counter vl.O can be used in this way to allow rapid
and accurate quantification of a wide variety of histological features both inside
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and outside chlamydial biology, including cytokine expression, pathological changes
and infectious processes that would otherwise be difficult to quantify.
Inclusion Counter vl.O is largely automated and requires a fraction of the user's time
compared with traditional methods of assessing chlamydial growth. It typically
takes 20 minutes of the operators time to set up Batch Count inclusions vl.O or a few
seconds for each image image if Manual Density Slice vl.O is used, after which
Inclusion Counter vl.O will process up to 999 images automatically. These features,
combined with the public domain status of NIH Image and Inclusion Counter vl.O
provide a strong argument for the replacement of traditional counting methods.
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Chapter 4.0




Inclusion Counter vl.O provides an accurate, automated method of counting
chlamydial inclusion bodies in vitro. Values returned by Inclusion Counter vl.O for
the total area occupied by inclusion bodies per field are also highly accurate
(Chapter 3.0). However, the method used by Inclusion Counter vl.O to segment
chlamydial inclusion bodies from cellular background commonly results in the
segmentation of cellular debris and other artefacts which reduce specificity.
Furthermore, Inclusion Counter vl.O will only return accurate results if the operator
systematically goes through the process of selecting the appropriate combination of
RGB colour channels, calculating the grey value thresholds and determining the
minimum and maximum area of the inclusion bodies. In order to address these
issues, a novel 24-bit colour segmentation system was developed and implemented
for Inclusion Counter v2.0 using the public domain image analysis package Object-
Image [Vischer et al, 1994], This chapter describes the development and evaluation
of Inclusion Counter v2.0.
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4.2 Materials and Methods
4.2.1. Image acquisition
All aspects of this work were carried out using the same images that were used
during the development of Inclusion Counter vl.O (Chapter 3.0).
4.2.2 Automated enumeration and measurement of inclusions
Inclusion Counter v2.0 was designed and developed in Object-Image 1.62n6
(Norbert Vischer: November 1998) using Inclusion Counter vl.O (Chapter 3.0) as a
structural framework. The accuracy of the data generated by Inclusion Counter v2.0
was compared against the results generated by manual measurement of inclusion
bodies in 200 digital images of ovine ST.6 cells infected with the S26/3 OEA strain
of C. psittaci as described previously (Chapter 3.3.4).
4.2.3 Statistical Analysis




Inclusion Counter v2.0 used the same guard frame, 2-D rolling ball background
subtraction [Sternberg, 1983], image scaling and automated batch processing
routines as Inclusion Counter vl.O. However, it differed significantly from Inclusion
Counter vl.O in the way that it segmented chlamydial inclusion bodies from cellular
background and to a lesser degree in the range of measurement parameters it
returned.
Rgure41: "Point and click" colour segmentation
The cursor (highlighted by the arrow) is placed over an inclusion body in an indexed colour
image generated from the original RGB image. When the mouse button is depressed,
Inclusion Counter v2.0 samples the grey level values at that location in each of the colour
channels of the original RGB image. Inclusion counter v2.0 then sets the grey level threshold
for each of the red, green and blue channels.
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4.3.1 "Point and click" colour segmentation in Inclusion Counter v2.0
Inclusion Counter v2.0 removed the requirement for the operator to manually
calculate and set a grey level threshold. This was achieved by directly sampling the
grey level values of each colour channel component of the inclusion bodies. Inclusion
Counter v2.0 (Part 1) prompted the operator to open an image of ST.6 cells
containing inclusion bodies and click on an inclusion (Figure 4.1). Using the x,y
coordinate of the cursor as a reference, Inclusion Counter v2.0 measured the grey
level values at that location in each of the component channels of the original image
and used the resultant values to threshold each channel individually (Figures 4.2A,
4.2B and 4.2C). Inclusion Counter v2.0 then compared the resultant binary images
from each channel and produced a composite image using a Boolean AND function.
The resultant binary image generated by the Boolean AND function only contained
pixels which occurred at the same place in all three binary images (Figure 4.2D).
Inclusion Counter v2.0 also kept a copy of the binary images of each channel
allowing the operator the option of selectively discarding one or more channels
during future analysis. In addition, both the size of the area sampled and the degree
of sensitivity with which the thresholds were set could be easily adjusted by the
operator. In the case of the image in Figure 4.2, the red channel did not contribute
significantly to the segmentation process. Furthermore, the sensitivity level was set
to a very low level (± 10 grey level values) resulting in excessive background
segmentation in the Boolean AND image (Figure 4.2D).
Figure 4.3 shows the results of "point and click" thresholding in the green and blue
channels only, with the sensitivity set to ±1 grey level values.
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Figure4.2A: "Point and click" threshold image of the red channel
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Figure 42C: "Point and click" threshold image of the blue channel
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Figure43: Boolean AND image derived from thresholding in the green and blue
channels of the RGB image
(Area sampled:= 9x9 pixels and sensitivity:=1)
This process was repeated until satisfactory segmentation was achieved, at which
point the operator saved the threshold values by selecting New Colour Range Record
from the Special menu. This created a 'Colour Range Record', a 100x100 resolution
image with a background grey level value of zero (white) and recorded the upper
and lower grey value thresholds for each colour channel as pixels with x,y locations:
red (lower=l,l/upper=l,2); green (lower=l,3/upper=l,4); and blue
(lower=l,5/upper=l,6). This process was then repeated for at least two more
images (picked at random from the batch of images requiring processing) with the
minor modification that the operator added new threshold values to the existing
'Colour Range Record' file by choosing Add To Open Colour Range Record from the
Special menu. Add To Open Colour Range Record added a further image to the 'Colour
Range Record' stack in which it recorded the new upper and lower thresholds for
each colour channel as described above. Once satisfied with the 'Colour Range
Record' the operator could rename, close and save the Colour Range Record file as
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required.
4.3.2 Batch processing using the Colour Range Record
Inclusion Counter v2.0 automatically processed up to 999 images at a time using a
similar technique to Inclusion Counter vl.O (Chapter 3.0). The operator selected the
appropriate colour channels for analysis from the Special menu, set the scale, set the
minimum and maximum size for inclusion bodies, opened the first image in the
batch requiring processing and selected the correct 'Colour Range Record' file.
Inclusion Counter v2.0 used the 'Colour Range Record' file to calculate a mean value
(+ 1 standard deviation) for the threshold settings in each colour channel and
applied this to all of the images requiring processing. The results for inclusion
number, total area occupied by inclusion bodies, percentage area occupied by
inclusion bodies and the values for the mean/standard deviations from the mean
inclusion body area, length and width of each image were exported to a separate
text file. Further data analysis could then be performed in any spreadsheet package
as required (Table 4.2).
Table4.1: An example of the spreadsheet output of Inclusion Counter v2.0
ROI Area 288408 /um2
Inclusions Mean STDEV Total % Mean STDEV Mean STDEV
Per ROI Area (Area) Area Area Length (Length) Width (Width)
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0
17 242 199 3866 1.34 27.15 11.92 9.94 5.54
13 166 133 1995 0.69 23.48 14.52 8.40 2.59
9 311 396 2803 0.97 27.71 20.01 11.08 6.63
19 194 212 3689 1.28 30.42 19.98 7.05 2.99
8 387 399 3096 1.07 35.71 22.15 11.34 5.44
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4.3.3. Length and width measurement by best fit ellipse
Mean length and width of chlamydial inclusions within the guard frame of each
image were calculated using Object-Image's built-in best fit ellipse algorithm and
measuring the major and minor axes of the resultant ellipse (Figure 4.4). Object-
Image uses a similar method for calculation of the best fit ellipse to that described
by Russ (1998).
Figure44: Best fit ellipse for a binary image of a inclusion body
Minor
4.3.4. Implementation of the HSV colour model in Object-Image 1.62n6
A macro command for the conversion of RGB Images into Hue, Saturation and
Value (HSV) images was implemented in Object-Image 1.62n6. This made it
possible, for the first time, to include a HSV colour segmentation system in Inclusion
Counter v2.0. Figure 4.5 shows the result of converting of a RGB 24-bit colour image
of a standard colour wheel into its hue, saturation and value component channels.
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Figure4.5: The hue (A), saturation (B) and value (C) components of a standard
colour wheel (D).
Hue = [;r/2-arctan{(2-R-G-B)/V3-(G-g)} + jr;G<g]
2x
Saturat' [Maximum(RGB) - Minimum(RGB)]
Minimum(RGB)
Value = Minimum (RGB)
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Figure46A: A 24-bit RGB colour image of inclusion bodies in ST.6 cells, with
artefacts (arrow), as displayed by a standard cathode ray tube monitor.
Figure46B: The hue component of Figure 4.3A
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Figure 4.6C: The saturation component of Figure 4.3A
Figure46D: The value component of Figure 4.3A
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Figure 4.6 shows the results of converting a 24-bit RGB colour image of chlamydial
inclusion bodies and ST.6 cells into its component HSV channels in Object-Image
1.62n6. Inclusion bodies appeared at greatest contrast to the cellular background in
the hue channel (Figure 4.6B) and there was a total absence of cellular artefacts
(Figure 4.6A: arrow) in the saturation channel (Figure 4.6C). These findings
prompted the implementation of the HSV colour model in Inclusion Counter v2.0.
4.3.5. Implementation of the HSV model in Inclusion Counter v2.0
HSV based "point and click" colour segmentation (Inclusion Counter v2.0 HSV) was
implemented using the same procedure as described for RGB based "point and
click" colour segmentation (Inclusion Counter v2.0 RGB).
4.3.6. Analysis of the results generated by Inclusion Counter v2.0
The semi-automated measurement system described in Chapter 3.0 was used to
assign definitive and verifiable values for inclusion number, mean inclusion area,
mean inclusion length, mean inclusion width, total area occupied by inclusion
bodies, percentage area occupied by inclusion bodies and the standard deviations
from the mean area, length and width to 200 digital images of ST.6 cells infected
with chlamydiae. Inclusion Counter v2.0 RGB and Inclusion Counter v2.0 HSV were
then evaluated for accuracy in counting and measuring inclusion bodies.
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Figue47: Comparison of the number of inclusion bodies in each image returned
by Inclusion Counter v2.0 and the definitive values.
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Simple linear regression analysis of the number of inclusion bodies per image
returned by Inclusion Counter v2.0 showed a significant positive correlation with the
definitive values assigned to the images (Figure 4.7). Inclusion Counter v2.0 RGB
(correlation coefficient = 0.9733; slope = 0.8451; intercept = 3.1888; P< 0.0001) and
Inclusion Counter v2.0 HSV (correlation coefficient = 0.9921; slope = 0.8249;
intercept = 2.1498; P< 0.0001).
127
Rgure48: Comparison of the values generated by Inclusion Counter v2.0 for
the total area occupied by inclusions in each image and the definitive values.
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Simple linear regression analysis of the values for the total area occupied by
inclusion bodies obtained using Inclusion Counter v2.0 showed a significant positive
correlation with the definitive values assigned to the images (Figure 4.8). Inclusion
Counter v2.0 RGB (correlation coefficient = 0.9714; slope = 0.7939; intercept = -
139.6086; P< 0.0001) and Inclusion Counter v2.0 HSV (correlation coefficient =
0.9887; slope = 0.7319; intercept = 282.1805; P< 0.0001).
Correlation between the percentage area occupied by inclusions obtained using
Inclusion Counter v2.0 and the definitive values assigned to the images was
statistically identical to those obtained for the total area occupied by inclusion
bodies.
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Figure4.9: Comparison of the values returned by Inclusion Counter v2.0 for
mean inclusion body area in each image and the definitive values.
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Simple linear regression analysis of the results generated by Inclusion Counter v2.0
for mean inclusion body area showed a significant positive correlation with the
definitive values assigned to the images (Figure 4.9). Inclusion Counter v2.0 RGB
(Correlation Coefficient = 0.6951; Slope = 0.3200; Intercept = 120.0956; P< 0.0001)
and between Inclusion Counter v2.0 HSV and manual measurement (Correlation
Coefficient = 0.8959; Slope = 0.6939; Intercept = 31.7685; P< 0.0001).
There was also a significant positive correlation between the values returned by
Inclusion Counter v2.0 for the standard deviation from the mean inclusion area in
each image and the definitive values assigned to the images. Inclusion Counter v2.0
RGB and manual measurement (Correlation Coefficient = 0.646; Slope = 0.411;
Intercept = 121.6544; P< 0.0001) and between Inclusion Counter v2.0 HSV and
manual measurement (Correlation Coefficient = 0.9049; Slope = 0.7756; Intercept =
32.1972; P< 0.0001).
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Figure410: Comparison of the values returned by Inclusion Counter v2.0 for
mean inclusion body length in each image and the definitive values.
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Simple linear regression analysis of the values for mean inclusion body length in each
image returned by Inclusion Counter v2.0 showed a significant positive correlation
with the definitive values assigned to the images (Figure 4.10). Inclusion Counter
v2.0 RGB (Correlation Coefficient = 0.7016; Slope = 0.4608; Intercept = 11.9695;
P< 0.0001) and Inclusion Counter v2.0 HSV (Correlation Coefficient = 0.8976;
Slope = 0.7557; Intercept = 4.6024; P< 0.0001).
There was also a significant positive correlation between the values returned by
Inclusion Counter v2.0 for the standard deviation from the mean inclusion body
length in each image and the definitive values assigned to the images. Inclusion
Counter v2.0 RGB and manual measurement (Correlation Coefficient = 0.5783;
Slope = 0.4307; Intercept = 9.8662; P< 0.0001) and between Inclusion Counter v2.0
HSV and manual measurement (Correlation Coefficient = 0.8673; Slope = 0.8091;
Intercept = 2.2846; P< 0.0001).
130
Figure411: Comparison of the values returned by Inclusion Counter v2.0 for
mean inclusion body width in each image and the definitive values.
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Simple linear regression analysis of the values returned by Inclusion Counter v2.0 for
the mean inclusion body width in each image showed a significant positive
correlation with the definitive values assigned to the images (Figure 4.11). Inclusion
Counter v2.0 RGB (Correlation Coefficient = 0.6568; Slope = 0.3763; Intercept =
4.683; P< 0.0001) and Inclusion Counter v2.0 HSV (Correlation Coefficient =
0.9121; Slope = 0.775; Intercept = 1.0074; P< 0.0001).
There was also a significant positive correlation between the values returned by
Inclusion Counter v2.0 for the standard deviation from the mean inclusion body
width in each image and the definitive values assigned to the images. Inclusion
Counter v2.0 RGB and manual measurement (Correlation Coefficient = 0.4971;
Slope = 0.3770; Intercept = 2.7080; P< 0.0001) and between Inclusion Counter v2.0
HSV and manual measurement (Correlation Coefficient = 0.8667; Slope = 0.8481;
Intercept = 0.5291; P< 0.0001).
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4.4 Discussion
Interface design for colour segmentation is an extremely complex task in itself [Russ,
1998]. Inclusion Counter vl.O (Chapter 3.0) avoided this problem by allowing the
operator to perform analysis on 8-bit greyscale images derived from a combination
of the red, green and blue channels of the original RGB colour image. In doing so, it
essentially discarded much of the information present in the images. In contrast,
Inclusion Counter v2.0 made full use of all of the information present within each
image before summarising it as binary image prior to analysis. This approach
resulted in much more stringent segmentation of inclusion bodies from the cellular
background. Furthermore, the way in which this was achieved by "point and click"
sampling of the grey level values of the inclusion bodies actually simplified the
process for the operator.
The values returned by Inclusion Counter v2.0 RGB for inclusion body number,
mean inclusion body area and total inclusion body area were marginally more
accurate that those previously generated by Inclusion Counter vl.O (Batch count
Inclusions vl.O; Chapter 3.0). However, accuracy gains with Inclusion Counter v2.0
HSV were highly marked compared to both Inclusion Counter vl.O and Inclusion
Counter v2.0 RGB. Values returned by Inclusion Counter v2.0 HSV for inclusion
body number and total area/% area occupied by inclusion bodies were
exceptionally accurate (Figures 4.7 and 4.8). Furthermore, Inclusion Counter v2.0
HSV returned notably more accurate values for area (Figures 4.9 and 4.10), length
(Figures 4.11 and 4.12) and width (Figures 4.13 and 4.14) compared to previous
versions of Inclusion Counter.
Whilst Inclusion Counter vl.O provided a solid argument for the use of image
analysis in the measurement of chlamydial growth in vitro, the accuracy of Inclusion
Counter v2.0 HSV exceeded initial expectations for this technology. Inclusion
Counter v2.0 HSV provided highly accurate, robust and repeatable results using
several different 'Colour Range Record' files. Its ability to return accurate values for
area and length parameters should allow much more detailed analysis of chlamydial
growth in vitro than any of the ELISA [Graham et al, 1995], RT-PCR [Khan et al,
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1996] or FACS [Dessus-Babus et al, 1998] based technologies currently available. In
addition, examination of tissue sections containing Neospora caninum parasites
stained with IPX suggests that Inclusion Counter v2.0 HSV can be used for in vitro
studies (data not shown).
Results generated by Inclusion Counter vl.O are clearly dependent on the quality
and specificity of the stain used and on the quality of the image capture system.
MZN is a non-specific acid fast stain. Whilst it generally provides good differential
staining of chlamydial inclusion bodies, it was not always uniform, and some
inclusions stained only faintly. Specific staining protocols such as
immunohistochemistry or in szfu-hybridisation will significantly improve the
accuracy of Inclusion Counter. Furthermore, the microscope used in these studies
was not optimised for use with plastic 96-well plates and problems associated with
maintaining a stable video signal required changes to be made to the illumination
and condenser settings throughout image acquisition. This is not recommended when
batch processing images using thresholding and is likely to have compromised the
accuracy of the results generated by Inclusion Counter in these studies. The use of an
inverted microscope with plastic optimised objectives would solve this problem and
improve the accuracy of Inclusion Counter even further. There is no reason why
results obtained using Inclusion Counter v2.0 HSV under optimal conditions should
not approach 100% accuracy.
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Chapter 5.0
Mechanisms of ROvlFN-y mediated inhibition of C.
psittaci growth in ovine cells.
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5.1. Introduction
The ability of IFN-y to restrict chlamydial growth in a wide variety of target cells
has highlighted the importance of this cytokine in the immune response to
chlamydiae. Consequently, a considerable amount of interest has focused on
characterising the anti-chlamydial effects of IFN-y. Whilst in vivo studies have
established a significant role for IFN-y in limiting chlamydial growth during the
primary immune response, in vitro studies have been focused on the effects of IFN-y
on the intracellular growth of chlamydiae.
Initially, results from studies using murine and human mononuclear phagocytes were
unanimous in agreement that the anti-chlamydial mechanism of IFN-y was oxygen-
independent [Rothermel et al, 1986; Byrne and Krueger, 1983]. However, it has since
become clear that there are significant differences between the mechanisms through
which IFN-y restricts chlamydial growth in human and murine cells.
In 1986, Bryne et al (1986) showed that IFN-y inhibited the growth of C. psittaci in a
human uroepithelial cell line (T24) by upregulating tryptophan catabolism, which
has been shown to be mediated by the enzyme indoleamine 2,3-dioxygenase (IDO)
[Gupta et al, 1994], thereby restricting the availability of tryptophan to the
pathogen. Furthermore, the anti-chlamydial effects of IFN-y were almost completely
reversed by the addition of excess exogenous tryptophan to the culture conditions
[Byrne et al, 1986]. Upregulation of tryptophan catabolism has since been confirmed
as the primary mechanism through which IFN-y activates human cells to restrict the
growth of C. psittaci, C. trachomatis and C. pneumoniae [Beatty et al, 1994; Mehta et
al, 1998; Murray et al, 1989; Summersgill et al, 1995; Thomas et al, 1993].
Addition of exogenous tryptophan has also been reported to result in the
restoration of near normal levels of chlamydial growth in human HEp-2 cells treated
with TNF-a, suggesting the anti-chlamydial effects of TNF-a are also mediated
through increased tryptophan catabolism in human cells. Similarly, IFN-a, IFN-(3
and IL-1 have also been shown upregulate tryptophan catabolism in human cells
[Hu et al, 1995; Murray et al, 1989; Paguirigan et al, 1994].
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In contrast to the situation in human cells, the mechanism by which IFN-y restricts
chlamydial growth in murine cells is not associated with upregulated tryptophan
catabolism [De La Maza et al, 1985], IFN-y has been reported to lyse murine L cells
infected with C. psittaci or C. trachomatis [Byrne et al, 1989]. IFN-y pretreated murine
McCoy cells have been shown to produce nitric oxide (NO") following infection with
C. trachomatis. More importantly, addition of exogenous N-guanidino-monomethyl
L-arginine (l-NMMA), which inhibits the enzyme inducible nitric oxide synthase
(iNOS), prevented NO" production in these cells and reversed anti-chlamydial
effects of IFN-y in a dose dependent manner, suggesting that NO' free radicals may
have an anti-chlamydial function [Mayer et al, 1993]. More recently, IFN-y mediated
inhibition of C. trachomatis has been shown to correlate with NO" production in the
murine RAW 264.7 macrophage cell line and can be reversed by exogenous L-
NMMA [Chen et al, 1996]. Treatment of mice with L-NMMA has been shown to
increase chlamydial replication in vivo and to reduce the ability of a chlamydiae-
specific T-cell clone to protect mice against MoPn [Igietseme, 1996],
An in vivo study in sheep demonstrated local production of IFN-y by an immune
ewe following secondary challenge with live S26/3 C. psittaci. In vitro work, based
on those observations, have shown that ROvIFN-y restricts the growth of S26/3 C.
psittaci in ovine ST.6 cells and, moreover, that this effect can be partially reversed by
the addition of exogenous l-tryptophan [Graham et al, 1995].
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additional mechanisms involved in ROvIFN-y mediated restriction of C. psittaci
growth in ovine ST.6 cells and also to investigate its effects in ex vivo derived ovine
BAL cells.
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5.2. Materials and Methods
5.2.1. Pretreatment and infection of ovine ST.6 cells
ST.6 cells were suspended in IMDM+5% FBS at a density of 5X10' cells/ml, seeded
in volumes of 100 jul into 96-well flat-bottomed microtitre plates and allowed to
grow to confluence. Cultures were then incubated for 24 hours in IMDM+2% FBS
supplemented with ROvIFN-y, RBovIFN-a or Polyinosinic Acid-Polycytidylic Acid
(PolyPPolyC; ICN Biomedicals, Thame, UK) at concentrations matched for anti¬
viral activity (Chapter 2.3.3.). Control cultures were incubated in the presence of
IMDM+2% FBS alone. Cultures were then incubated with 100 jul of IMDM+5% FBS
containing lxl05 S26/ 3 C. psittaci IFU/ml for 6 hours, after which they were washed
once in IMDM+5% FBS and incubated for a further 5 days in IMDM+2% FBS.
Uninfected control were maintained in IMDM+2% FBS alone. The supernatants
were harvested and stored at -20°C.
In a separate experiment, ST.6 cultures were pre-treated for 24 hours with various
concentrations of ROvIFN-y and infected with lXlO4 S26/3 C. psittaci IFU/ml (as
described above). Cultures were subsequently maintained in either 200 jul of
IMDM+2% FBS alone, IMDM+2% FBS supplemented with 500 jUg/ml of L-
tryptophan, IMDM+2% FBS supplemented with 0.5 juM of L-NMMA, or IMDM+2%
FBS supplemented with 500 gg/ml of L-tryptophan and 0.5 juM of L-NMMA.
Cultures were incubated for 7 days, after which the supernatants were harvested
and stored at -20°C.
5.2.2. Measurement of C. psittaci multiplication in ST.6 cells




BAL cells were obtained from four SPF ewe lambs (approximately one year old)
and 10 conventionally reared adult ewes by the procedure described previously
(Chapter 2.1.6.).
5.2.4. Phenotypic characterisation of ovine BAL cells
BAL cells surface marker expression was characterised by flow cytometry using the
monoclonal antibodies detailed in Table 5.1 (following the protocol described in
Chapter 2.2.1.). Adherent cells were stained for non-specific esterase activity
(Chapter 2.2.2.) and imaged under oil immersion at a magnification of xlOOO using a
JVC TK-1280E CCD colour camera module attached to a Olympus BX-50
conventional compound microscope (Chapter 2.4.5.). The ability of adherent BAL
cells to phagocytose 3jum latex beads was also determined (Chapter 2.2.3.) and
imaged at a magnification of x400 as described above. The percentages of non¬
specific esterase positive cells and cells containing latex beads were measured using
a modified version of CellCounting.obj distributed with Object-Imagel.62n6 (Norbert
Vischer: November 1998).
Table 5.1: Antibodies used for phenotypic FACS analysis of ovine BAL cells
Antibody
VPM 49





















[Dutia et al, 1990]
[Dutia et al, 1990]
[Maddox et al, 1985]
[Mackay et al, 1988]
[Hunig, 1985]
[Naessens and Howard 1991]
[Hopkins et al, 1993]
[Gupta et al, 1996]
[Gupta et al, 1996]
[Bird et al, 1995]
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5.2.5. Stimulation of murine RAW 264.7 cells
Murine RAW 264.7 cells were adjusted to 2xl04 cells/ml in phenol red-free
Dulbecco's Modified Eagle's Medium (GIBCO BRL) supplemented with 10% FBS
(PhF-DMEM+10% FBS). 100 pi aliquots of the resultant suspension were seeded
into the central 32 wells of 96-well flat-bottomed microtitre plates and incubated
under standard conditions for 48 hours. RAW 264.7 cultures were then incubated
with various combinations of RMuIFN-y (Genzyme ltd, Suffolk, UK), bacterial LPS,
live or heat inactivated S26/ 3 C. psittaci in 100 pi of PhF-DMEM+10% FBS. Culture
supernatants were harvested after a further 8-96 hours and stored at -20°C. Cell
viability was assessed by nigrosine exclusion. In later experiments, culture
supernatants were supplemented with 100 juM of carboxy-PTIO in an attempt to
enhance the sensitivity of the Griess reaction.
5.2.6. Stimulation of ovine BAL cells
BAL cells stored in liquid nitrogen were thawed, washed once and adjusted to
2x10° cells/ml in IMDM+10% FBS supplemented with 25 jug/ml of gentamicin. 100
jul aliquots of the resultant cell suspensions were seeded into the central 32 wells of
96-well flat-bottomed microtitre plates and allowed to adhere for 6 hours. Adherent
cells were washed once with 200 gl of PhF-DMEM+10% FBS and incubated for 12
hours in 100 pi of PhF-DMEM+10% FBS. BAL cells were then incubated (in parallel
with murine RAW 264.7 cultures) with various combinations of ROvIFN-y, bacterial
LPS, live or heat inactivated S26/3 C. psittaci in 100 pi of PhF-DMEM+10% FBS
and assayed for NO' production as described above.
5.2.7. Measurement of nitric oxide production using the Griess reaction
Sodium nitrite standards (0.78-100 juM) were prepared in PhF-DMEM+10% FBS
and stored on ice. Culture supernatants were removed from storage (at -20°C) and
allowed to thaw for 30 minutes at RT. 50 p\ aliquots of the culture supernatants,
sodium nitrite standards and PhF-DMEM+10% FBS alone were then added to F-
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type 96-well ELISA plates. 100 p\ of Griess reagent (Appendix 1.13) was added to
each well, the plates were incubated for 10 minutes at RT and the absorbance of the
coloured azo product was measured at 540 nm using a Titretec Multiscan ELISA
reader. The concentration of nitrite present in the samples was extrapolated from
the standard curve provided by the sodium nitrite standards.
5.2.6. ROvlFN-y mediated restriction of C. psittaci in ovine BAL cells
BAL cells were removed from liquid nitrogen, washed once and adjusted to 2xl06
cells/ml in IMDM+10% FBS supplemented with 25 jug/ml of gentamicin. 300 jul
aliquots of the resultant cell suspension were incubated for 6 hours in 8-well
Permanox chamber-slides. Non-adherent cells were discarded, after which adherent
cells were washed once with 300 p 1 of PhF-DMEM+10% FBS and incubated for 12
hours in 200 /ul of PhF-DMEM+10% FBS. 100 jul aliquots of ROvIFN-y were added
to BAL cultures to yield final concentrations of 2.5, 25 and 250 U/ml. 100 jul of
PhF-DMEM+10% FBS alone was added to control cultures. After 24 hours, the
culture supernatants were replaced with 300 pi of PhF-DMEM+10% FBS containing
2xl04 S26/ 3 C. psittaci IFU/ml. Uninfected control cultures were incubated with 300
iul of PhF-DMEM+10% FBS alone. BAL cells were incubated for a further 60 hours,
after which they were fixed and stained with IPX (Chapter 2.4.4.). Chlamydial
replication was analysed by semi-quantitative image analysis (Chapter 2.4.6.) of
standard white light microscopy images acquired at a magnification of xlOOO under
oil immersion using a JVC TK-1280E CCD colour camera module attached to a
Olympus BX-50 conventional compound microscope (Chapter 2.4.5.). Supernatants
were assayed for nitrite as described previously.
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5.3. Results
5.3.1. Comparative analysis of the anti-chlamydial effects of RBovlFN-a and
ROvlFN-y.
C. psittaci growth was measured indirectly by LPS-ELISA in ST.6 cultures
pretreated with ROvIFN-y and RBovIFN-a at concentration which were matched for
anti-viral activity (Chapter 2.3.3.). ROvIFN-y restricted C. psittaci growth in a dose
dependent manner. In contrast, there was no evidence of reduced chlamydial growth
in cultures pretreated with RBovIFN-a (Figure 5.1). Pretreatment of cultures with
0.25 or 2.5 U/ml of ROvIFN-y significantly reduced chlamydial LPS production
compared to both the infected controls (Table 5.2) and cultures pretreated with
matched concentrations of RBovIFN-a (Figure 5.1). Very low LPS levels were
detected in the supernatants of cultures which had been pretreated with 25 and 250
U/ml of ROvIFN-y (Figure 5.1).
Table 5.2: Statistical analysis of the anti-chlamydial effects of ROvlFN-y and
RBovIFN-a at concentrations matched for anti-viral activity.
Anti-viral RBovIFN-a ROvIFN-y





Results of unmatched two-tailed Student's *t' test analysis where the null hypothesis is:
Differences between chlamydial LPS levels in the infected controls and in cultures
pretreated with ROvlFN-y or RBovIFN-a occurred by chance.
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Figure5.1: The chlamydial growth in ST.6 cells following pretreatment with
ROvlFN-y or RBovlFN-cx.
LPS (ng/ml)
250 25 2.5 0.25 Controls
Anti-viral activity (U/ml)
Triplicate cultures were pretreated with matched concentrations of ROvlFN-y (□) or
RBovlFN-a (■) for 24 hours prior to infection with 1x105 IFU/ml of the OEA S26/3 strain of C.
psittaci. Error bars represent ±1 standard deviation from the mean. Statistical significance was
determined by unmatched two-tailed Student's't' test analysis, where the null hypothesis
was: Differences between chlamydial LPS production in cultures pretreated with ROvlFN-y
and RBovlFN-a occurred by chance. The null hypothesis was rejected at P value<0.05 (*)
and P value<0.01 (**). The null hypothesis was accepted at P value>0.1 (tt). Infected
controls (■) and uninfected controls (□ not visible).
5.3.2. Comparative analysis of the anti-chlamydial effects of Polyl: PolyC and
ROvIFN-y.
C. psittaci growth was measured indirectly by LPS-ELISA in ST.6 cultures
pretreated with ROvIFN-y and Polyl: PolyC at concentrations matched for anti-viral
activity. ROvIFN-y reduced in a C. psittaci growth in a dose dependent manner
similar to that described above. 150 U/ml of Polyl: PolyC appeared to inhibit C.
psittaci growth on the basis of results generated by the LPS-ELISA. However,
microscopic analysis of the ST.6 cultures prior to infection indicated that Polyl:
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PolyC was cytotoxic at this concentration (250 /ig/ml). Similar results were also
observed in the ovine interferon bioassay (data not shown). There was no evidence
of reduced chlamydial growth in cultures pretreated with the lower concentrations
of Polyl: PolyC (Figure 5.2). In contrast, as little as 1.5 U/ml of ROvIFN-y
significantly reduced chlamydial LPS production compared to the infected controls
(Figure 5.2 and Table 5.3).
Figure5.2: The chlamydial growth in ST.6 cells following pretreatment with
ROvlFN-y or Poly I: Poly C.
LPS (ng/ml)
Anti-viral activity (U/ml)
Triplicate cultures were pretreated with matched concentrations of ROvlFN-y (□) or Polyl:
PolyC (■) for 24 hours prior to infection with 1x105 IFU/ml of the OEA S26/3 strain of C.
psittaci. Error bars represent ±1 standard deviation from the mean. Statistical significance was
determined by unmatched two-tailed Student's't' test analysis, where the null hypothesis
was: Differences between chlamydial LPS production in cultures pretreated with ROvlFN-y
and RBovlFN-a occurred by chance. The null hypothesis was rejected at P value<0.05 (*)
and P value<0.01 (**). The null hypothesis was accepted at P value>0.1 (tt)- infected
controls (■) and uninfected controls (□ not visible).
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Table 5.3: Statistical analysis of the anti-chlamydial effects of ROvIFN-y and Poly
I: Poly C at concentrations matched for anti-viral activity.
Anti-viral
activity (U/ml)
















Results of unmatched two-tailed Student's't' test analysis where the null hypothesis is:
Differences between chlamydial growth, measured indirectly by LPS-ELISA, in infected
controls and cultures pretreated with ROvlFN-y or Poly I: Poly C occurred by chance.
5.3.3. Mechanisms of ROvIFN-y mediated inhibition of C. psittaci in ST.6 cells.
C. psittaci growth was measured indirectly by LPS-ELISA in ST.6 cultures
pretreated with ROvIFN-y and maintained IMDM+2% FBS alone, IMDM+2% FBS
containing 500 gg/ml of l-tryptophan, IMDM+2% FBS containing 0.5 juM of l-
NMMA, or IMDM+2% FBS containing 500 /ug/ml of l-tryptophan and 0.5 gM of l-
NMMA. ROvIFN-y reduced in a C. psittaci growth in a dose dependent manner in
cultures maintained in IMDM+2% FBS alone (Figure 5.3). This effect was
significantly ablated (P<0.05 in all cases) in the presence of l-tryptophan (Figure
5.3). In contrast, the addition of 0.5 gM of exogenous l-NMMA was not associated
with a significant reduction in the anti-chlamydial effects of ROvIFN-y (Figure 5.4).
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Triplicate cultures were maintained in IMDM+2% FBS alone (□) or IMDM+2% FBS
supplemented with 500 pg/ml of L-tryptophan (■). Error bars represent ±1 standard
deviation from the mean. Statistical significance was determined by unmatched two-tailed
Student's't' test analysis, where the null hypothesis was: Differences between chlamydial
growth in cultures maintained in IMDM+2% FBS alone and cultures maintained in IMDM+2%
FBS supplemented with 500 ijg/m\ of L-tryptophan occurred by chance. The null hypothesis
was rejected at: P value<0.05 (*); P va!ue<0.01 (**); and P value<0.001 (***).
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Triplicate cultures were maintained in IMDM+2% FBS alone (□) or IMDM+2% FBS containing
0.5 /;M of L-NMMA (■). Error bars represent ±1 standard deviation from the mean. Statistical
significance was determined by unmatched two-tailed Student's T test analysis, where the
null hypothesis was: Differences between chlamydial growth in cultures maintained in
IMDM+2% FBS alone and cultures maintained in IMDM+2% FBS containing 0.5 /jM of L-
NMMA occurred by chance. The null hypothesis accepted at: P value>0.05 (|); P value>0.1
(«); and P value>0.5 (|||).
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Figure 5.5 The effects of L-NMMA and L-tryptophan on C. growth in ST.6










Triplicate cultures were maintained in IMDM+2% FBS alone (□) or IMDM+2% FBS containing
0.5 /jM of L-NMMA and 500 pg/ml of L-tryptophan (■). Error bars represent ±1 standard
deviation from the mean. Statistical significance was determined by unmatched two-tailed
Student's't' test analysis, where the null hypothesis was: Differences between chlamydial
growth in cultures maintained in IMDM+2% FBS alone and cultures maintained in IMDM+2%
FBS containing 0.5 pM of L-NMMA and 500 pg/ml of L-tryptophan occurred by chance. The
null hypothesis was rejected at: P value<0.05 (*); P value<0.01 (**); and P value<0.001
(***). The null hypothesis accepted at: P value>0.1 (tt).
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Figure5.6 Comparative analysis of C. psittaci growth in ST.6 cells pretreated
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Triplicate cultures were maintained in IMDM+2% FBS supplemented with 500 /vg/ml of L-
tryptophan (■) or IMDM+2% FBS containing 0.5 /vM of L-NMMA and 500 pg/ml of L-
tryptophan (□). Error bars represent ±1 standard deviation from the mean. Statistical
significance was determined by unmatched two-tailed Student's T test analysis, where the
null hypothesis was: Differences between chlamydial growth in cultures maintained in
IMDM+2% FBS containing 500 /ug/ml of L-tryptophan and cultures maintained in IMDM+2%
FBS containing 0.5 pM of L-NMMA plus 500 pg/ml of L-tryptophan occurred by chance. The
null hypothesis was accepted at: P value>0.05 ($); P value>0.1 (tt)', and P value>0.5
(ttt).
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The ability of exogenous l-NMMA to reverse the anti-chlamydial effects ROvIFN-y
was further scrutinised in the context of ST.6 cultures maintained in IMDM+2% FBS
supplemented with both l-tryptophan and l-NMMA. Whilst C. psittaci growth in
these cultures was significantly enhanced compared to cultures maintained in
IMDM+2% FBS alone (Figure 5.5), it did not differ significantly from cultures
maintained in IMDM+2% FBS containing l-tryptophan (Figure 5.6). Analysis of
culture supernatants using the Griess reaction indicated that NO* was not
produced by any of the ST.6 cultures. Chlamydial LPS production was significantly
reduced in cultures that were pretreated with ROvIFN-y and maintained in
IMDM+2% FBS alone or IMDM+2% FBS containing 0.5 ,uM of l-NMMA, but not in
cultures that were maintained in IMDM+2% FBS containing 500 |Ug/ml of l-
tryptophan or IMDM+2% FBS containing 500 jug/ml of l-tryptophan and 0.5 juM of
l-NMMA (Table 5.4).
Table5.4: Statistical analysis of the effects of l-tryptophan and l-NMMA on













250 0.0017 (-) 0.0910 (-) 0.0001 (-) 0.2634 (-)
100 0.0001 (-) 0.0051 (-) 0.0001 (-) 0.4265 (-)
25 0.0001 (-) 0.4866 (+) 0.0005 (-) 0.6643 (+)
10 0.0001 (-) 0.1629 (+) 0.0009 (-) 0.9756 (-)
2.5 0.0001 (-) 0.2045 (+) 0.0011 (-) 0.0841 (+)
1 0.0013 (-) 0.0191 (+) 0.0000 (-) 0.0285 (+)
Unmatched two-tailed Student's't' test analysis where the null hypothesis is: Differences
between chlamydial growth, measured indirectly by LPS-ELISA, in infected controls and
cultures pretreated with ROvlFN-y and maintained in IMDM+2% FBS alone or in conjunction
with L-tryptophan and/or L-NMMA occurred by chance.(+/-) indicates increase/decrease.
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Logarithmic transformation and linear regression were used to exclude the
possibility that l-tryptophan increased C. psittaci growth in a manner that was
independent of the anti-chlamydial effects of ROvIFN-y. LPS concentrations were
Log2 transformed, based on the assumption that chlamydial LPS production was
proportional to C. psittaci replication by binary fission. ROvIFN-y concentrations
were Log10 transformed to allow for the range of Logl0 dilutions used in this
experiment. A highly significant inverse linear relationship was observed between
the concentration of chlamydial LPS (Log2) produced by infected cultures and the
concentration of ROvIFN-y (Log10) with which they were pretreated (Table 5.5). The
intercepts and gradients of the regression lines obtained for cultures maintained in
IMDM+2% FBS alone or IMDM+2% FBS containing 0.5 juM of l-NMMA were
almost identical to each other. Similarly, linear regression of the ROvIFN-y dose
response of cultures maintained in IMDM+2% FBS supplemented with 500 iug/ml l-
tryptophan or IMDM+2% FBS containing both l-tryptophan and l-NMMA
produced virtually indistinguishable results. However, the gradient of the ROvIFN-y
dose response curve of cultures supplemented with exogenous l-tryptophan was
significantly shifted towards 0 compared to that of cultures maintained in the
absence of exogenous l-tryptophan (Figure 5.7 and Table 5.5).
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Figure5.7: Exogenous L-tryptophan abrogates the anti-chlamydial dose
response of ST.6 cells to ROvlFN-y.
Log2 LPS (ng/ml)
IFN-y (Log10 U/ml)
Anti-chlamydial dose response of ST.6 cells to ROvlFN-y in the presence of IMDM+2% FBS
alone (+: Regression values ), IMDM+2% FBS supplemented with 500 /jg/mi of L-
tryptophan (+: Regression values ), IMDM+2% FBS supplemented with 0.5/vM of L-
NMMA (+: Regression values ) and IMDM+2% FBS supplemented with 0.5 pM of L-
NMMA and 500 pg/ml of L-tryptophan ( : Regression values ).





























5.3.4. Phenotypic analysis of ovine BAL cells
FACS analysis of ovine BAL cells revealed a single peak of cells with increased
median fluorescence when probed with monoclonal antibodies specific for ovine
CD45, CD14 and immunoglobulin light chain surface molecules (Figure 5.8 and
Appendix 2). In contrast, there was little evidence of cells expressing significant
amounts of CD2, CD21, VPM 30 (ruminant B-cell) antigen or the y6 TCR receptor
(Appendix 2). Adherent BAL cells (Figure 5.9) were further characterised by non¬
specific esterase staining (Figure 5.10) and incubation with latex beads (Figure 5.11).
Large numbers of BAL cells from all four SPF ewe lambs stained positively for non¬
specific esterase and black granulation was seen in >96% of cells. The majority of
BAL cells also internalised latex bead (Table 5.6).
Table 5.6: Phenotypic analysis of adherent ovine BAL cells
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FACS analysis of ovine BAL cells from SPF ewe lamb #1. Control Mab VPM49: anti-Border
Disease Virus (—), VPM65: anti-CD14 (—) and +ve control Mab SBU LCA (1.28): anti-
CD45 (—) with gate (R1) set to exclude erythrocytes and dead cells.
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FACS analysis of ovine BAL cells from SPF ewe lamb #2. Control Mab VPM49: anti-Border
Disease Virus VPM65: anti-CD14 (—) and +ve control Mab SBU LCA (1.28): anti-









Figure5.8C: CD14 expression on SPF ewe lamb #3 BAL cells
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FACS analysis of ovine BAL cells from SPF ewe lamb #3. Control Mab VPM49: anti-Border
Disease Virus (—), VPM65: anti-CD14 (—) and +ve control Mab SBU LCA (1.28): anti-








Figure5.8D: CD14 expression on SPF ewe lamb #4 BAL cells
FSC-Height
250 -I
ii | i I" 'i! i | » i r » | t »i r | ii i i "j
50 100 150 200 250
FL1-Height
|' i i i r | i i r r j r r i ■ i | i" r i r>i"y
0 50 100 150 200 250
SSC-Height
FACS analysis of ovine BAL cells from SPF ewe lamb #4. Control Mab VPM49: anti-Border
Disease Virus (——), VPM65: anti-CD14 (—-) and +ve control Mab SBU LCA (1.28): anti-
CD45 (—) with gate (R1) set to exclude erythrocytes and dead cells.
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Figured Adherent ovine BAL cells (hematoxylin).
Figure5.10 Non-specific esterase staining in adherent ovine BAL cells
(hematoxylin counterstain).
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Figure5i11 Uptake of latex beads by ovine BAL cells
5.3.5. Nitric oxide production in murine RAW 264.7 cell controls
RAW 264.7 cells were used to determine the optimal concentrations of LPS, IFN-y
and C. psiitaci required to induce nitric oxide production in this cell line (data not
shown). Maximum levels of nitrite were detected in the culture supernatants of
RAW 264.7 cells maintained for 48 hours or longer in the presence of lxlO5 IFU/ml
of live C. psittaci and 500 U/ml or more of RMuIFN-y. Heat inactivated C. psittaci
and LPS (S. minnesota RE-595 or E. coli 026:b6) were less effective at inducing nitric
oxide production in RAW 264.7 cells than live C. psittaci. Heat inactivated C. psittaci
(lxlO5 EB/ml) and LPS (10 mg/ml) induced optimal levels of NO" production when
maintained in the culture conditions for 48 hours or longer in the presence of 500
U /ml of RMuIFN-y.
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5.3.6. Direct comparison of nitric oxide production in ovine BAL cells and murine
RAW 264.7 cells
NO' production was measured in ovine BAL and RAW 264.7 cultures maintained in
various combinations of recombinant IFN-y, LPS and heat inactivated or live C.
psittaci for 48 hours (Figure 5.12). Ovine BAL and RAW 264.7 cultures maintained
in DMEM+10% FBS supplemented with 3.9, 7.8, 15.6, 31.3, 62.5, 125, 250 or 500
U/ml of recombinant IFN-y did not produce significant amounts of nitric oxide
compared to cultures maintained in DMEM+10% FBS alone (unmatched two-tailed
Student's 't' test analysis: P value = 1 in all cases). Significant (unmatched two-
tailed Student's 't' test analysis: P value <0.01) amounts of nitric oxide were
produced by RAW 264.7 cultures maintained in DMEM+10% FBS containing 1
jug/ml of LPS and 250 U/ml or more of RMuIFN-y. Nitric oxide production reached
a similar level of significance (unmatched two-tailed Student's 't' test analysis: P
value <0.01) in RAW 264.7 cultures maintained in the presence of 250 U/ml or
more of RMuIFN-y and 1x10s EB/ml of heat inactivated C. psittaci. RAW 264.7
cultures infected with 1x10s IFU/ml of live C. psittaci produced significant
(unmatched two-tailed Student's't' test analysis: P value <0.01) amounts of nitric
oxide in the presence of 62.5 U/ml or more of RMuIFN-y (Figure 5.12A).
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Figure5.12: Nitric oxide production by murine RAW 264.7 cells and ovine BAL
cells over 48 hours.
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RMuIFN-y (U/ml)
















Nitrite accumulation in triplicate cultures of murine RAW 264.7 (A) and ovine BAL (B) cells
over 48 hours incubation with various concentrations of IFN-y and: DMEM+10% FBS alone
( ); DMEM+10% FBS +1 /yg/ml LPS ( ); DMEM+10% FBS + 1x105 IFU/m of
C. psittaci(—• , not visible in B); DMEM+10% FBS + 1x10s EB/ml of heat inactivated C.
psittaci (- not visible in B). Error bars represent ±1 standard deviation from the mean.
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Rgure5.13: Time course of nitric oxide production by murine RAW 264.7 cells
and ovine BAL cells in the presence of carboxy-PTIO.
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Nitrite accumulation in triplicate cultures of murine RAW 264.7 (A) and ovine BAL (B) cells
over 17 hours post stimulation. Cultures were maintained in DMEM+10% FBS
supplemented with 10 pg/ml of LPS (—® , not visible in B), 1 jug/ml of LPS + 1000 U/ml
of IFN-y (~~"• , not visible in B), or 10 /yg/ml of LPS + 1000 U/ml of IFN-y (—® not
visible in B). Control cultures were maintained in DMEM+10% FBS alone ( ). 100 juM
carboxy PTIO was maintained in the culture conditions throughout the experiment. Error bars
represent ±1 standard deviation from the mean.
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Ovine BAL cells from all four SPF ewe lambs failed to produce significant levels of
nitric oxide (unmatched two-tailed Student's *t* test analysis: P value =1 in all cases)
in response to any of the stimuli (Figure 5.12A). There was no evidence of increased
nitric oxide production when these experiments were repeated using up to 1000
U/ml of ROvIFN-y and 100 jug/ml of LPS (data not shown). There was no evidence
for nitric oxide production in response to any of the above stimuli by BAL cell
obtained from 10 conventionally reared adult ewes (data not shown). Whilst there
was evidence of an immediate cytotoxic effect in cultures infected with 1x10s
IFU/ml of C. psittaci, viability remained high (>90%) in the case of all other
treatments.
In an attempt to increase the sensitivity of the Griess reaction, experiments were
repeated in the presence of carboxy-PTIO [Amano and Noda, 1995]. Carboxy-PTIO
increased nitrite accumulation in RAW 264.7 cultures, allowing detection of
significant (unmatched two-tailed Student's't' test analysis: P value <0.01) amounts
of nitric oxide production by 10 hours post stimulation in cultures treated with
10|Ug/ml of LPS alone (Figure 5.13A) and significantly enhanced nitrite
accumulation in RAW 264.7 cultures maintained for up to 96 hours (data not
shown). Carboxy-PTIO did not result in the detection of significant (unmatched
two-tailed Student's't' test analysis: P value = 1) amounts of nitrite in ovine BAL
cultures (Figure 5.13B) and there was no evidence for nitric oxide production in
cultures maintained for 96 hours in the presence of up to 10 jug/ml of LPS and 1000
U/ml of ROvIFN-y (data not shown).
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5.3.7. ROvlFN-y mediated restriction of chlamydial growth in ovine alveolar
macrophages
Figure5.14 Typical C. psittaciinclusionmorphology (arrow) in untreated ovine
alveolar macrophages (IPX/hematoxylin).
Approximately 20% of BAL cells in cultures which had not been pretreated with
ROvIFN-y developed a single large (5.8±2.4 |/m diameter: n=100) inclusion body
which stained intensely with MOMP-specific IPX (Figure 5.14). Multiple inclusion
bodies (2-3/cell) were very rare in these cultures (>1% of cells) and were typically
only marginally smaller than those in cells containing one body (3.2-1.7 jUm
diameter: n=30). This pattern was consistent in BAL cells from all four SPF lambs.
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Figure 5.15 Typical (black arrow) and aberrant (red arrow) C. psittaci inclusion
morphology in ovine BAL cells pretreated with 2.5 U/ml of ROvlFN-y
(IPX/hematoxylin).
Cultures that had been pretreated with ROvIFN-y prior to infection showed an
increase in the amount of cells staining positively with IPX. Approximately 30% of
BAL cells pretreated with 2.5 U/ml of ROvIFN-y stained positively for C. psittaci
MOMP. However, the majority of BAL cells pretreatment with 2.5 U/ml ROvIFN-y
contained aberrantly small (0.9±0.2 (jm diameter: n=193) multiple inclusion bodies
(Figure 5.15: Red arrow), although more typical inclusion bodies were also evident in
these cultures (Figure 5.15: Black arrow). Cells containing multiple inclusion bodies
also tended to exhibit increased plasma membrane projections. This pattern was
consistent in BAL cells from all four sheep.
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Figure5.16 Aberrant C. psittaci inclusion morphology (arrow) in ovine BAL cells
pretreated with 25 U/ml of ROvlFN-y (IPX/hematoxylin).
As the concentration of ROvIFN-y was increased the frequency of cells staining
positively for MOMP increased. However, very few cells treated with 25 U/ml of
ROvIFN-y contained morphologically "normal" inclusion bodies (<1% of cells
containing inclusion bodies: n=112). Furthermore, the number of aberrant inclusion
bodies within each cell increased, although the size remained constant (0.8±0.3 jttm
diameter: n=213). There was also evidence of increased plasma membrane
projections in cells containing antigen and a change in the spatial arrangement of
BAL cells toward a more clumped distribution (Figure 5.16). This pattern was
consistent in BAL cells derived from all four sheep.
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Figure5.17 Aberrant C. psittaci inclusion morphology (arrow) in ovine BAL cells
pretreated with 250 U/ml of ROvlFN-y (IPX/hematoxylin).
10 pm
Approximately 40% of BAL cells from cultures which were pretreated with 250
U/ml of ROvIFN-y contained vesicles which stained positively for MOMP by IPX.
Morphologically "normal" inclusion bodies were not observed in any of the BAL
cultures pretreated with 250 U/ml of ROvIFN-y. Some cells contained as many as
20 small (1.0±0.2 jum diameter: n=198) vesicles of chlamydial antigen and exhibited
increased plasma membrane projections (Figure 5.18). This pattern was consistent
in BAL cells derived from all four sheep.
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5.4. Discussion
Initial attempts to delineate the mechanisms through which ROvIFN-y inhibits the
growth of C. psittaci in ovine ST.6 cells suggested that they are independent from its
anti-viral activities. Pretreatment of ST.6 cultures with ROvIFN-y, Poly I: Poly C or
RBovIFN-a prevented cytopathic growth of SFV in the ovine interferon bioassay.
However, when used at concentrations matched for anti-viral activity, only
ROvIFN-y was shown to restrict the growth of C. psittaci in ST.6 cells (Figures 5.1
and 5.2). Although 150 U/ml of Poly I: Poly C appeared to restrict C. psittaci LPS
production, this effect was due to a reduction in number of ST.6 host cells resulting
from the cytotoxic effect of Poly I: Poly C at this concentration (500 ^g/ml), rather
than a direct anti-chlamydial effect. These findings parallel the results of previous
studies in human macrophages and T24 cells which showed that RHuIFN-y, but not
recombinant human IFN-a (RHuIFN-a) or recombinant human IFN-p (RHuIFN-p),
inhibited the growth of C. psittaci, Toxoplasma gondii and Leishmania donovani
[Murray et al, 1989].
The mechanisms through which IFN-y restricts the growth of chlamydiae in human
and murine cells appear to be distinct [De La Maza et al, 1985; Murray and
Teitelbaum, 1992]. Whilst initial studies in ovine ST.6 cells suggest a role for
tryptophan depletion [Graham et al, 1995], the possibility that NO' production
contributes to the anti-chlamydial effects of ROvIFN-y required clarification.
Addition of exogenous l-tryptophan to ST.6 cultures that were pretreated with
ROvIFN-y resulted in significantly increased chlamydial growth (Figures 5.3 and
Table 5.4). However, there was also evidence that exogenous l-tryptophan
increased chlamydial growth in control cultures that were not pretreated with
ROvIFN-y (Figures 5.3). In contrast, NO' production was not detected in the
supernatants of ST.6 cells that had been pretreated with ROvIFN-y (data not
shown). In addition, there was no evidence that l-NMMA reversed the anti-
chlamydial effects of ROvIFN-y (Figures 5.4 - 5.6 and Table 5.4) and it would
appear that NO' production is unlikely to be involved in ROvIFN-y mediated
restriction of C. psittaci growth in ovine ST.6 cells. Whilst these findings show that
exogenous l-tryptophan can enhance C. psittaci growth in ROvIFN-y pretreated ST.6
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cells, they do not rule out the possibility that this effect is unrelated to the anti-
chlamydial effects of ROvIFN-y.
To confirm that ROvIFN-y and L-tryptophan depletion are directly related, the data
were logarithmically transformed to allow linear regression of the ROvIFN-y dose
response. If exogenous L-tryptophan completely abrogates the anti-chlamydial
effects of ROvIFN-y in the absence of an independent increase in C. psittaci growth,
the intercept of the dose response curve would remain constant regardless of
whether cultures were maintained in L-tryptophan or not. However, the gradient of
the dose response curve would be shifted to zero in cultures that were
supplemented with exogenous L-tryptophan.
Alternatively, if exogenous L-tryptophan enhances C. psittaci growth through a
mechanism that is independent of the anti-chlamydial effects of ROvIFN-y, the
gradient of the dose response curve for cultures supplemented with exogenous i-
tryptophan would be identical to that of cultures maintained in IMDM+2% FBS
alone. In this case only the intercept value would change in cultures supplemented
with exogenous L-tryptophan, with the effect that the dose response curve would be
shifted vertically but remain parallel to that obtained for cultures that were not
supplemented with exogenous L-tryptophan.
Whilst the linear regressions obtained for the ROvIFN-y dose responses in the
experiment detailed here did not conform exactly to either of these two extremes,
the gradients of the dose response curves obtained for cultures supplemented with
exogenous L-tryptophan were markedly shifted towards zero suggesting that
tryptophan availability and the ability of ROvIFN-y to restrict C. psittaci growth are
directly related (Figure 5.7 and Table 5.5). Despite the fact that C. psittaci growth
was enhanced by exogenous L-tryptophan in cultures that were not pretreated with
ROvIFN-y, these results strongly support a role for tryptophan catabolism in
ROvIFN-y mediated restriction of C. psittaci growth in ovine ST.6 cells.
Although these finding suggest that the anti-chlamydial effects of ovine IFN-y may
share similarities with that of human IFN-y [Byrne et al, 1986; Mehta et al, 1998;
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Murray et al, 1989; Summersgill et al, 1995; Thomas et al, 1993], the mechanisms
through which IFN-y restricts the growth of chlamydiae are also likely to be affected
by the phenotype of the target cell. Murray et al (1989) reported that whilst both
RHuIFN-y the type 1 interferons, RHuIFN-a and RHuIFN-(3, upregulate tryptophan
catabolism in human macrophages, only RHuIFN-y was capable of restricting the
growth of C. psittaci, T. gondii and L. donovani. However, they also reported that the
anti-microbial effects of RHuIFN-y were partially reversed by exogenous tryptophan
and concluded that although tryptophan depletion contributes to the anti-microbial
effects of IFN-y it does not appear to be sufficient or required to restrict the growth
of intracellular pathogens in human macrophages. Investigation of the mechanisms
responsible for ROvIFN-y mediated restriction of C. psittaci growth was
subsequently extended to include ex vivo derived ovine BAL cells.
Phenotypic and functional analysis confirmed that BAL cells were analogous to
macrophages. FACS analysis showed that ovine BAL cells comprised a single
homogeneous population expressing CD45 and CD14 but not CD2, CD21, y6 TCR
or VPM 30. Although there was little evidence for BAL cells expressing ovine CD21
or the ruminant B-cell marker, VPM 30 antigen [Hopkins et al, 1993], the entire
population of BAL cells stained positively for immunoglobulin light chain
(Appendix 2). The most likely explanation for these apparently conflicting results is
that the anti-immunoglobulin antibody, VPM 8 [Bird et al, 1995], recognised in vivo
acquired immunoglobulin bound to BAL cell Fc receptors. Furthermore, BAL cells
were highly adherent, phagocytic and stained positively for non-specific esterase
activity in a maimer that suggests they were functionally analogous to macrophages
[Yam et al, 1971],
The murine macrophage RAW 264.7 cell line produced abundant amounts of NO' in
response to stimulation with RMuIFN-y in combination with LPS, heat inactivated
S26/3 C. psittaci or live S26/3 C. psittaci (Figure 5.12). NO' detection was enhanced
when RAW 264.7 cultures were maintained in the presence of 100 pM of carboxy-
PTIO (Figure 5.13), which increases nitrite accumulation and improves the
sensitivity of the Griess reaction [Amano et al, 1995]. In contrast, NO' production
was not induced in ovine BAL macrophages from all four SPF ewe lambs, even
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when they were stimulated with much higher concentrations of LPS and
recombinant IFN-y than were required for optimal NO' production in RAW 264.7
cultures. In addition, NO' production could not be induced in BAL macrophages
derived from a further 10 conventionally reared adult ewes. Inclusion of carboxy-
PTIO in the culture conditions did not result in the detection of significant amounts
of nitrite in any of the BAL macrophages cultures examined here. These findings
suggest that, like human macrophages [Murray and Teitelbaum, 1992] but in
contrast to murine macrophages [Chen et al, 1996], NO* production is unlikely to be
involved in ROvIFN-y mediated restriction of C. psittaci in ovine macrophages.
Both human and murine macrophages have been shown to be susceptible to
infection with C. psittaci or C. trachomatis [Manor and Sarov, 1986; Wyrick and
Brownridge, 1978; Wyrick et al, 1978; Zhong and De La Maza, 1988]. In contrast, C.
pneumoniae growth has been shown to be restricted in human macrophages infected
ex vivo [Gaydos et al, 1996], An immediate cytotoxic effect was observed in ovine
BAL macrophages that were incubated with live S26/ 3 C. psittaci at ratio of 1.0 EB
per macrophage, but in agreement with previous studies using murine macrophages
[Wyrick and Brownridge; 1978, Wyrick et al, 1978; Su and Caldwell, 1995] and
ovine BAL macrophages [Entrican et al, 1999], this effect was abolished when EB
were heat inactivated or the ratio of EB to macrophages was reduced. Microscopic
examination of ovine BAL macrophages, 60 hours after they were infected with C.
psittaci at a ratio of 0.1 EB per macrophage, revealed large, typically singular,
chlamydial inclusion bodies which stained intensely by IPX in approximately 20% of
macrophages (Figure 5.14). These finding suggest that, not only do ovine BAL
macrophages support C. psittaci growth, but they appear to be more susceptible to
infection than the ST.6 cell line which was used to determine the number of C.
psittaci EB (IFU /ml) of used in this experiment. The reason for this is not clear, but
it may be related to differences in the phagocytic ability of the two cell types.
Whilst ROvIFN-y did not induce NO' production in ovine BAL macrophages
infected with C. psittaci, it did have a number of interesting effects on the growth of
the pathogen. The finding that ROvIFN-y increased the percentage of BAL
macrophages that contained what appeared to be inclusion bodies is surprising
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given that IFN-y has been extensively shown to inhibit C. psittaci inclusion body
formation in human and murine macrophages [Rothermel et al, 1983, 1986; Murray
and Teitelbaum, 1992; Murray et al, 1989; Carlin and Weller, 1995], Furthermore,
ROvIFN-y mediated restriction of C. psittaci LPS production in ST.6 cells is
associated with a reduction in the number of cell containing inclusion bodies (data
not shown). Interestingly, ROvIFN-y also appeared to increase plasma membrane
activity in BAL macrophages, an effect which was most notable in cultures which
were pretreated with 250 U/ml of ROvIFN-y (Figure 5.17). The increase in the
percentage of cells containing MOMP suggests that this may reflect increased
phagocytic activity.
Although ROvIFN-y increased the percentage of BAL macrophages containing
inclusion bodies it also had a highly marked effect on inclusion body morphology.
Typical inclusion body morphology (Figure 5.14) was rare in BAL macrophages that
were pretreated with 25 U/ml ROvIFN-y and entirely absent from cultures
pretreated with 250 U /ml. Instead, BAL macrophages from these culture contained
multiple small (0.9±0.3 jum diameter), spherical vesicles which stained positively for
C. psittaci MOMP by IPX (Figure 5.17).
There are a number of possible explanations for this finding. The vesicles of MOMP
observed in BAL macrophages pretreated with ROvIFN-y may be phagolysosomes
containing MOMP derived from degraded C. psittaci rather that classical inclusion
bodies containing viable replicating chlamydiae. Under these circumstances the
increase in both the percentage of macrophages with vesicles containing MOMP and
the number of vesicles per cell may be explained by the presence of large numbers of
non-viable chlamydiae in inoculum used to infect the cultures. This is supported by
the observation that during the preparation of tissue culture-derived stocks of the
S26/3 C. psittaci (Chapter 2.1.8.) the titre of infectious EB (IFU/ml) commonly falls
by over 1 Log10 after freezing in chlamydial transport medium (data not shown).
Alternatively, ROvIFN-y may block the aggregation of endosomes containing
chlamydiae in BAL macrophages infected with multiple EB and normal inclusion
body formation in a manner that is similar to effects of intracellular free Ca2+
depletion described in murine McCoy and human HeLa 229 cells infected with C.
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trachomatis [Majeed et al, 1993; 1994], Whilst this could represent a novel
mechanism through which ROvIFN-y restricts the growth of C. psittaci in ovine
macrophages it does not explain the increase in the number of cells with vesicles
containing MOMP. Another possibility is that C. psittaci initially forms normal
inclusion bodies that are subsequently degraded in ROvIFN-y pretreated BAL
macrophages. Further studies incorporating confocal microscopy may help to clarify
this novel effect of ROvIFN-y in ovine macrophages.
Whilst it is clear that ROvIFN-y induced aberrant C. psittaci inclusion body
morphology in ovine BAL macrophages, these studies did not confirm whether
infection of BAL macrophages was associated with the production of infectious
chlamydiae or if ROvIFN-y was capable of inhibiting C. psittaci growth in these cells.
Future time course studies and titration of BAL macrophage supernatants for
infectious chlamydiae would resolve this issue.
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Chapter 6.0
Persistent C. psittaci Infection of Ovine Cells
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6.1 Introduction
Persistent subclinical infection of the non-pregnant ewe with the agent responsible
for OEA was first confirmed in 1951 [McEwen et al, 1951b]. The ability of C. psittaci
to persist in the non-pregnant ewe without inducing protective immunity to OEA is
not only critical for its survival and dissemination but also severely complicates the
diagnosis and control of this pathogen [Buxton, 1994; Rodolakis, 1998], However,
the question as to how C. psittaci persists in immunocompetent sheep without
inducing protective immunity remains largely unresolved. Given that C. psittaci does
not appear to cause significant pathology prior to pregnancy [Amin and Wilsmore,
1995; Buxton et al, 1996; Huang et al, 1990], it can be assumed that the immune
response in the naive non-pregnant ewe is able to restrict, but not eradicate, the
pathogen. Current diagnostic technology is limited to the identification of ewes
which have already aborted as a result of OEA and is consequently of limited
prophylactic value. Identification of the immune mechanisms through which
persistence is established and maintained in the ewe would not only provide a basis
for the identification of persistently infected animals but might also have extensive
ramification for vaccine design.
IFN-y has been reported to induce and maintain persistent C. trachomatis infection in
human HeLa 229 cells [Beatty et al, 1993; 1994a; 1994b; 1995] and more recently in
polarised human epithelial cells [Kane and Byrne, 1998]. IFN-y mediated
persistence has also been reported in human HEp-2 cells infected with C.
pneumoniae [Mehta et al, 1998]. Similarly, short term in vitro studies have shown
that ROvIFN-y can restrict the growth of the S26/3 strain of C. psittaci in ovine ST.6
cells [Graham et al, 1995] (Chapter 5) and ovine alveolar macrophages (Chapter 5)
in a dose dependent manner. However, whether ROvIFN-y eradicates chlamydiae
from ovine cultures or simply restricts chlamydial growth in a reversible manner
similar to that described in human cells [Beatty et al, 1995; Kane and Byrne, 1998;
Mehta et al, 1998] has not been established. Consequently, it was of interest to
determine the role, if any, ROvIFN-y plays in establishing and maintaining
persistence in ovine cells.
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6.2 Materials and Methods
6.2.1 Infection of ST-6 cells and treatment with ROvlFN-y
ST.6 cells were seeded into 25 cm2 vented tissue culture flasks (Costar, High
Wycombe, U.K.) at a density of 5xl04 cells/ml in 6 ml of IMDM+5% FBS (culture
medium). After 3 days, when ST.6 cell monolayers were still sub-confluent, cells
were incubated with 1 ml of culture medium containing 3x10" C. psittaci strain S26/ 3
EB. Mock-infected controls were incubated with 1 ml of culture medium alone. After
6 hours, the supernatants were removed and replaced with 6 ml of culture medium
containing concentrations of between 0 and 100 U/ml of ROvIFN-y. The exact
concentrations of ROvIFN-y used in these experiments are displayed in Table 6.1.
Table6.1: ST.6 culture treatments
Experiment ROvlFN-y (U/ml) ROvlFN-y (U/ml)
Number Infected cultures uninfected cultures
6.3.1 0,0.1,0.5,1.0,5.0,10.0 0
6.3.2 10, 100 0
6.2.2 Maintenance of persistently infected ST.6 cells
Cultures were passaged into fresh 25 cm2 vented tissue culture flasks every 7 days
following the procedure outlined in section 2, with the following adaptations. The
cells were detached with trypsin/versene, washed in 10 ml of culture medium,
centrifuged at 400 g for 5 minutes and resuspended in fresh culture medium. The
cells from each flask were passaged at a 1 : 3 ratio and seeded into two fresh flasks
in 6 ml volumes. ROvIFN-y was then added to only one of each pair of new cultures
to give the same final concentration of ROvIFN-y that the cells had been maintained
in during the previous 7 days. The other flask was maintained in ROvIFN-y-free
culture medium for the duration of the experiment or until chlamydiae lysed all the
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ST.6 cells. This method of passaging cultures was used throughout the experiments.
The procedure is represented diagrammatically in Figure 6.1.
6.2.3 Measurement of C. psittacimultiplication
Cultures were examined for evidence of C. psittaci growth at intervals of 7 days.
Culture supernatants were collected prior to passage and assayed for chlamydial
LPS by ELISA (Chapter 2.5.1.). In experiment 6.3.2, culture supernatants were also
titrated on ST.6 cells to determine the numbers, if any, of infectious chlamydiae
present (Chapter 2.5.2.). Giemsa stain was used to identify C. psittaci inclusion
bodies (Chapter 2.4.3.).
6.2.4 Statistics
Spearman's Rank correlations were performed where evidence of dose dependent
effects were observed. Triplicate data was generated by the LPS-ELISA and
titration of supernatants. However, because each replicate represented the same
culture supernatant it would be inappropriate to use these data for comparative
statistics.
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7 Days after infection
14 Days after infection
21 Days after infection
28 Days after infection
▼ T
Figure &1: ROvlFN-y was maintained in the culture medium for the duration of the
experiment (i—1) At each passage, secondary cultures were established and
maintained in ROvlFN-y-free culture medium (r"1). This generated cultures in which
ROvlFN-y was maintained for: (*) the first 7 days after infection; (**) the first 14 days




6.3.1 Restriction of C. psittaci growth in ovine ST.6 ceils maintained in ROvlFN-
Y for 21 days
25 cm2 vented tissue culture flasks containing confluent monolayers of ST.6 cells
were infected with 3x10" C. psittaci strain S26/3 EB on day 0. An uninfected control
culture was incubated in parallel with culture medium alone. One of the infected
cultures was maintained in ROvIFN-y-free culture medium and used as the infected
control. The remaining infected cultures were maintained in culture medium
containing 0.1, 0.5, 1, 5 or 10 U/ml of ROvIFN-y for periods of 7, 14 and 21 days.
The uninfected control was maintained for the duration of the experiment and used
to provide background values for the LPS-ELISA.
The results of LPS-ELISA analysis of culture supernatants on day 14 are displayed
in figure 6.2A. ROvIFN-y reduced C. psittaci LPS production in a dose dependent
manner, regardless of whether it was maintained in the culture medium for 7 or 14
days after infection (Spearman Rank Correlation Coefficient {ROvIFN-y/ml :
IFU/ml}: rs = -1.00, p<0.01 in both cases). There was evidence of an increase in
chlamydial growth when ROvIFN-y was removed from the culture medium on day 7.
LPS was not detected in the culture maintained for 14 days in 10 U/ml of ROvIFN-
V-
The results of LPS-ELISA analysis of culture supernatants on day 21 are displayed
in figure 6.2B. Cultures treated with 5 or less U/ml of ROvIFN-y failed to control
chlamydial growth, resulting in complete lysis of these cultures and the absence of
detectable dose dependent restriction of chlamydial LPS production (Spearman
Rank Correlation Coefficient {ROvIFN-y/ml: IFU/ml}: ROvIFN-y maintained for 21
days r9 = 0.00, p>l and for 14 days rs = -0.3, p>0.6). LPS production was not
detected in the culture maintained in 10 U/ml for 21 days. However, detectable
concentrations of LPS were found when ROvIFN-y was removed from the culture
medium in the last 7 days of culture.
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Chlamydial growth in ovine ST.6 cells 14 days after infection, measured indirectly using an
LPS-ELISA to assay the concentration of chlamydial LPS in triplicate supernatant samples
from each culture. ROvlFN-y was maintained in cultures for 14 days (H) or for the first 7 days
of culture (H)< Infected control (■). Uninfected control (■).
LPS (ng/ml)
ROvlFN-y (U/ml)
Chlamydial growth in ovine ST.6 cells 21 days after infection, measured indirectly using an
LPS-ELISA to assay the concentration of chlamydial LPS in triplicate supernatant samples
from each culture. ROvlFN-y was maintained in cultures for 21 days (Q) or for the first 14
days of culture (H). Infected control (H). Uninfected control (■).
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Despite the absence of detectable chlamydial LPS in the culture supernatants,
chlamydial inclusion bodies were clearly visible in all the infected cultures
throughout this experiment.
6.3.2 Persistence C. psittaci infection of ovine ST.6 ceils maintained in ROvlFN-
y for up to 28 days after infection.
The initial findings detailed in 6.3.1 suggested that it may be possible to induce
persistent C. psittaci infection of ovine ST.6 cells through the action of ROvIFN-y
alone. The presence of replicating chlamydiae in cultures from which the
supernatants were found to be negative for chlamydial LPS by ELISA indicated that
the use of the LPS-ELISA alone was not suitable for determining whether
chlamydial growth had been completely arrested. In the next experiment, the
maximum concentration of ROvIFN-y used was increased by a factor of 10,
chlamydial LPS production was measured using the LPS-ELISA and the numbers of
infectious EB present in the culture supernatants were determined by titration. 25
cm2 vented tissue culture flasks containing confluent monolayers of ST.6 cells were
infected with 3x10" C. psittaci strain S26/3 EB on day 0. An uninfected control
culture was incubated in parallel with culture medium alone. Infected cultures were
maintained in culture medium containing 10 or 100 U/ml of ROvIFN-y for periods
of 7,14, 21 and 28 days. The uninfected control was maintained for the duration of
the experiment and used to provide negative controls for the LPS-ELISA and
titration analysis.
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Figure63 Analysis of C. psittaci growth in ST.6 cells treated with ROvlFN-y for
14 Days.
fa LPS (ng/ml)




Chlamydial growth in ovine ST.6 cells 14 days after infection, measured indirectly using an
LPS-ELISA to assay the concentration of chlamydial LPS in triplicate supernatant samples
from each culture. ROvlFN-y was maintained in cultures for 14 days (■) or for the first 7 days








Chlamydial growth in ovine ST.6 cells 14 days after infection, measured by titration of
inclusion forming units (IFU) in triplicate supernatant samples from each culture. ROvlFN-y
was maintained in cultures for 14 days (□) or for the first 7 days of culture (HI). Uninfected
control (■ not visible).
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6.3.2.1 Analysis of C. psittaci growth on day 14
The results of LPS-ELISA analysis of culture supernatants on day 14 are displayed
in figure 6.3A. LPS was not detected in cultures maintained for 14 days in medium
containing ROvIFN-y. When ROvIFN-y was removed from the culture conditions on
day 7, the amount of LPS increased in the culture treated with 10 U /ml, but
remained at background levels in the culture treated with 100 U/ml. The results of
titration analysis of culture supernatants for infectious chlamydiae on day 14 are
displayed in figure 6.3B. Infectious EB were not detected in the supernatants of the
cultures maintained for 7 or 14 days in medium containing 100 U/ml of ROvIFN-y.
Infectious EB were found in the supernatants of the cultures maintained in 10 U /ml
for 7 and 14 days after infection. Removal of ROvIFN-y from the culture conditions
on day 7 resulted in a 10 fold increase in the numbers of infectious EB present in the
supernatant of the culture that had been treated with 10 U/ml of ROvIFN-y, but
had no effect on the culture treated with 100 U /ml.
6.3.2.2 Analysis of C. psittaci growth on day 21
The results of LPS-ELISA analysis of culture supernatants on day 21 are displayed
in figure 6.4A. Chlamydial LPS production was not detected when cultures were
maintained in 10 or 100 U/ml of ROvIFN-y for 21 days. Detectable amounts of LPS
were recorded in cultures maintained in 10 U/ml for 7 and 14 days, and in the
culture maintained in 100 U/ml for 7 days. The results of titration analysis of
culture supernatants for infectious chlamydiae on day 21 are displayed in figure
6.4B. Infectious EB were found in all of the cultures that were treated with 10 U /ml
of ROvIFN-y, regardless of how long it was maintained in the culture medium.
Infectious EB were not detected in cultures maintained for 14 or more days in 100
U/ml of ROvIFN-y. However, infectious EB were recovered when ROvIFN-y was
removed from the culture conditions on day 7. In all cases, the shorter the duration
of exposure to ROvIFN-y, the higher the concentration of LPS and greater the
number of infectious EB found in culture supernatants.
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Chlamydial growth in ovine ST.6 cells 21 days after infection, measured indirectly using an
LPS-ELISA to assay the concentration of chlamydial LPS in triplicate supernatant samples
from each culture. ROvlFN-y was maintained in cultures for 21 days (B). for the first 14 days
(■) or for the first 7 days of culture (B)- Uninfected control (B)<
10 100 0
ROvlFN-y (U/ml)
Chlamydial growth in ovine ST.6 cells 21 days after infection, measured by titration of
inclusion forming units (IFU) in triplicate supernatant samples from each culture. ROvlFN-y
was maintained in cultures for 21 days (B). for the first 14 days (B) or for the first 7 days of
culture (B)> Uninfected controls (B not visible).
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Chlamydial growth in ovine ST.6 cells 28 days after infection, measured indirectly using an
LPS-ELISA to assay the concentration of chlamydial LPS in triplicate supernatant samples
from each culture. ROvlFN-y was maintained in cultures for 28 days (□), for the first 21 days
(■), for the first 14 days (□) or for the first 7 days of culture (@). Uninfected control (■).
10 100 0
ROvIFN-y (U/ml)
Chlamydial growth in ovine ST.6 cells 28 days after infection, measured by titration of
inclusion forming units (IFU) in triplicate supernatant samples from each culture. rOvlFN-y
was maintained in cultures for 28 days (□), for the first 21 days (■), for the first 14 days (El)
or for the first 7 days of culture (H). Uninfected controls were not inoculated with C.psittaci
EB (■ not visible).
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6.3.2.3 Analysis of C. psittaci growth on day 28
The results of LPS-ELISA analysis of culture supernatants on day 28 are displayed
in figure 6.5A. Chlamydial LPS production was restricted to background levels
when ROvIFN-y was maintained in the culture media for 28 days. Removal of
ROvIFN-y from the culture conditions on day 21 had no detectable effect on the LPS
concentration of the culture treated with 100 U/ml of ROvIFN-y but resulted in a
increase in LPS production in the culture treated with 10 U/ml of ROvIFN-y. LPS
was detected in the culture supernatants of all cultures in which ROvIFN-y was
removed from the culture medium on or before day 14. The results of titration
analysis of culture supernatants for infectious chlamydiae on day 28 are displayed
in figure 6.5B. Infectious EB were found in all of the cultures treated with 10 U/ml.
Infectious EB were not detected in cultures maintained for 21 or 28 days in 100
U/ml of ROvIFN-y. However, Infectious EB were detected when cultures treated
with 100 U /ml of ROvIFN-y were transferred into ROvIFN-y-free culture medium on
or before day 14.
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6.4 Discussion
For IFN-y to mediate persistent chlamydial infection, its effects must be nonlethal to
the pathogen and must also be reversible. Beatty et al (1993; 1994a; 1994b) showed
that treatment of HeLa 229 cells with 0.2 ng/ml of RHuIFN-y shortly after infection
with C. trachomatis (serovar A) could induce and maintain persistent infection.
Removal of RHuIFN-y from the culture conditions, up to 30 days after infection,
resulted in the recovery of viable infectious chlamydiae and restored the normal
cytolytic growth cycle of C. trachomatis [Beatty et al, 1995].
In the results of the initial experiment in ovine ST.6 cells, presented in section 6.3.1,
relatively low concentrations of ROvIFN-y (0.1 U/ml to 10 U/ml) were able to
restrict chlamydial LPS production in ST.6 cells in a dose dependent manner but
did not eradicate it completely from the cultures. Chlamydial LPS production was
reduced to a level below the detection limit of the LPS-ELISA when ST.6 cells were
maintained in 10 U/ml of ROvIFN-y (figure 6.2). When ROvIFN-y was removed
from the culture medium on days 7 and 14 there was an increase in chlamydial LPS
production, showing that the effects of ROvIFN-y are reversible. However, whilst
the concentrations of ROvIFN-y used in this experiment were able to restrict the
chlamydial LPS production, they did not prevent C. psittaci-mediated lysis of all the
ST.6 cultures by day 35. The presence of replicating chlamydiae in these cultures in
the absence of detectable levels of LPS indicated that the LPS-ELISA was not a
suitable method for determining if C. psittaci growth had been completely inhibited.
This finding also suggests C. psittaci LPS expression may be depressed in
persistently infected ST.6 cultures in a similar manner to that described for
persistent C. trachomatis infection in human cells [Beatty et al, 1993; 1994a; 1994b].
It was decided that traditional methods of assessing chlamydial growth by titration
of infectious chlamydiae and visual enumeration of chlamydial inclusions would
have to be used in conjunction with the LPS-ELISA in future experiments.
A second experiment was carried out using concentrations of 10 and 100 U/ml to
establish whether ROvIFN-y could inhibit chlamydial growth completely. The results
of this experiment are presented in section 6.3.2. 10 U/ml of ROvIFN-y was able to
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reduce chlamydial LPS production to background levels (<1 ng/ml) when it was
maintained in the culture medium for up to 21 days. However, LPS was not
detected until more than lxlO5 IFU/ml were present in the culture supernatants and
infectious chlamydiae were detected in the supernatant of the cultures treated with
10 U/ml, even when ROvIFN-y was maintained in the culture medium throughout
the experiment (Figures 6.3 - 6.5). In contrast, both chlamydial LPS and EB
production were completely inhibited when ST.6 cells were maintained in culture
medium containing 100 U/ml of ROvIFN-y. Normal chlamydial growth resumed in
cultures treated with 100 U/ml when they were transferred into ROvIFN-y-free
medium for more than 14 days (Figures 6.4 and 6.5). It therefore seem possible that
IFN-y could mediate persistent C. psittaci infection by restricting the growth and
production of infectious chlamydiae in a reversible manner.
These experiments provided the first direct evidence that relatively low levels of
ROvIFN-y, less than half the concentration of OvIFN-y produced in vivo by immune
sheep after secondary challenge with live C. psittaci [Graham et al, 1995], can induce
and maintain persistent infection of ovine cells with an OEA strain of C. psittaci.
However, they did not provide any information on the morphology of persistent C.
psittaci in ovine cells treated with ROvIFN-y. RHuIFN-y induced persistent C.
trachomatis (serovar A) infection of HeLa 229 cells is characterised by small
inclusion bodies containing large aberrant chlamydiae which fail to differentiate into
infectious EB. When RHuIFN-y was removed from this culture system, for more than
48 hrs, viable EB were recovered from culture supernatants and typical inclusion
morphology was restored [Beatty et al, 1993; 1994a; 1995], In contrast, the
morphology of inclusion bodies in murine McCoy cells [Rodolakis et al, 1989] and
murine L-cells [Perez-Martinez and Storz, 1985] persistently infected with OEA
strains of C. psittaci, in the absence of IFN-y or any other microbistatic agents,
fluctuated temporally between periods where inclusions could not be found in cells
and periods where cells contained abnormally large inclusion bodies.
None of the concentrations of ROvIFN-y used in either of the experiments detailed
here eradicated C. psittaci from infected cultures and it was clear that further work
was required to determine if higher concentrations of ROvIFN-y or prolonged
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exposure to ROvIFN-y could kill C. psittaci. In addition, persistent infection in vivo
can be maintained from one breeding season to the next [Wilsmore et al, 1984] and








Beatty et al (1995) reported that treatment of HeLa 229 cells with 0.5 ng/ml of
RHuIFN-y shortly after infection with C. trachomatis could induce and maintain a
persistent infection for up to 30 days in vitro. However, the same group have also
shown that at higher concentrations (2 ng/ml), RHuIFN-y was capable of
eradicating C. trachomatis from infected HeLa 229 cultures [Beatty et al, 1993]. The
results of the previous experiments (Chapter 6.0) showed that ROvIFN-y could
induce persistent infection of ovine ST.6 cells with the S26/3 OEA strain of C.
psittaci, but was unable to eradicate C. psittaci from infected cells at concentrations
of up to 100 U /ml of biological activity. These findings raised fundamental
questions about the nature of ROvIFN-y mediated persistence of C. psittaci in ovine
cells.
• Can ROvIFN-y maintain chlamydial persistence for prolonged periods of time,
reflecting of the situation in vivo more accurately?
• Is there a critical concentration and/or exposure time above which ROvIFN-y
eradicates C. psittaci from infected ovine cells?
In order to address these questions the range of ROvIFN-y concentrations used and
duration over which cultures were maintained, both in the presence of ROvIFN-y
and after its removal, were extended in this experiment. Furthermore, because
RHuIFN-y mediated C. trachomatis persistence was shown to be associated with
aberrant inclusion body morphology [Beatty et al, 1993; 1994a; 1994b; 1995], it was
of interest to determine whether ROvIFN-y mediated C. psittaci persistence was also
associated with similar changes in inclusion morphology.
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7.2 Materials and Methods
7.2.1 Infection of ST-6 cells and treatment with ROvIFN-y
ST.6 cells were seeded into 25 cm2 vented tissue culture flasks at a density of 5x104
cells/ml in 6 ml IMDM+5% FBS (culture medium). After 3 days, when ST.6 cell
monolayers were still sub-confluent, cells were incubated with 1 ml of culture
medium containing 3x10" C. psittaci strain S26/3 EB. Mock-infected controls were
incubated with 1 ml of culture medium alone. After 6 hours, the supernatants were
removed and replaced with 6 ml of culture medium containing 0 - 1000 U/ml of
ROvIFN-y.
7.2.2 Maintenance of persistently infected ST.6 cells
Cultures were passaged into fresh 25 cm2 vented tissue culture flasks every 7 days
(Chapter 2.1.4.), with the following adaptations. Cells were detached with
trypsin/versene, washed in 10 ml of culture medium, centrifuged at 400 g for 5
minutes and resuspended in fresh culture medium. The cells from each flask were
adjusted to a density of 5x10" cells/ml before seeding into two fresh flasks in 6 ml
volumes. ROvIFN-y was then added to only one of each pair of new cultures to give
the same final concentration of ROvIFN-y that the cells had been maintained in
during the previous 7 days. The other flask was maintained in ROvIFN-y-free
culture medium for the duration of the experiment or until chlamydiae lysed all the
ST.6 cells.
7.2.3 Measurement of C. psittaci multiplication
Culture supernatants were assayed for chlamydial LPS by ELISA (see section 2)
and titrated on fresh ST.6 cells to determine the numbers, if any, of infectious
chlamydiae present (see section 2.5.2.) on the day of passage and at 2 and 4 days
after passage. In addition, cytospins were performed on samples of cells taken at
189
the time of passage (see section 2.4.1.) and the percentage of cells containing
chlamydial inclusions was initially quantified in 300 randomly sampled cells. If
none were found in the first 300 cells the entire cytospin was examined. Giemsa
stain was used to stain C. psittaci inclusion bodies (Chapter 2.4.3.).
7.2.4 Statistics
Spearman's Rank correlations were performed where evidence of dose dependent
effects were observed. It was not possible to use replicates in these experiments
because of the logistical problems associated with the exponential increase in the
numbers of cultures generated at each passage. Triplicate data was generated by the
LPS-ELISA and titration of supernatants. However, because each replica
represented the same culture supernatant these data were not used for comparative
statistics and are presented as mean values.
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7.3 Results
25 cm2 vented tissue culture flasks containing confluent monolayers of ST.6 cells
were infected with 3xl04 C. psittaci strain S26/3 EB on day 0. Two uninfected
control cultures were established in parallel. Two of the infected cultures were
maintained in ROvIFN-y-free culture medium and used as infected controls. The
remaining infected cultures were maintained for up to 63 days in culture medium
containing 5, 25,100, 250 or 1000 U/ml of ROvIFN-y. Cultures were maintained for
105 days after infection or until they were lysed by C. psittaci. Treatment of cultures
with 1000 U/ml of ROvIFN-y was stopped on day 35 due to the growth inhibitory
effects of ROvIFN-y on the ST.6 cells at this concentration. The uninfected controls
were maintained for the duration of the experiment, one in culture medium
containing 250 U/ml of ROvIFN-y and one in culture medium alone. The mean LPS-
ELISA, titration and cytospin data generated for these cultures were used to
produce the baselines for the experiment. For the sake of clarity, data presented
here has been limited to the results of analysis of culture supernatants and
cytospins performed at the time of passage.
7.3.1 Infected control ST.6 Cell Cultures
C. psittaci completely lysed the infected control cultures by day 21 (figure 7.1). LPS
was first detected in the suoernatants of the infected controls on dav 4 (data not
1 J
shown). LPS production exceeded the maximum concentration detectable using the
LPS-ELISA (without dilution of the samples = 110 ng /ml), by day 14 and remained
above this level until the cultures were lysed by C. psittaci on day 21 (figure 7.1A).
Infectious chlamydiae were detected in the supernatants of the infected controls
from day 4 onward. Maximum numbers of infectious EB (mean=1.92xl06 IFU/ml)
were detected on day 14. Thereafter the number of infectious EB present in the
supernatants fell by 15-fold to a mean value of 1.25x10s on day 21 (Figures 7.1B).
Inclusions were only found in the infected controls on day 14 (Figures 7.1C).
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7.3.2 Cultures maintained in medium containing ROvlFN-y for 7 Days
The effects ofmaintaining ST.6 cultures in medium containing ROvIFN-y for the first
7 days of the experiments are shown in figure 7.1. Chlamydial growth was
restricted, when compared to the infected controls, during the time that cultures
were maintained in the presence of ROvIFN-y. Chlamydial growth increased
following the removal of ROvIFN-y on day 7. ROvIFN-y retarded C. psittaci
mediated lysis of cultures in a dose dependent manner (Spearman Rank Correlation
Coefficient {ROvIFN-y/ml : ST.6 culture survival/days} rs = 0.8944, p<0.05).
Cultures treated with 5, 25 and 100 U/ml were lysed by day 28. Cultures treated
with 250 and 1000 U/ml were lysed by days 35 and 42 respectively.
The results of LPS-ELISA analysis of culture supernatants are shown in Figure 7.1A.
LPS was not detected in any of the infected cultures during the time they were
maintained in ROvIFN-y. LPS production was retarded by approximately 7 days in
cultures that had been treated with 5 or 25 U/ml of ROvIFN-y, reaching detectable
concentrations on day 14 and exceeding the detection limit of the LPS-ELISA on
day 21. LPS was not detected in cultures that had been treated with 100, 250 or
1000 U/ml until day 21, 14 days after it was detected in the infected control
cultures. Thereafter, chlamydial LPS production reached the maximum detection
limit of the ELISA on day 21, in the culture that was treated with 100 U /ml, and
day 28 in cultures that had been treated with 250 or 1000 U/ml.
The results of titration analysis of culture supernatants for infectious chlamydiae
are displayed in figure 7. IB. In contrast to LPS, infectious EB were detected in the
supernatants from all the infected cultures on day 7. ROvIFN-y restricted the
production of infectious EB on day 7 in a dose dependent manner (Spearman Rank
Correlation Coefficient {ROvIFN-y/ml : IFU/ml} rs = -1.00, p<0.01). The
supernatant of the culture treated with the lowest concentration of ROvIFN-y
contained approximately 7-fold fewer infectious EB (9.4xl02 IFU/ml) compared to
the infected controls (7.04xl03 IFU/ml) on day 7. EB production increased in all the
infected cultures after ROvIFN-y was removed. Analogous to the results of the LPS-
ELISA, maximal numbers of infectious EB were detected on day 21 in the
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supernatants of cultures that had been treated with 5, 25 or 100 U/ml, and on day
28 in cultures that had been treated with 250 or 1000 U /ml. The maximum number
of infectious EB detected in the supernatant of the culture treated with 5 U /ml of
ROvIFN-y was approximately 80-fold higher, at 1.58x10s IFU/ml, than that seen in
the infected control cultures. Peak EB production in cultures that had been treated
with 25 and 100 U/ml of ROvIFN-y was approximately 7-fold higher, at 1.2X107
IFU/ml and 1.4xl07 IFU/ml respectively, than the maximum number of infectious
EB recovered from the infected controls. The maximum numbers of infectious EB
found in cultures treated with 250 and 1000 U/ml of ROvIFN-y and were similar to
those of the infected controls, at 2.6X106 IFU/ml and2.8xl06 IFU/ml respectively. In
general, the number of infectious EB present in the culture supernatants fell by about
10-fold prior to culture lysis.
The percentage of ST.6 cells containing C. psittaci inclusions are shown in figure
7.1C. Inclusions were not detected in any of the cultures on day 7. Low numbers of
inclusions were detected on day 14 in cultures which had been treated with 5, 25
and 100 U/ml of ROvIFN-y and the maximum percentages of cells containing
inclusions, two-three times that of the infected controls, were recorded in these
cultures on day 21. Inclusions were not detected in cultures that had been treated
with 250 or 1000 U/ml of ROvIFN-y until day 21 and the percentage of cells
containing inclusions peaked in these cultures on days 28 and 35 respectively.
7.3.3 Cultures maintained in medium containing ROvIFN-y for 14 Days
The effects ofmaintaining ST.6 cultures in medium containing ROvIFN-y for the first
14 days of the experiments are shown in figure 7.2. Chlamydial growth was
restricted, compared to the infected controls, when ROvIFN-y was maintained in the
culture medium. Chlamydial growth rate increased in cultures that had been treated
with 5, 25 or 100 U/ml of ROvIFN-y but remained undetectable in cultures treated
with 250 or 1000 U/ml following removal of ROvIFN-y on day 14. The culture
treated with 5 U/ml of ROvIFN-y was lysed by day 28 and cultures treated with 25
or 100 U/ml of ROvIFN-y were lysed by day 35. Chlamydial mediated lysis did not
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occur in cultures treated with 250 or 1000 U/ml of ROvIFN-y and C. psittaci
appeared to have been eradicated from these cultures.
The results of LPS-ELISA analysis of culture supernatants are shown in Figure 7.2A.
Chlamydial LPS concentrations remained below the detection limit of the LPS-
ELISA during the period that ROvIFN-y was maintained in the culture media.
Following removal of ROvIFN-y, LPS production increased in cultures treated with
100 U/ml of ROvIFN-y or less. LPS concentrations exceeded the maximum
detection limit of the ELISA on day 21 in the culture that was treated with 5 U/ml
of ROvIFN-y and on days 28 and 35 in cultures that were treated with 25 and 100
U/ml of ROvIFN-y. LPS was not detected at any time point in cultures that were
treated with 250 or 1000 U/ml of ROvIFN-y.
The results of titration analysis of culture supernatants for infectious chlamydiae
are displayed in figure 7.2B. Production of infectious EB was restricted in a dose
dependent manner when ROvIFN-y was maintained in the culture media (Spearman
Rank Correlation Coefficient {ROvIFN-y/ml : IFU/ml} rs = -0.812, p<0.05). ST.6
cells maintained in 5 U /ml produced fewer infectious EB than the infected controls.
However, there was a 8-fold increase in the number of infectious EB present in the
culture supernatant from day 7 to day 14 (9.4xl02 IFU/ml to 7.5xl03 IFU/ml)
despite the continual presence of ROvIFN-y in the culture medium. The rate of EB
production increased to a level similar to that of the infected controls when
ROvIFN-y was removed from the culture conditions. Maximum numbers of
infectious EB were detected on day 21 (3.9xl06 IFU/ml), after which numbers fell
by over 5-fold to 7.5xl05 IFU/ml prior to lysis of the host culture. The numbers of
infectious EB remained almost constant between days 7 and 14 when 25 U /ml of
ROvIFN-y was maintained in the culture medium. EB production increased to levels
above the maximum rate seen in the infected controls when ROvIFN-y was
withdraw on day 14. Peak numbers of infectious EB, 4.5xl07 IFU/ml, were detected
on day 28, 23-fold higher than the maximum numbers seen in the infected controls,
after which it fell by over 100-fold prior to lysis of all the ST.6 cells in that culture
on day 35. EB production was completely inhibited in cultures treated with 100 and
250 U/ml by day 14. When ROvIFN-y was removed from the culture medium,
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infectious EB were recovered from the supernatant of the culture treated with 100
U/ml but not the culture treated with 250 U/ml. Infectious EB peaked at 2.45x10®
IFU/ml in the culture treated with 100 U/ml on day 35 just before to host culture
lysis. The supernatant from ST.6 cells treated with 1000 U/ml contained very low
numbers of infectious EB on day 14 (20 IFU/ml). Infectious EB were not detected
after day 14 in cultures treated with 250 or 1000 U/ml.
The percentage of ST.6 cells containing C. psittaci inclusions are shown in Figure
7.2C. Inclusion formation was prevented when ROvIFN-y was maintained in the
culture medium at concentrations of 25 U/ml or greater. The culture that was
treated with 5 U/ml of ROvIFN-y developed low numbers of inclusions during the
period that ROvIFN-y was present in the culture conditions and the percentage of
cells containing inclusions rose to levels comparable to that of the infected controls
after cells were transferred into ROvIFN-y-free culture medium. Inclusion formation
was retarded by 14 and 21 days respectively in cultures treated with 25 U/ml or
100 U/ml of ROvIFN-y. Inclusions could not be demonstrated in cultures that were
treated with 250 and 1000 U/ml at any point in the experiment.
7.3.4 Cultures maintained in medium containing ROvIFN-y for 21 Days
The effects of maintaining ST.6 cultures in medium containing ROvIFN-y for the first
21 days of the experiment are shown in figure 7.3. Chlamydial growth was
restricted during the time that ROvIFN-y was maintained in the culture conditions.
However, although 5 U/ml of ROvIFN-y retarded chlamydial growth and ST.6
culture lysis by approximately 7 days, compared to the infected controls, there was
an increase in chlamydial growth in this culture during the period that ROvIFN-y
was maintained in the culture conditions. The rate of chlamydial growth increased
in cultures that were treated with 25 or 100 U/ml following removal of ROvIFN-y
from the culture conditions and eventually lysed these cultures on days 42 and 84
respectively. In contrast, no evidence of C. psittaci was found in cultures that were
treated with 250 or 1000 U/ml of ROvIFN-y after day 14.
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The results of LPS-ELISA analysis of culture supernatants are shown in Figure 7.3A.
LPS was detected on days 14 and 21 when ST.6 cells were maintained in 5 U/ml of
ROvIFN-y and the maximum concentration of LPS detectable using the LPS-ELISA
was exceeded by day 28, 7 days after ROvIFN-y was removed from the culture
conditions. Chlamydial LPS was not detected during the first 21 days of the
experiment when cultures were maintained in medium containing 25 or more U/ml
of ROvIFN-y. There was an immediate increase in LPS production in the culture that
was treated with 25 U/ml when cells from this culture were transferred into
ROvIFN-y-free culture medium and the maximum detection limit of the ELISA was
exceeded on day 35. LPS was not detected in the culture maintained in 100 U/ml of
ROvIFN-y until Day 91, 70 days after removal of ROvIFN-y. Supernatants from
cultures that had been treated with 250 or 1000 U/ml did not contain chlamydial
LPS at concentrations detectable using the LPS-ELISA at any point in the
experiment. Bacterial contamination of the culture that was treated with 250 U/ml
of ROvIFN-y occurred on day 50, preventing collection of data for this culture after
day 49.
The results of titration analysis of culture supernatants for infectious chlamydiae
are displayed in figure 7.3B. The culture that was treated with 5 U/ml of ROvIFN-y
produced large numbers of infectious EB during the period that ROvIFN-y was
maintained in the culture conditions. There was a slight increase in the rate of EB
production following the removal of ROvIFN-y from this culture on day 21 and peak
numbers of 9xl06 IFU/ml of infectious EB were recorded on day 28, approximately
5-fold more than the maximum number of infectious EB detected in the infected
controls. Infectious EB were also detected in the culture supernatant of cells treated
with 25 U/ml of ROvIFN-y. However, unlike the culture maintained in 5 U/ml, the
number of infectious EB present in the supernatant of this culture declined with
time, reaching 30 IFU/ml on day 21. When ROvIFN-y was removed from the culture
conditions the number of infectious EB increased, peaking at 1.9xl07 IFU/ml on day
35,10-fold higher than the maximum number of infectious EB found in the infected
controls, then falling to 6.36xl05 IFU/ml over the last 7 days of culture. Infectious
EB were not detected in cultures when they were maintained in 100 or more U/ml of
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ROvIFN-y. Infectious EB were recovered from the culture treated with 100 U/ml,
but only after ROvIFN-y had been absent from the culture conditions for 63 days.
Infectious EB were not detected after day 14 in cultures treated with 250 or 1000
U/ml of ROvIFN-y.
The percentage of ST.6 cells containing C. psittaci inclusions are shown in Figure
7.3C. The culture that was treated with 5 U/ml of ROvIFN-y developed similar
numbers of inclusions as the infected controls during the period that ROvIFN-y was
present in the culture conditions, but inclusion formation was delayed by 7 days.
Inclusions were not detected when ROvIFN-y was maintained in the culture medium
at concentrations of 25 U/ml or greater. Inclusion formation did not occur in
cultures treated with 25 U/ml or 100 U/ml of ROvIFN-y until 14 and 63 days after
ROvIFN-y was removed from the culture conditions. Inclusions could not be
demonstrated in cultures that had been maintained in 250 and 1000 U/ml of
ROvIFN-y at any time point.
7.3.5 Cultures maintained in medium containing ROvlFN-y for 28 Days
The effects of maintaining ST.6 cultures in ROvIFN-y for the first 28 days of the
experiment are shown in figure 7.4. Chlamydial growth was restricted, compared to
the infected controls, during the time that ROvIFN-y was maintained in the culture
medium. However, although the culture that was maintained in 5 U/ml restricted C.
psittaci growth, it fail to control it completely and was lysed by day 28 despite the
continual presence of ROvIFN-y. Chlamydial growth rate increased in cultures
treated with 25 or 100 U/ml when ROvIFN-y was removed from the culture
conditions on day 28 and completely lysed both cultures by days 42 and 91
respectively. There was no evidence of chlamydial growth after day 14 in cultures
that were treated with 250 or 1000 U/ml of ROvIFN-y.
The results of LPS-ELISA analysis of culture supernatants are shown in Figure 7.4A.
LPS was detected in increasing concentrations on days 14, 21 and 28 in the culture
maintained in 5 U/ml of ROvIFN-y. Chlamydial LPS was not detected during the
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first 28 days of the experiment when cultures were maintained in 25 U /ml or more
of ROvIFN-y. There was an immediate increase in LPS production in the culture that
was treated with 25 U/ml when ROvIFN-y was removed from the culture
conditions, exceeding the maximum detection limit of the ELISA on day 42. LPS
was not detected in the culture maintained in 100 U/ml until day 84, 56 days after
the cells were transferred into ROvIFN-y-free medium. Supernatants from cultures
that had been treated with 250 or 1000 U/ml did not contain detectable
concentrations of chlamydial LPS at any point during the experiment.
The results of titration analysis of culture supernatants for infectious chlamydiae
are displayed in figure 7.4B. The culture that was treated with 5 U /ml of ROvIFN-y
produced less infectious EB than the infected controls, reaching a maximum of
1.07x10s IFU/ml on day 21. The number of infectious EB detected in the culture
supernatant of cells treated with 25 U /ml of ROvIFN-y declined with time, reaching
its lowest level of 10 IFU/ml on day 28. As soon as ROvIFN-y was removed from
the culture there was an increase in EB production, reaching a maximum of 2.6XlO6
IFU/ml on day 35. Infectious EB were not detected in cultures treated with 100
U/ml or more after day 14 when ROvIFN-y was maintained in the culture
conditions. Infectious EB were found in the supernatant of the culture treated with
100 U/ml after ROvIFN-y was removed from the culture conditions for more than
42 days. Infectious EB were not recovered from cultures treated with 250 or 1000
U/ml after day 7.
The percentage of ST.6 cells containing C. psittaci inclusions are shown in Figure
7.4C. Inclusion formation was prevented when 25 U/ml or more of ROvIFN-y was
present in the culture medium. The culture that was treated with 5 U /ml developed
the same number of inclusions as the infected controls during the period that
ROvIFN-y was present in the culture medium, but inclusion formation was retarded
by 7 days. Inclusions were not found in cultures treated with 25 U/ml or 100 U/ml
until 7 and 56 days, respectively, after ROvIFN-y was removed from the culture
conditions. Inclusions were not found in cultures that were treated with 250 and
1000 U/ml of ROvIFN-y at any time point in the experiment.
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7.3.6 Cultures maintained in medium containing ROvIFN-y for 35 Days
The effects ofmaintaining ST.6 cultures in medium containing ROvIFN-y for the first
35 days of the experiments are shown in figure 7.5. Chlamydial growth was
inhibited completely by day 35 in the surviving cultures during the time that they
were maintained in the presence of ROvIFN-y. Chlamydial growth was restored
after ROvIFN-y was removed from cultures that had been treated with 25 or 100
U/ml but not in the cultures treated with 250 or 1000 U/ml of ROvIFN-y. Cultures
treated with 25 and 100 U/ml were lysed by days 42 and 91, seven and 56 days
after cells were transferred into ROvIFN-y-free culture medium. There was no
evidence of Chlamydial growth in cultures that were treated with 250 or 1000 U/ml
of ROvIFN-y after day 14.
The results of LPS-ELISA analysis of culture supernatants are shown in Figure 7.5A.
Chlamydial LPS was not detected during the first 35 days of the experiment when
cultures were maintained in 25 or more U/ml of ROvIFN-y. There was an immediate
increase in LPS production in the culture that had been treated with 25 U/ml
following the removal of ROvIFN-y. The concentration of LPS exceeded the
maximum detection limit of the ELISA on day 49 in this culture. LPS was not
detected in the culture maintained in 100 U/ml of ROvIFN-y until Day 77, 42 days
after cells from this culture were transferred into ROvIFN-y-free culture medium.
Supernatants from cultures that had been treated with 250 or 1000 U/ml of
ROvIFN-y did not contain detectable levels of chlamydial LPS at any point in the
experiment.
The results of titration analysis of culture supernatants for infectious chlamydiae
are displayed in figure 7.5B. Infectious EB production was completely inhibited by
day 35 in the culture treated with 25 U/ml of ROvIFN-y. Infectious EB were
recovered immediately after cells from this culture were transferred into ROvIFN-y-
free culture medium. Peak numbers of infectious EB (1.78X107 IFU/ml) were
recorded on day 49, over 9-fold more than the maximum numbers detected in the
infected controls. Infectious EB were not detected after day 7 in the culture treated
with 100 units/ml during the time that ROvIFN-y was maintained in the culture
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conditions. Infectious EB were recovered from the supernatant of this culture when
ROvIFN-y had been absent from the culture conditions for more than 35 days and
reached peak numbers (1.16xl06 IFU/ml) on day 91. Infectious EB were not were
not detected after day 14 in cultures treated with 250 or 1000 U/ml of ROvIFN-y.
The percentage of ST.6 cells containing C. psittaci inclusions are shown in Figure
7.5C. Inclusion formation was prevented when ROvIFN-y was maintained in the
culture medium at concentrations of 25 U /ml or greater. Cultures treated with 25 or
100 U/ml of ROvIFN-y only developed inclusions on days 42 and 77 after they
had been transferred into ROvIFN-y-free culture medium for 7 and 35 days
respectively. Inclusions could not be demonstrated in cultures that had been
maintained in 250 and 1000 U /ml of ROvIFN-y at any point in the experiment.
7.3.7 Cultures maintained in medium containing ROvlFN-yfor49 Days
The effects ofmaintaining ST.6 cultures in medium containing ROvIFN-y for the first
49 days of the experiments are shown in figure 7.6. Chlamydial growth was
completely inhibited in all the surviving cultures after day 28 whilst ROvIFN-y was
maintained in the culture conditions. Chlamydial growth resumed shortly after
cultures that were treated with 25 or 100 U/ml were transferred into ROvIFN-y-free
culture medium on day 49. Cultures treated with 25 and 100 U/ml were lysed by
day 77 and day 63 respectively. Evidence of chlamydial growth was not detected
after day 14 in cultures that were treated with 250 or 1000 U/ml of ROvIFN-y.
The results of LPS-ELISA analysis of culture supernatants are shown in Figure 7.6A.
Chlamydial LPS was not detected during the time that cultures were maintained in
25 or more U/ml of ROvIFN-y. There was an increase in LPS production in the
cultures that had been treated with 25 or 100 U/ml when ROvIFN-y was removed
from the culture conditions, reaching the maximum detection limit of the ELISA on
days 70 and 63 respectively. Supernatants from the culture that had been treated
with 250 U/ml did not contain detectable amounts of chlamydial LPS at any point
in the experiment.
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The results of titration analysis of culture supernatants for infectious chlamydiae
are displayed in figure 7.6B. Infectious EB could not be demonstrated after day 35
in the culture that was treated with 25 U/ml of ROvIFN-y. Removal of ROvIFN-y
from this culture on day 49 resulted in the recovery of infectious EB on day 63. The
number of infectious EB peaked on day 77 (1.94X105 IFU/ml) in this culture, 10-fold
less that the maximum number of infectious EB found in the infected controls.
Infectious EB were not detected in the supernatant of the culture treated with 100
U/ml after day 7 when ROvIFN-y was maintained in the culture conditions.
Infectious EB were recovered from the supernatant of this culture 7 days after cells
were transferred into ROvIFN-y-free culture medium and reached peak numbers on
day 63 (3.57xl06 IFU/ml), approximately twice that of the infected controls.
Infectious EB were not found in cultures treated with 250 U/ml of ROvIFN-y after
day 14.
The percentage of ST.6 cells containing C. psittaci inclusions are shown in Figure
7.6C. Inclusion formation was prevented during the time that ROvIFN-y was
maintained in the culture medium in the surviving cultures. Inclusion formation did
not occur until 14 and 7 days after ROvIFN-y was removed from the culture
conditions in cultures treated with 25 U/ml or 100 U/ml respectively. Inclusions
were not found at any point during the experiment in the culture that had been
treated with 250 U/ml of ROvIFN-y.
7.3.8 Cultures maintained in medium containing ROviFN-y for 63 Days
The effects ofmaintaining ST.6 cultures in medium containing ROvIFN-y for the first
63 days of the experiments are shown in figure 7.7. Chlamydial growth was
completely inhibited in all the surviving cultures by day 35 and remained
undetectable as long as ROvIFN-y was maintained in the culture conditions.
Chlamydial growth was restored when cells from the cultures that had been treated
with 25 or 100 U/ml were transferred into ROvIFN-y-free culture medium on day
63. Cultures treated with 25 and 100 U/ml were lysed by days 77 and day 91
respectively. Lysis did not occur in cultures that were treated with 250 U/ml of
ROvIFN-y.
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The results of LPS-ELISA analysis of culture supernatants are shown in Figure 7.7A.
Chlamydial LPS was not detected during the time that cultures were maintained in
25 or more U/ml of ROvIFN-y . There was an increase in LPS production in the
culture that had been treated with 25 U /ml when ROvIFN-y was removed from the
culture conditions, reaching the maximum detection limit of the ELISA on day 70.
LPS was not detected in the culture maintained in 100 U/ml of ROvIFN-y until day
84, 21 days after ROvIFN-y was removed. Supernatants from the culture that had
been treated with 250 U /ml of ROvIFN-y did not contain detectable concentrations
of chlamydial LPS at any point in the experiment.
The results of titration analysis of culture supernatants for infectious chlamydiae
maintained in ROvIFN-y for 63 days are displayed in figure 7.7B. After day 28,
infectious EB were not found in the culture treated with 25 U /ml of ROvIFN-y until
day 70, seven days after ROvIFN-y had been removed from the culture conditions.
Maximum numbers of infectious EB (1x10" IFU/ml) were recovered from the
supernatant of this culture on day 77. Infectious EB were not detected after day 7 in
the culture treated with 100 units/ml while ROvIFN-y was present in the culture
conditions. C. psittaci EB production resumed when cells that had been treated for
63 days with 100 U/ml of ROvIFN-y were transferred into ROvIFN-y-free culture
medium and peak numbers of infectious EB (3.48x10s IFU/ml) were recovered
medium on day 84, 21 days after ROvIFN-y was removed. Infectious EB were not
detected after day 7 in the culture supernatant of cells treated with 250 U/ml of
ROvIFN-y .
The percentage of ST.6 cells containing C. psittaci inclusions are shown in Figure
7.7C. Inclusion formation was prevented in all the surviving cultures during the time
that ROvIFN-y was present in the culture conditions and inclusion formation did
not occur until 7 and 21 days after cells from cultures treated with 25 U/ml or 100
U/ml of ROvIFN-y were transferred into ROvIFN-y-free medium. Inclusions could
not be demonstrated in the culture that had been treated with 250 U /ml of
ROvIFN-y at any point in the experiment.
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Figure7.1: Cultures maintained in medium containing ROvlFN-y for 7 Days
ST.6 cultures were incubated with ROvlFN-y for the first 7 days after infection
with C. psittaci at concentrations of:1000 U/ml ( ), 250 U/ml ( ),
100 U/ml ( ), 25 U/ml ( ), 5 U/ml ( ). The Infected controls
( ) were maintained in ROvlFN-y-free culture medium until they were
lysed by C. psittaci. Uninfected controls (—+—) were maintained for the
duration of the experiment. The shaded area ( ) represents the period during
which ROvlFN-y was maintained in the cultures. C. psittaci mediated lysis of
cultures occurred at the time point indicated by (*, ,*,*,* or *). psittaci
mediated lysis occurred in the following 7 days, preventing further cytospin
analysis (**, ** ** ** 0r **).
A: Mean concentration of chlamydial LPS in culture supernatants, measured by
LPS-ELISA analysis of triplicate supernatant samples from each culture.
B: Mean number inclusion forming units (IFU/ml) present in culture supernatants,
measured by titration of triplicate supernatant samples from each culture.
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Figure 72:Cultures maintained in medium containing ROvlFN-y for 14 Days
ST.6 cultures were incubated with ROvlFN-y for the first 14 days after infection
with C. psittaciat concentrations of:1000 U/ml ( ), 250 U/ml ( ),
100 U/ml ( ), 25 U/ml ( ), 5 U/ml ( ). The Infected controls
( ) were maintained in ROvlFN-y-free culture medium until they were
lysed by C. psittaci. Uninfected controls (—•—) were maintained for the
duration of the experiment. The shaded area ( ) represents the period during
which ROvlFN-y was maintained in the cultures. C. psittaci mediated lysis of
cultures occurred at the time point indicated by (*, ,*,*,* or *). psittaci
mediated lysis occurred in the following 7 days, preventing further cytospin
analysis(**, ,*W* or**).
A: Mean concentration of chlamydial LPS in culture supernatants, measured by
LPS-ELISA analysis of triplicate supernatant samples from each culture.
B: Mean number inclusion forming units (IFU/ml) present in culture supernatants,
measured by titration of triplicate supernatant samples from each culture.
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Figure7.3: Cultures maintained in medium containing ROvlFN-y for 21 Days
ST.6 cultures were incubated with ROvlFN-y for the first 21 days after infection
with C. psittaci at concentrations of:1000 U/ml ( ), 250 U/ml ( ),
100 U/ml ( ), 25 U/ml ( ), 5 U/ml ( ). The Infected controls
( ) were maintained in ROvlFN-y-free culture medium until they were
lysed by C. psittaci. Uninfected controls (—•—) were maintained for the
duration of the experiment. The shaded area ( ) represents the period during
which ROvlFN-y was maintained in the cultures. C. psittaci mediated lysis of
cultures occurred at the time point indicated by (\ ,*,*,* or *). psittaci
mediated lysis occurred in the following 7 days, preventing further cytospin
analysis (* *, ,**,**,** or**). The character denotes bacterial contamination
of the culture treated with 250 U/ml of rOvlFN-y on day 49.
A: Mean concentration of chlamydial LPS in culture supernatants, measured by
LPS-ELISA analysis of triplicate supernatant samples from each culture.
B: Mean number inclusion forming units (IFU/ml) present in culture supernatants,
measured by titration of triplicate supernatant samples from each culture.
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Figure7.4: Cultures maintained in medium containing ROvlFN-y for 28 Days
ST.6 cultures were incubated with ROvlFN-y for the first 28 days after infection
with C. psittaci at concentrations of:1000 U/ml ( ), 250 U/ml ( ),
100 U/ml ( ), 25 U/ml ( ), 5 U/ml ( ). The Infected controls
( ) were maintained in ROvlFN-y-free culture medium until they were
lysed by C. psittaci. Uninfected controls (—•—) were maintained for the
duration of the experiment. The shaded area ( ) represents the period during
which ROvlFN-y was maintained in the cultures. C. psittaci mediated lysis of
cultures occurred at the time point indicated by (*,*,* or *). C. psittaci mediated
lysis occurred in the following 7 days, preventing further cytospin analysis (**,
★ ★ * *
Q|T
A: Mean concentration of chlamydial LPS in culture supernatants, measured by
LPS-ELISA analysis of triplicate supernatant samples from each culture.
B: Mean number inclusion forming units (IFU/ml) present in culture supernatants,
measured by titration of triplicate supernatant samples from each culture.
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Figure7.5: Cultures maintained in medium containing ROvlFN-y for 35 Days
ST.6 cultures were incubated with ROvlFN-y for the first 35 days after infection
with C. psittaci at concentrations of:1000 U/ml ( ); 250 U/ml ( );
100 U/ml ( ); and 25 U/ml ( ). The Infected controls ( )
were maintained in ROvlFN-y-free culture medium until they were lysed by C.
psittaci. Uninfected controls (—•—) were maintained for the duration of the
experiment. The shaded area ( ) represents the period during which ROvlFN-
y was maintained in the cultures. C. psittaci mediated lysis of cultures occurred at
the time point indicated by (*, * or *). C. psittaci mediated lysis occurred in the
following 7 days, preventing further cytospin analysis (**,** or **).
A: Mean concentration of chlamydial LPS in culture supernatants, measured by
LPS-ELISA analysis of triplicate supernatant samples from each culture.
B: Mean number inclusion forming units (IFU/ml) present in culture supernatants,
measured by titration of triplicate supernatant samples from each culture.
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Figure7.6: Cultures maintained in medium containing ROvlFN-y for 49 Days
ST.6 cultures were incubated with ROvlFN-y for the first 49 days after infection
with C. psittaci at concentrations of:1000 U/ml ( ); 250 U/ml ( );
100 U/ml ( ); and 25 U/ml ( ). The Infected controls ( )
were maintained in ROvlFN-y-free culture medium until they were lysed by C.
psittaci. Uninfected controls (—•—) were maintained for the duration of the
experiment. The shaded area ( ) represents the period during which ROvlFN-
y was maintained in the cultures. C. psittaci mediated lysis of cultures occurred at
the time point indicated by (*, * or *). C. psittaci mediated lysis occurred in the
following 7 days, preventing further cytospin analysis (**,** or **).
A: Mean concentration of chlamydial LPS in culture supernatants, measured by
LPS-ELISA analysis of triplicate supernatant samples from each culture.
B: Mean number inclusion forming units (IFU/ml) present in culture supernatants,
measured by titration of triplicate supernatant samples from each culture.
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Figure7.7: Cultures maintained in medium containing ROvlFN-y for 63 Days
ST.6 cultures were incubated with ROvlFN-y for the first 63 days after infection
with C. psittaciat concentrations of: 250 U/ml ( ); 100 U/ml and
25 U/ml ( ). The Infected controls ( ) were maintained in ROvlFN-
y-free culture medium until they were lysed by C. psittaci. Uninfected controls
(—•—) were maintained for the duration of the experiment. The shaded area
( ) represents the period during which ROvlFN-y was maintained in the
cultures. C. psittaci mediated lysis of cultures occurred at the time point indicated
by (*, * or *). C. psittaci mediated lysis occurred in the following 7 days,
preventing further cytospin analysis (**,** or **).
A: Mean concentration of chlamydial LPS in culture supernatants, measured by
LPS-ELISA analysis of triplicate supernatant samples from each culture.
B: Mean number inclusion forming units (IFU/ml) present in culture supernatants,
measured by titration of triplicate supernatant samples from each culture.
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In the experiments detailed in Chapter 6.0, persistent C. psittaci infection was
maintained in ST.6 cells for a maximum period of 28 days in the presence of 100
U/ml of ROvIFN-y. However, persistent infection in the ewe can be maintained for
much longer periods [Wilsmore et al, 1984] and the experiment detailed here was
designed primarily to address this discrepancy. Infection of pregnant ewes with the
S26 / 3 OEA strain of C. psittaci does not result in active infection in the placenta or
fetus until approximately day 60 of gestation [Buxton et al, 1990]. In the experiment
detailed here, ST.6 cells were cultured in the presence of ROvIFN-y for a maximum
period of 63 days after infection with the S26/3 OEA strain of C. psittaci and
observed for signs of chlamydial growth until 105 days after infection or until they
were lysed by the chlamydiae.
In order to determine whether ROvIFN-y could eradicate C. psittaci from infected
ST.6 cultures, the range of concentrations of ROvIFN-y used in this experiment was
increased to include 250 U /ml, the maximum concentration of biologically active
OvIFN-y found in vivo [Graham et al, 1995], However, the maximum concentration
of OvIFN-y detected in vivo was derived from efferent lymph collected over an 18
hour period suggesting that at peak production of OvIFN-y is likely to be
significantly higher. Consequently the range of ROvIFN-y concentrations used in this
experiment was extended further to include 1000 U/ml.
The anti-chlamydial effects of the different concentrations of ROvIFN-y used in the
experiment detailed here fell into three categories.
1. 5 U/ml of ROvIFN-y retarded chlamydial growth in ST.6 cells, compared to the
infected controls, but failed to control chlamydial growth resulting in C. psittaci
mediated lysis.
2. Concentrations of 25 and 100 U/ml of ROvIFN-y had a microbistatic effect on
C. psittaci growth in ST-6 cells and induced persistent infection as long as they
were maintained in the culture conditions.
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3. Concentrations of 250 U/ml or 1000 U/ml of ROvIFN-y, although initially
microbistatic, appeared to become microbicidal when they were maintained in
the culture conditions for 14 or more days.
Whilst ST.6 cells that were maintained in culture medium containing 5 U/ml of
ROvIFN-y failed to control C. psittaci growth completely and were lysed on day 28
(Figure 7.4), LPS production and inclusion formation were inhibited entirely when
cultures were maintained in the presence 25 or 100 U/ml of ROvIFN-y. In addition,
ST.6 cultures maintained in 25 or 100 U/ml of ROvIFN-y did not produce infectious
chlamydiae after days 35 and 14 respectively. C. psittaci resumed its typical
cytolytic developmental cycle when ST.6 cells were transferred into ROvIFN-y-free
culture medium, even after 63 days of culture in the presence of 25 or 100 U/ml of
ROvIFN-y. This suggested that these concentrations of ROvIFN-y can induce and
maintain C. psittaci persistence in ST.6 cells (Figure 7.7). Persistent C. psittaci
infection was established more rapidly in cultures maintained in 100 U/ml of
ROvIFN-y than cultures maintained in 25 U/ml of ROvIFN-y. With the exception of
cultures treated with ROvIFN-y for the first 49 days after infection, chlamydial
growth recovered more rapidly following removal of ROvIFN-y from cultures
previously maintained in 25 U/ml of ROvIFN-y compared to cultures that had been
treated with 100 U/ml (Figure 7.6).
In the case of RHuIFN-y mediated C. trachomatis persistence in human HeLa 229
cells, the recovery rate of infectious chlamydiae was shown to decrease over time
[Beatty et al, 1995], suggesting that chlamydial growth was inhibited completely in
this model. Here, the rate at which infectious C. psittaci were recovered from infected
ovine cultures, following removal of ROvIFN-y, did not decrease over time. By
maintaining cultures that were initially infected with 3xl04 infectious EBs for 63
days, passaging cells at ratio of approximately 1:3 every 7 days, a static population
of chlamydiae would effectively be diluted out of the cultures by day 63, reaching
levels of about 2 infected cells/culture. This was clearly not the case in this
experiment. In cultures that were treated with 100 U/ml of ROvIFN-y, the rate at
which chlamydial growth recovered following the removal of ROvIFN-y actually
appeared to increase with time (Spearman Rank Correlation Coefficient {Duration
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of ROvIFN-y treatment/days : ST.6 culture survival/days following removal of
ROvIFN-y} rs = -0.9000, p<0.05, {Duration of ROvIFN-y treatment/days : recovery
of infectious EB} rs = -0.9000, p<0.05). These findings suggest that despite the
apparent absence of inclusion bodies in persistently infected cells or infectious
chlamydiae and LPS in the culture supernatants, low level multiplication and
transmission can occur in persistently infected ST.6 cultures. It is possible that very
low numbers of EB (<10 IFU/ml) might be present in the supernatants of
persistently infected ST.6. Alternatively, C. psittaci may enter adjacent cells through
some as yet undefined method [Wyrick, 1998].
As in the case of RFIuIFN-y mediated restriction of C. trachomatis [Beatty et al,
1993], ovine ST.6 cells appear to be able to kill C. psittaci following treatment with
higher concentrations, 250 and 1000 U/ml, of ROvIFN-y. However, it would appear
that ROvIFN-y must be maintained in the culture conditions for at least 14 days to
ensure elimination of C. psittaci from infected cultures (Figures 7.2).
These findings strongly support a role for OvIFN-y both as a potential effector
mechanism in immunity to C. psittaci and as a factor involved in the induction and
maintenance of persistent infection in the non-pregnant ewe. Furthermore, the
concentrations of ROvIFN-y that induced persistent C. psittaci infection or effected
eradication of C. psittaci from infected cultures were, with the exception of 1000
U /ml, within the range of OvIFN-y produced by immune ewes following secondary
challenge with live C. psittaci [Graham et at, 1995].
The nature of chlamydial persistence is likely to influence antigen presentation in
vivo and have profound consequences on the outcome of the immune response.
Persistent C. trachomatis (serovar A) described in human HeLa 229 treated with 0.2
or 0.5 ng/ml of RHuIFN-y [Beatty, 1993; 1994a; 1994b; 1995] was characterised by
small but conspicuous inclusion bodies containing large aberrant RBs which failed to
differentiate into infectious EB. When IFN-y was removed from the culture system
for more than 48 hrs, viable EB were recovered from the culture supernatants and
typical C. trachomatis inclusionmorphology was restored [Beatty et al, 1995]. Similar
reversible changes in chlamydiae morphology and developmental cycle have also
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been reported following penicillin treatment of murine cells infected with C. psittaci
[Matsumoto and Manire, 1970] and nutrient depletion [Coles et al, 1993]. In
contrast, the inclusion morphology described for spontaneously occurring C. psittaci
persistence in murine McCoy cells [Rodolakis et al, 1989] and murine L-cells [Perez-
Martinez and Storz, 1985; Moulder et al, 1980] was reported to fluctuate between
periods when inclusion bodies could not be demonstrated in infected cultures and
periods of cytolytic chlamydial growth associated with unusually large and
conspicuous inclusion bodies. More importantly, RHuIFN-y mediated persistence
was associated with changes in the relative expression of potentially protective and
immunopathogenic chlamydial antigens. Expression of MOMP, the 60 KDa
cysteine-rich OMP and LPS were down regulated compared to HSP 60 [Beatty et al,
1995]. Similar changes in the relative expression of MOMP and HSP 60 have been
demonstrated in aberrant C. trachomatis isolated from the synovial tissues of
patients with reactive arthritis [Gerard et al, 1998].
In the experiment detailed here, ROvIFN-y mediated C. psittaci persistence was not
associated with inclusions formation of any kind. Inclusion bodies were not found
by light microscopy in cytospins prepared from persistently infected ST.6 cultures
maintained in culture medium containing 25 or 100 U/ml of ROvIFN-y. However,
inclusion body formation was restored when these cultures were transferred into
ROvIFN-y-free culture medium (figure 7.7C). This may help to explain why C.
psittaci is very difficult to detect by classical histology in ewes infected out-with
pregnancy [Huang et al, 1990; Buxton et al, 1996].
The reasons for the apparent differences between persistent forms of C. psittaci and
C. trachomatis in cells treated with IFN-y are not clear. It is possible that the
mechanism by which IFN-y activates cells to inhibit chlamydial growth acts at
different stages in the developmental cycle of each species or that differences in host
cell species or phenotype are responsible. Further work is required to establish
whether ROvIFN-y mediated persistence of OEA strains of C. psittaci is associated
with attenuated antigen expression, similar to that seen in C. trachomatis.
If the amount of IFN-y produced in vivo is directly related to the amount of antigen
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present, then persistent infection could develop as a result of low level antigenic
stimulation at the time of initial infection. By entering a persistent state in response
to low levels of IFN-y produced early on in the ontogeny of the immune response, C.
psittaci may be able to avoid inducing an acquired immune response to antigens that
would protect the ewe against abortion. This would allow C. psittaci to persist until
the next pregnancy, when IFN-y production is thought to be down regulated
[Raghupathy, 1997], invade the placenta, cause disease and spread to other ewes.
The development of immunity to OEA which follows clinical disease may result
from the massive antigenic stimulus associated with multiplication of C. psittaci in
the placenta [Buxton et al, 1990].
It is unreasonable to assume that IFN-y is the only factor involved in persistence. A
number of other cytokines have been shown to exert anti-chlamydial effects in vitro
through similar mechanisms to IFN-y and may also play a role in persistence. TNF-a.
and IFN-p act in synergy to inhibit C. trachomatis in human HEp-2 cells [Shemer-
Avni et al, 1988; 1989]. In addition, spontaneously occurring persistent infection has
been reported in human peripheral blood monocytes infected C. trachomatis (serovar
K) [Koehler et al, 1996; 1997]. Although there is no evidence in the literature support
this in ovine monocytes it may have important ramifications for C. psittaci
persistence in sheep.
The findings detailed here indicate that the S26/3 OEA strain of C. psittaci can
persist in ovine cells in viiro for least 63 days in the presence of physiological levels
of ROvIFN-y. This has important implications for the persistence of C. psittaci in
ewes infected outwith pregnancy and supports a role for the host immune response
both in the maintenance of persistence and protection. These findings also
demonstrated that OvIFN-y is able to eradicate C. psittaci from infected ovine cells
in the absence of other immunological factors. In addition, this work has provided
an in vitro homologous model of OvIFN-y mediated persistent infection of ovine
cells with an ovine abortion isolate of C. psittaci which can now be used to further
characterise chlamydial persistence in the context of OEA.
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Chapter 8.0
A Role for the Tryptophan Pathway in Interferon-y
Mediated Persistence of Chlamydia psittaci
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8.1 Introduction
The anti-chlamydial action of ROvIFN-y on ovine ST.6 cells can be partially
reversed by the addition of exogenous L-tryptophan [(Chapter 5.0); Graham et al,
1995]. In the previous experiments (Chapters 6.0 and 7.0) it was shown that
concentrations of between 25-100 U /ml of ROvIFN-y induced and maintained C.
psittaci persistence, whereas 250 U/ml or more resulted in eradication of
chlamydiae from infected ST.6 cultures. It was therefore of interest to determine
whether L-tryptophan was able to abrogate the anti-chlamydial effects of ROvIFN-y
over a longer time course and to see what effects, if any, the addition of exogenous
L-tryptophan had on the induction and maintenance of C. psittaci persistence in ST.6
cells.
The experiments detailed in this chapter were designed to address the following
questions:
• Can the addition of exogenous L-tryptophan to ST.6 cultures at the time of
initial infection prevent the induction of ROvIFN-y-mediated C. psittaci
persistence?
• Can exogenous L-tryptophan prevent eradication of C. psittaci from ST.6 cultures
maintained in the presence of high concentrations of ROvIFN-y?
• Can exogenous L-tryptophan abrogate the chlamydiastatic effects of 25-100
U/ml of ROvIFN-y and induce cytolytic C. psittaci growth in persistently
infected ST.6 cells.
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8.2 Materials and Methods
8.2.1 Infection of ST-6 cells and treatment with ROvlFN-y
ST.6 cells were seeded into sixteen 25 cm2 vented tissue culture flasks at a density
of 5x104 cells/ml in 6 ml IMDM+5% FBS (culture medium). After 3 days, when the
ST.6 cell monolayers were still sub-confluent, 10 of the flasks were incubated with 1
ml of culture medium containing 3x104 C. psittaci strain S26/3 EB. The remaining 4
flasks were incubated with 1 ml of culture medium alone and used as uninfected
controls. After 6 hours, the supernatants were removed and replaced with 6 ml of
culture medium containing various concentrations of ROvIFN-y and L-tryptophan
(Table 8.1).
Table 8.1: Treatment protocols for ST.6 cultures
















8.2.2 Maintenance of persistently infected ST.6 cells
Cultures were passaged into fresh 25 cm2 vented tissue culture flasks every 7 days
(Chapter 2.1.4.) as follows. The cells were detached with trypsin/versene, washed
in 10 ml of culture medium, centrifuged at 400 g for 5 minutes and resuspended in
fresh culture medium. The cells from each flask were adjusted to a density of 5x10"
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cells/ml before seeding into two fresh flasks in 6 ml volumes. ROvIFN-y and/ or 500
Mg/ml of L-tryptophan was then added to only one of each pair of new cultures to
give the same final concentrations that the cells had been maintained in during the
previous 7 days. The other flask was maintained in culture medium alone for the
duration of the experiment or until chlamydiae lysed all the ST.6 cells.
8.2.3 Measurement of C. psittaci multiplication
Culture supernatants were titrated in triplicate on fresh ST.6 cells to determine the
numbers, if any, of infectious chlamydiae present (Chapter 2.5.2.). In addition,
cytospins were prepared from samples of cells removed from cultures at the time of
passage (Chapter 2.4.1.) and examined for the presence of ST.6 cells containing
chlamydial inclusion bodies. Giemsa stain was used to stain C. psittaci inclusion
bodies (Chapter 2.4.3.).
8.2.4 Addition of exogenous L-tryptophan to persistently infected cultures
Two flasks of ST.6 cells which had been infected with 3x10" IFU/ml of C. psittaci
were maintained in culture medium containing 50 U/ml of ROvIFN-y and passaged
as described in 8.2.2. Chlamydial growth was monitored by titration and cytospin
analysis as described in 8.2.3. 500 jug/ml of L-tryptophan was added to one of the
cultures seven days after C. psittaci persistence was first established. The other
culture was maintained in ROvIFN-y alone. Both cultures were maintained under
these conditions for a further 14 days or until C. psittaci lysed all of the ST.6 cells in
the cultures. Following the addition of exogenous L-tryptophan, chlamydial growth
was measure by LPS ELISA (Chapter 2.5.1) and periodic titration of infectious EB




Infectious chlamydiae were detected in the supernatants of the infected controls on
days 7 and 14 and both cultures were completely lysed on day 14 (Figure 8.1).
However, the supernatant from the infected control maintained in culture medium
supplemented with 500 jug/ml of L-tryptophan contained approximately 7-fold
fewer infectious EB (2.65xl05 IFU/ml) than the control maintained in culture
medium alone (1.97xl06 IFU/ml) on day 14. Inclusion bodies were visible ill
cytospins prepared from both of the controls on day 7.
8.3.2 Induction of C. psittaci persistence by ROvIFN-y
ROvIFN-y restricted chlamydial growth in a dose dependent manner and removal of
ROvIFN-y from the cultures was associated with an increase in chlamydial growth.
Concentrations of 12.5 U/ml (Figure 8.1) and 25 U/ml (Figure 8.2) of ROvIFN-y
reduced the number of infectious chlamydiae produced by infected ST.6 cells and
delayed cell lysis. However, at these concentrations ROvIFN-y failed to control
chlamydial growth completely, resulting in total lysis of the ST.6 cell cultures by day
35, even when ROvIFN-y was maintained in the culture conditions. Persistent C.
■psittaci infections were established when cultures were maintained in the presence of
50 U/ml (Figure 8.3) or 100 U/ml (Figure 8.4) of ROvIFN-y for 21 and 14 or more
days respectively. Persistent chlamydiae reverted to their normal lytic growth cycle
when ROvIFN-y was removed from the culture conditions (Table 8.2). In contrast,
maintaining infected ST.6 cultures in the presence of 200 U/ml (Figure 8.5) of
ROvIFN-y for more than 14 days appeared to kill C. psittaci. Infectious EB and
inclusion bodies were not found in this culture after day 14 (Table 8.2).
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Figure&1: The effects of exogenous L-tryptophan on C. psittaci growth in ST.6












I'M n i | n h i i j













11 i ll 111 In ri 'j
7 14 21 28 35 42
Days After Infection
0 7 14 21 28 35 42




| 11 rm | in i'tt | iiti j'T'i i hi |ii niij in n i[
0 7 14 21 28 35 42
7 14 21 28 35 42
Days After Infection
Figure 8.1: ST.6 cells were infected
with 3x104 IFU/ml of C. psittaci and
maintained in culture medium
supplemented with 12.5 U/ml of
ROvIFN-y (—) or 12.5 U/ml ROvlFN-y
& 500 /vg/ml of L-tryptophan (—).
Infected controls were maintained in
culture medium alone (—) or in culture
medium supplemented with 500 pglm\
of L-tryptophan (—). C. psittaci
mediated lysis of the ST.6 cultures
occurred at the time points indicated by
*, \ * and *. The shaded area indicates
the presence of ROvlFN-y and/or L-
tryptophan in the culture conditions for
the first 7 (A), 14 (B), 21 (C), 28 (D) or





Figure&2: The effects of exogenous L-tryptophan on C. growth in ST.6
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Figure 8.2: ST.6 cells were infected
with 3x10" IFU/ml of C. psittaci and
maintained in culture medium
supplemented with 25 U/ml of ROvlFN-
y (—) or 25 U/ml ROvlFN-y & 500
pg/ml of L-tryptophan (—). Infected
controls were maintained in culture
medium alone (—) or in culture
medium supplemented with 500 pg/ml
of L-tryptophan (—). C. psittaci
mediated lysis of the ST.6 cultures
occurred at the time points indicated by
*, *, * and *. The shaded area indicates
the presence of ROvlFN-y and/or L-
tryptophan in the culture conditions for
the first 7 (A), 14 (B), 21 (C), 28 (D) or
35 (E) days after infection ( ).
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8.3.3 Addition of exogenous L-tryptophan to ST.6 cultures at the time of
infection
ROvIFN-y-mediated inhibition of C. psittaci growth in ST.6 cells was partially
abrogated when 500 jug/ml of l-tryptophan was maintained in the culture
conditions during the time that the cells were exposed to ROvIFN-y. This effect was
strictly dependent on both the concentration of ROvIFN-y used and the time that
the cultures were maintained in the presence of ROvIFN-y and l-tryptophan.
The effects of exogenous l-tryptophan on chlamydial growth in cultures maintained
in 12.5 U/ml of ROvIFN-y are shown in Figure 8.1. There was a small increase in the
number of infectious chlamydiae present in the culture supernatants (2 to 5.6-fold)
when the culture medium was supplemented with 500 |Ug/ml of l-tryptophan during
the time that the ST.6 cells were exposed to ROvIFN-y (Figure 8.5E). In addition,
cultures maintained in the presence of ROvIFN-y and 500 |Ug/ml of l-tryptophan
were typically lysed by C. psittaci 7 days earlier than cultures maintained in
ROvIFN-y alone. However, chlamydial growth and host cell lysis was retarded in
cultures treated with ROvIFN-y and l-tryptophan compared to the infected
controls. Chlamydial growth increased when cells from these cultures were
transferred into culture medium alone.
The effects of exogenous l-tryptophan were more marked in cultures treated with 25
U/ml of ROvIFN-y (Figure 8.2). There was a small (3.4-fold) increase in the number
of infectious chlamydiae present in the supernatants of cultures maintained in the
presence of ROvIFN-y and 500 jug/ml of l-tryptophan for 7 days compared to the
culture maintained in ROvIFN-y alone (Figure 8.2A). However, when ROvIFN-y and
l-tryptophan were maintained in the culture conditions for 14 days or more the
number of infectious EB present in the culture supernatants rose to between 67 and
1406-fold more than that in the culture maintained in ROvIFN-y alone (Figure 8.2D).
In addition, the presence of exogenous l-tryptophan resulted in earlier lysis of the
ST.6 cultures compared to the culture maintained in ROvIFN-y alone (Figure 8.2E).
Transfer of cells from the culture maintained in ROvIFN-y and 500 |Ug/ml of l-
tryptophan into culture medium alone on days 14 resulted in an increase in
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chlamydial growth (Figure 8.2B).
Persistent C. psittaci infection was not established in cultures maintained in 50 U /ml
of ROvIFN-y and 500 jug/ml of L-tryptophan (Figure 8.3). On day 7 there was a
12.7-fold increase in the number of infectious chlamydiae present in the culture
supernatant of ST.6 cells maintained in both ROvIFN-y and L-tryptophan compared
to the culture maintained in ROvIFN-y alone. This discrepancy increased to 46.8-
fold on day 14 (Figure 8.5B), after which chlamydial persistence was established in
the culture maintained in ROvIFN-y alone (Figure 8.5D). The number of infectious
EB present in the supernatant of the culture maintained in the presence of both
ROvIFN-y and L-tryptophan remained constant at approximately 5xl03 IFU/ml
until day 35 when it peaked at 1.1x10' IFU/ml accompanied by lysis of the ST.6
cell culture (Figure 8.5E).
Persistent C. psittaci infection was not established in cultures maintained in culture
medium containing both 100 U/ml of ROvIFN-y and 500 jug/ml of L-tryptophan
(Figure 8.4). On day 7 there was a 22-fold increase in the number of infectious
chlamydiae present in the culture supernatant of ST.6 cells maintained in ROvIFN-y
and L-tryptophan compared to that in the culture maintained in ROvIFN-y alone
(Figure 8.4A). Infectious chlamydiae could not be demonstrated in the supernatant
of cells maintained in culture medium containing 100 U /ml of ROvIFN-y by day 14
(Figure 8.4C). In contrast, when infected ST.6 cells were maintained in the presence
of both 100 U/ml of ROvIFN-y and 500 jug/ml of L-tryptophan, the number of
infectious chlamydiae in the culture supernatant remained static at approximately
100 IFU /ml until day 28, at which point no infectious EB could be demonstrated in
the culture supernatant. However, this trend was reversed on day 35 when the
number of infectious EB in the culture supernatant rose to 8.6xl03 IFU/ml and C.
psittaci lysed all of the ST.6 cells in the culture.
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Figurea3: The effects of exogenous L-tryptophan on C. psittaci growth in ST.6
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Figure 8.3: ST.6 cells were infected
with 3x10" IFU/ml of C. psittaci and
maintained in culture medium
supplemented with 50 U/ml of ROvlFN-
Y (—) or 50 U/ml ROvlFN-y & 500
/vg/mi of L-tryptophan (—). Infected
controls were maintained in culture
medium alone (—) or in culture
medium supplemented with 500 pg/ml
of L-tryptophan (—). C. psittaci
mediated lysis of the ST.6 cultures
occurred at the time points indicated by
*, *, * and *.The shaded area indicates
the presence of ROvlFN-y and/or L-
tryptophan in the culture conditions for
the first 7 (A), 14 (B), 21 (C), 28 (D) or
35 (E) days after infection ( ). Arrows
indicate the point at which persistence
was established.
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Figure&4: The effects of exogenous L-tryptophan on C. psittaci growth in ST.6
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Figure 8.4: ST.6 cells were infected
with 3x104 IFU/ml of C. psittaci and
maintained in culture medium
supplemented with 100 U/ml of
ROvlFN-y (—) or 100 U/ml ROvlFN-y
& 500 /vg/ml of L-tryptophan (—).
Infected controls were maintained in
culture medium alone (—) or in culture
medium supplemented with 500 jL/g/ml
of L-tryptophan (—). C. psittaci
mediated lysis of the ST.6 cultures
occurred at the time points indicated by
*, *, * and *. The shaded area indicates
the presence of ROvlFN-y and/or L-
tryptophan in the culture conditions for
the first 7 (A), 14 (B), 21 (C), 28 (D) or
35 (E) days after infection ( ). Arrows
indicate the point at which persistence
was established.
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Figure85: The effects of exogenous L-tryptophan on C. psittaci growth in ST.6
cell maintained in 200 U/ml of ROvlFN-y
chlamydiae (IFU/ml)
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Figure 8.5: ST.6 cells were infected
with 3x104 IFU/ml of C. psittaci and
maintained in culture medium
supplemented with 200 U/ml of
ROvIFN-y (—) or 200 U/ml ROvlFN-y
& 500 pg/ml of L-tryptophan (—).
Infected controls were maintained in
culture medium alone (—) or in culture
medium supplemented with 500 pg/ml
of L-tryptophan (—). C. psittaci
mediated lysis of the ST.6 cultures
occurred at the time points indicated by
*, *, * and *. The shaded area indicates
the presence of ROvlFN-y and/or L-
tryptophan in the culture conditions for
the first 7 (A). 14 (B), 21 (C), 28 (D) or
35 (E) days after infection ( ). Arrows
indicate the point after which live
chlamydiae were not recovered.
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C. psittaciwas eradicated from culture maintained in 200 U/ml of ROvIFN-y and
500 jug/ml of L-tryptophan for 21 days or more (Figure 8.5). Cultures maintained in
the presence of ROvIFN-y and L-tryptophan failed to control chlamydial growth
during the first 14 days after infection (Figure 8.5B). However, chlamydiae
appeared to be eradicated from cultures when both 200 U/ml of ROvIFN-y and 500
/ig/ml of L-tryptophan were maintained in the cultures for 21 days or more (Figure
8.5C). Independently of the presence of L-tryptophan, there was no evidence of
chlamydial growth after day 21 throughout the rest of the experiment (Table 8.2).
Table 8.2: Outcome of Maintaining ST.6 cells infected with C. in culture
medium containing ROvlFN-y or ROvlFN-y and L-tryptophan.
ROvlFN-y L-tryptophan Persistence Eradication Lysis
12.5 U/ml No No No Day 35
12.5 U/ml 500 pg/ml No No Day 28
25 U/ml No No No Day 35
25 U/ml 500 pg/ml No No Day 28
50 U/ml No Yes No Day 56
50 U/ml 500 pg/ml No No Day 35
100 U/ml No Yes No Day 63
100 U/ml 500 pg/ml No No Day 35
200 U/ml No No Yes No
200 U/ml 500 pg/ml No Yes No
234
8.3.4 Addition of exogenous L-tryptophan to persistently infected ST.6 cells
In an experiment performed in parallel to that described in 8.3.3, persistent C.
psittaci infections were established in two ST.6 cultures by maintaining them in
culture medium supplemented with 50 U/ml of ROvIFN-y for the first 35 days after
infection.
Chlamydial growth was monitored periodically by titration and cytospin analysis
to ensure that a persistent infection had been established. Infectious chlamydiae
were not found in the supernatants of either of the cultures on day 35 and the ST.6
cells themselves were free from inclusion bodies. 500 jug/ml L-tryptophan was
added to one of the cultures on day 35 and maintained in the culture conditions
until day 70, at which point C. psittaci had lysed all of the ST.6 cells in the culture
(Figure 8.6B) The other culture was maintained in the presence of 50 U/ml of
ROvIFN-y alone until day 84 (figure 8.6A). On days 35 and 49, cells from both
cultures were transferred into ROvIFN-y / L-tryptophan-free culture medium and
maintained until C. psittaci lysed all of the ST.6 cells in the cultures (Figure 8.6).
Similar quantities of chlamydial LPS (Figure 8.6) and infectious chlamydiae (Table
8.3) were detected in the supernatants of both cultures following the removal of
ROvIFN-y on Day 35. Addition of exogenous L-tryptophan on day 35 resulted in
more rapid recovery of chlamydial LPS (Figure 8.6B) and infectious EB (Table 8.3)
when ST.6 cells were subsequently transferred into ROvIFN-y-free culture medium
on day 49. Chlamydial LPS (Figure 8.3A) and infectious EB (Table 8.3) were not
found in the supernatants of the ST.6 culture maintained in the presence of ROvIFN-
y alone after day 21. However, addition of exogenous L-tryptophan on day 35
reversed this effect. Infectious EB (table 8.3) and chlamydial LPS (Figure 8.6B) were
recovered from the culture supernatant on days 14 and 21 respectively and all of
the ST.6 cells in this culture were lysed by day 70.
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FigureE6A: ST.6 cells maintained in ROvlFN-y alone
Days after infection
Figure 8.6A: ST.6 cells were infected with C. psittaci and maintained in culture medium
supplemented with 50 U/ml ROvlFN-y for 35 days (—), 49 Days (—) or 84 days (—).
Uninfected controls (—) were maintained for the duration of the experiment. The asterisks (*
and *) indicate C. psittacimediated lysis of the ST.6 cultures.
Figurea6B: Addition of exogenous L-tryptophan to persistently infected ST.6
cells
Chlamydial LPS (ng/ml)
21 28 35 42 49 56 63 70 77 84
Days after infection
Figure 8.6B: ST.6 cells were infected with C. psittaci and maintained in culture medium
supplemented with 50 U/ml of ROvlFN-y for 35 days (—), on day 35 (arrow) 500 pg/ml of L-
tryptophan was added to the culture maintained in ROvlFN-y. ST.6 cells were maintained in
the presence of ROvlFN-y and L-tryptophan for a further 14 days (—) or until C. psittaci lysed
all of the ST.6 cells in the culture (—). Uninfected controls (—) were maintained for the
duration of the experiment.The asterisks (*, *, and *) indicate C. psittaci mediated lysis of the
ST.6 cultures.
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Table &3: Titration of infectious chlamydiae on days 49 and 77
ROvlFN*y L-tryptophan Day 49 Day 77
exposure (Days) exposure (Days) (IFU/ml) (IFU/ml)
0-35 - 4.35x106 Lysedonday63
0-35 - 1 x10e Lysed on day 63
0-49 - 0 1x103
0-49 35-49 0 1x108
0-84 - 0 0
0-70 (lysis) 35-70 (lysis) 5 Lysed on day 70
-ve Controls -ve Controls 0 0
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8.4 Discussion
These findings support a role for tryptophan depletion as a mechanism through
which persistent C. psittaci infection of ovine ST.6 cells is induced and maintained
by low levels (50-100 U/ml) of ROvIFN-y ■ In addition, they lend further support to
the role of OvIFN-y in both microbistatic and microbicidal control of C. psittaci in
ovine cells (Chapters 6.0 and 7.0). Similar studies in human HeLa 229 cells have
demonstrated a role for tryptophan depletion in RHuIFN-y mediated C. trachomatis
persistence [Beatty et al, 1994a; 1995]. In those studies, the addition of exogenous
tryptophan to persistently infected cultures maintained in 0.5 ng/ml of RHuIFN-y
was sufficient to restore normal C. trachomatis development and cytolytic growth.
Furthermore, whilst RHuIFN-y has been shown to upregulate tryptophan catabolism
and induce C. trachomatis persistence in human ME180 cells, it does not increase
tryptophan catabolism or chlamydial growth in the IDO deficient mutant cell line
ME180-1R3B6A [Beatty et al, 1994a]. C. trachomatis persistence has also been
shown to occur HeLa 229 cells maintained in tryptophan depleted culture medium
in the absence of RHuIFN-y [Beatty et al ; 1994a; 1995]. Similarly, amino acid
deficient culture medium has been reported to induce C. trachomatis and C. psittaci
persistence in McCoy cells [Coles et al, 1993].
Although the results detailed in this chapter support a role for tryptophan depletion
in ROvIFN-y mediated C. psittaci persistence in ovine ST.6 cells, cultures that were
treated with both ROvIFN-y and exogenous L-tryptophan restricted chlamydial
growth more effectively than the infected controls. This agrees with previous studies
in which ROvIFN-y mediated restriction of C. psittaci growth in short-term culture
experiments was only partially reversed by exogenous L-tryptophan [(Chapter 5.0);
Graham et al, 1995].
There are several possible explanations for the failure of exogenous L-tryptophan to
completely ablate the anti-chlamydial effects of ROvIFN-y. Exogenous L-tryptophan
may simply enhance C. psittaci growth in a manner that is independent from the
effects of ROvIFN-y. However, this seems unlikely because exogenous L-tryptophan
did not result in increased C. psittaci growth in infected ST.6 cells maintained in
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ROvIFN-y-free culture medium (Figures 8.1 - 8.5). It is conceivable that the ST.6
cultures were able to catabolise all of the exogenous L-tryptophan present in the
culture supernatants prior to it being replenished every 7 days. However,
tryptophan catabolism was not measured in these studies and without further
work, the ability of 1x10° ST.6 cells (the approximate number of confluent ST.6 cells
supported by a 25 cm2 flask) to catabolise 3 mg of L-tryptophan in 7 days can only
be speculated on. The failure of exogenous L-tryptophan to prevent eradication of
chlamydiae from ST.6 cultures treated with 200 U/ml of ROvIFN-y may therefore
be due to the use of sub-optimal concentrations of L-tryptophan in this study.
Alternatively, ROvIFN-y may induce additional as yet undefined anti-chlamydial
mechanisms in ovine cells, particularly at higher concentrations where exogenous L-
tryptophan had little effect on the microbicidal effects of ROvIFN-y. Further studies
using the L-tryptophan agonist /IDO inhibitor 1-methyl-tryptophan [Munn et al,
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proliferation by recombinant MOMP
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9.1. Introduction
Studies employing MHC II -/- and CD4 -/- mice have identified a requirement for
CD4 +ve T-cells in the development of protective immunity to C. trachomatis in the
mouse [Magee et al, 1995; Morrison et al, 1995; Williams et al, 1997]. The ability of
different inbred strains of mice to resist primary infection with C. trachomatis has
been shown to correlate with their ability to mount a Thl-like cytokine response
[Darville et al, 1997] and more specifically to produce IFN-y [Yang et al, 1996].
Whilst CD4 +ve and CD8 +ve T-cells are both capable of IFN-y production [Simon
et al, 1993; Magee et al, 1995], antibody-mediated depletion studies have shown
that CD4 +ve T-cells contribute significantly more to both IFN-y production and
protective immunity in mice infected intranasally with C. trachomatis [Magee et al,
1995],
In vitro studies using ST.6 cells and BAL macrophages have shown that IFN-y can
restrict the growth of C. psittaci in ovine cells [Graham et al, 1995]. Little is known
about the in vivo cellular source of IFN-y production in sheep in response to C.
psittaci infection or if its production is altered during pregnancy. However,
generalised suppression of mitogen induced PBM proliferation has been reported in
ewes during the later stages of pregnancy [Burrells et al, 1978; McCafferty, 1994].
Identification of the C. psittaci-specific T-cells responsible for IFN-y production in
immune sheep and to what extent its production is altered by hormonal changes
during pregnancy would help to clarify which of the antigen-presentation pathways
should be targeted in OEA vaccine design.
The experiments detailed in this chapter were designed to address these questions
by employing dual label FACS analysis of surface marker expression and
intracellular OvIFN-y expression in PBM following stimulation with UV inactivated
C. psittaci or recombinant MOMP and by quantitative ELISA analysis of the effects
of various pregnancy associated hormones on the cytokine profiles of C. psittaci-
and MOMP-specific T-cell lines derived from immune ewes.
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9.2. Materials and Methods
9.2.1. Sheep
13 adult ewes which had aborted after subcutaneous injection with of lxlO5 egg
lethal dose 50 of S26/3 C. psittaci on day 90 of gestation [Jones et al, 1995], were
screened for C. psittaci specific PBM proliferation using a lymphocyte stimulation
assay (LST assay; Chapter 2.7.). The interval between abortion and screening was
18 months. Two naive ewes which had previously been shown to be seronegative for
chlamydiae-specific antibody by CFT were acquired from a C. psittaci free flock at
MRI and used as negative controls.
9.2.2. Recombinant MOMP
Initial experiments were performed using FMOMP [Flerring et al, 1994] which had
been previously prepared for use in tissue culture by western blot and nitrocellulose
resolubilisation as described by McCafferty (1992). Following a change in MOMP
cloning strategy at MRI, FMOMP was replaced by TMOMP [Herring et al, 1998] in
later experiments (Chapter 2.6).
9.2.3. C. psittaci specific lymphocyte stimulation assay
In initial experiments, PBM from immune ewes and controls were screened for
proliferative responses to UV inactivated C. psittaci EB and FMOMP by LST assay
(Chapter 2.7.). ConA (ICN Biomedicals) and S. minnesota RE-595 LPS (Sigma-
Aldrich) were included in the assay as positive controls. Culture medium alone was
used to provide negative control values. FMOMP was substituted with TMOMP in
later LST screening experiments. Results were expressed as a stimulation index (SI).
OT CPM experimental
Ol — *mmm•■—~~————
Mean CPM of negative controls
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9.3 Results
9.3.1. Screening of Post-OEA ewes and controls for FMOMP specific PBM
proliferation
PBM from 13 adult post-OEA ewes and 2 controls were screened for proliferative
responses to C. psittaciand FMOMP (Table 9.1).
Table9.1: 3H-thymidine incorporation by PBM from post-OEA and control ewes
following stimulation with C. psittaci antigens
Sheep # Antigen / 10 5 2.5 1.25 0.625 Mean CPM of -ve
mitogen pg/mi pg/ml j/g/ml fg/ml Jig/ml controls
2652 EB antigen 24.9 39.4 39.3 57.0 -
Control FMOMP - 5.7 3.8 3.6 3.2
ewe #1 ConA - 292.2 - 243.4 -
LPS 6.9 - - - - 47
2693 EB antigen 0.5 0.6 0.8 0.9 -
Control FMOMP - 0.9 0.8 0.8 0.9
ewe #2 ConA - 32.8 - 28.1 -
LPS 3.8 - - - - 54
2620 EB antigen 193.6 201.7 128.0 131.4 -
OEA FMOMP - 193.0 128.7 77.3 56.7
ewe #1 ConA - 550.0 - 445.0 -
LPS 35.2 - - - . 23.3
2628 EB 89.3 105.9 96.5 103.1 -
OEA FMOMP - 23.2 19.0 18.9 16.7
ewe #2 ConA - 609.5 - 478.2 -
LPS 80.2 - - - - 21.2
2629 EB antigen 28.4 30.1 21.0 13.6 -
OEA FMOMP - 13.5 9.4 4.4 3.6
ewe #3 ConA - 191.1 - 169.2 -
LPS 22.9 - - - - 59
2659 EB antigen 7.8 13.8 11.0 5.3 -
OEA FMOMP - 23.9 13.6 9.8 5.3
ewe #4 ConA - 457.6 - 199.5 -
LPS 22.9 - - - - 59.85
2662 EB antigen 1.9 2.3 1.6 2.7 -
OEA FMOMP - 6.4 5.4 2.8 3.3
ewe #5 ConA - 22.4 - 17.3 -
LPS 17.9 - - - - 546
Table 9.1: Results are expressed as mean SI values of duplicate cultures. Mean CPM
values (1 SI) for the negative controls from each sheep are provided in the far right column.
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Table9.1 (continued): 3H-thymidine incorporation by PBM from post-OEA and
control ewes following stimulation with C. psittaci antigens
Sheep # Antigen / 10 5 2.5 1.25 0.625 Mean CPM of -ve
mitogen pg/ml pg/ml pg/ml pg/ml pg/ml controls
2635 EB antigen 1.1 1.4 1.2 1.2 -
FMOMP - 1.5 1.5 1.9 1.6
ConA - 2.6 - 2.0 -
LPS 2.2 - . - - 4792.5
2645 EB antigen 2.7 4.2 3.4 5.6 -
FMOMP - 3.6 3.4 4.4 2.5
ConA - 481.5 - 325.0 -
LPS 68.6 - - . . 46
2664 EB antigen 0.2 0.3 0.5 0.7 -
FMOMP - 2.0 2.0 1.8 1.7
ConA - 2.0 - 1.5 -
LPS 2.1 - - - . 6209
2669 EB antigen 1.9 4.1 6.4 7.6 -
FMOMP - 13.6 13.1 14.8 16.1
ConA - 29.3 - 26.9 -
LPS 25.0 - . - - 445
2674 EB antigen 16.4 22.0 21.7 28.0 -
FMOMP - 8.4 6.6 9.0 5.4
ConA - 348.4 - 261.7 -
LPS 18.1 - - . . 61
2691 EB antigen 11.8 15.6 17.9 17.2 -
FMOMP - 8.9 12.5 7.3 5.1
ConA - 565.5 - 512.4 -
LPS 11.0 . . . - 25.3
2739 EB antigen 1.5 2.3 2.2 2.0 -
FMOMP - 1.9 1.4 1.1 0.7
ConA - 44.9 - 31.3 -
LPS 16.5 . . . . 343
2741 EB antigen 0.8 1.4 1.4 1.3 -
FMOMP - 0.5 0.8 0.7 0.7
ConA - 13.5 - 11.6 -
LPS 1.7 - - - - 1110
Table 9.1: Results are expressed as mean SI values of duplicate cultures. Mean CPM
values (1 SI) for the negative controls from each sheep are provided in the far right column.
FMOMP induced proliferation in PBM derived from 8 of the post-OEA ewes. There
was evidence of a dose dependent response to FMOMP in 5 of the post-OEA ewes
(Table 9.2: highlighted in red) and these animals were selected for use in further
experiments on this basis. There was also evidence of C. psittaci and FMOMP
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specific proliferation in one of the controls (2652; control ewe #1) which had
previously been shown to be seronegative for C. antibody.
9.3.2. Screening of selected post-OEA ewes and controls for TMOMP specific
PBM proliferation
Five post-OEA ewes, previously selected on the basis of dose dependent
proliferation in response to FMOMP (Table 9.2: highlighted in red), were screened
for TMOMP-specific PBM proliferation. TMOMP which had been prepared
previously for use in tissue culture by western blot and nitrocellulose resolubilisation
as described by McCafferty (1992) was cytotoxic and this approach was
abandoned. TMOMP was subsequently prepared for use in tissue culture using
polyacrylamide column chromatography (Chapter 2.6.4.). This technique allowed
purification of large quantities (>2 mg/48 hours) of TMOMP which was non-toxic
in cell culture at concentrations of up to 40 fig/ml.
Figure&1A: UV inactivated C. psittaci and TMOMP specific proliferation of PBM
from control ewes
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Figure 9.1A: Results are expressed as mean SI values of duplicate cultures. Mean CPM
values (1 SI) for the negative control cultures from each sheep are provided in the top-right
inset of each figure. PBM proliferation measured by 3H-thymidine incorporation in duplicate
cultures over 16 hours, following 72 hours incubation in the presence of UV inactivated C.
psittaci EB ( •——), TMOMP ( • ), 5 pg/ml of ConA (•) or 5 pg/ml of LPS (•).
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Figure9.1B: Proliferation of PBM from post-OEA ewes in response the whole
UV inactivated C. psittaci and TMOMP










50 1 3 4 6
Antigen/Mitogen (//g/ml)
























0 1 4 5
Antigen/Mitogen (pg/ml)
SI: Post-OEA ewe #5
1000-1 1 SI = 985.4 CPM

























5 60 12 4
Antigen/Mitogen (^g/ml)
Figure 9.1 B: Results are expressed as
mean SI values of duplicate cultures. Mean
CPM values (1 SI) for the negative control
cultures from each sheep are provided in
the top-right inset of each figure. PBM
proliferation measured by 3H-thymidine
incorporation over 16 hours, following 72
hours incubation in the presence of whole
UV inactivated C. psittaci EB ( • ),
TMOMP ( • ), 5 pg/ml of ConA (•) or
5 pg/ml of LPS (•).
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LST assays were performed on duplicate cultures, results are expressed as mean SI
values. UV inactivated C. psittaci EB and TMOMP induced proliferation in PBM
cultures derived from one of the controls (Figure 9.1A) and from 4 of the post-OEA
ewes (Figure 9.1B). There was little evidence for antigen- or mitogen-driven
proliferation in PBM cultures derived from post-OEA ewe #5 (Figure 9.1B). There
was no evidence of C. psittaci- or TMOMP-specific proliferation in PBM cultures
derived from the second control ewe (Figure 9.1A).
Large quantities (>200 mg) of TMOMP were produced for use in generating
TMOMP-specific ovine T-cell lines using the E. coli expression system detailed in
Chapter 2.6.1. The product was verified as TMOMP by direct dot-immunobinding
assay (Chapter 2.6.2.) and quantified by SDS PAGE and ID gel densitometery
(Figure 9.2).





Sigma 7.5 pg/ml 15 pg/ml
MW Standards TMOMP TMOMP
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9.3.3. TMOMP-specific ovine T-cell lines
Attempts to extend these studies beyond the initial screening of PBM from immune
ewes for C. psittaci and MOMP specific proliferation were hampered by animal
fatalities and problems associated with generating sufficient amounts of TMOMP.
Post-OEA ewe #5 died from natural causes in November 1996 (aged 6.5 years).
Post-OEA ewe #1 inexplicably lambed in March 1997, despite having been housed
under isolated conditions for over two years, and died as a result of trauma several
days after giving birth (aged 7 years).
By the time that significant amounts of polyacrylamide column chromatography
purified TMOMP were available for dual label FACS analysis and generating T-cell
lines, little or no proliferation could be induced in the PBM of any of the remaining
immune ewes in response to TMOMP or UV inactivated C. psittaci EB. Furthermore,
there was no evidence of ConA or LPS mediated proliferation by PBM from any of
the immune ewes despite repeated LST analysis (data not shown).
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9.4. Discussion
Chlamydial MOMP has been the focus of a great deal of interest as a potential
vaccine candidate against OEA strains of C. psittaci [Herring et al, 1998] and human
strains of C. trachomatis [Stagg, 1998]. However, experimental OEA vaccines based
on recombinant C. psittaci MOMP have so far proved largely ineffective at inducing
protective immunity [Herring et al, 1998]. Differences in the efficacy of experimental
OEA vaccines using the purified outer membrane of C. psittaci [Tan et al, 1990] and
recombinant MOMP [Herring et al, 1994] have been attributed to the failure of the
recombinant protein to adopt a trimeric conformation homologous to that of native
MOMP [Herring et al, 1998]. However, conformational epitopes are not required for
the induction MOMP specific T-cells. Vaccination of BALB/c H-2d mice with a
fusion peptide derived from C. trachomatis MOMP (using the glutathione-S-
transferase from Schistosoma japonicum which lacks T cell determinants recognised
by BALB/c H-2d mice) has been shown to elicit both C. trachomatis-specific T-cell
proliferation ex vivo and enhanced T-cell help for the production of protective
antibodies following secondary challenge with heat-inactivated C. trachomatis in vivo
[Allen et al, 1991]. Independent studies have identified a 12-mer peptide (TINKP)
of MOMP which stimulates proliferation and IFN-y production in T-cells from naive
human donors [Stagg et al, 1993]. Anti-MHC II antibodies but not anti-MHC I
antibodies block TINKP-specific proliferation suggesting that this epitope is
recognised in the context of MHC II and CD4 +ve T-cells. In addition, intradermal
vaccination of mice with TINKP induces chlamydiae-specific T-cell memory and
provides partial protection against salpingitis during secondary challenge with live
C. trachomatis [Knight et al, 1995].
Evaluation of the immune response elicited by OEA vaccines based on recombinant
C. psittaci MOMP have thus far focused on antibody rather than T-cell responses
[Herring et al, 1994; 1998], It is notable that PBM derived from one of the control
ewes (Control ewe #1) used in the experiments described here showed evidence of
C. psittaci-specific proliferation despite having previously screened negative for C.
psittaci specific antibody by CFT. Furthermore, efficacy studies have been restricted
to ewes infected with C. psittaci for the first time during pregnancy and have not
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taken into account the possibility that recombinant MOMP may increase the
resistance of non-pregnant ewes to persistent infection by priming MOMP-specific
T-cells. This is particularly important, not only because of the central role played by
persistent infection in the epidemiology of OEA, but also because pregnancy is
associated with a bias towards a Th2-like immune response and down regulation of
Thl-like cytokines including IFN-y [Raghupathy, 1997], Evaluation of the the ability
of recombinant MOMP to protect non-ewes against primary challenge with live C.
psittaci would be more representative of the natural situation where ewes become
persistently infected in one season and abort in the next [Wilsmore et al, 1984]. In
addition, ewes were vaccinated subcutaneously in the experiments described by
Herring et al (1994;1998), a route which has since been shown to induce few IFN-y
secreting T-cells or provide significant protection against secondary C. trachomatis
infection in mice [Igietseme et al, 1998 ].
Both FMOMP and TMOMP induced proliferation in PBM derived from immune
ewes in the experiments detailed here (Table 9.1 and Figure 9.1B) suggesting that
linear epitopes within MOMP are recognised by PBM from immune ewes. Dual
labelling of cell surface phenotypic antigens and intracellular OvIFN-y in PBM
challenged with TMOMP or UV inactivated C. psittaci ex vivo would have provided
an extremely useful insight into which ovine cell types are responsible for OvIFN-y
production in response to secondary challenge with C. psittaci in vivo [Graham et al,
1995]. Similarly, it was hoped that quantitative analysis of the effects of oestrogen
and progesterone on the production of ROvIFN-y by TMOMP-specific T-cell lines
would help to explain how persistent C. psittaci may become reactivated during
pregnancy. However, technical difficulties prevented further characterisation of C.






The overall aim of this thesis was to further the understanding of the interaction
between the ovine immune system and C. psittaci, with the ultimate objective of
improving diagnosis and prophylactic control of OEA. To this end, two main
avenues of research were pursued.
1. The development of an automated image analysis system for quantification of
chlamydial growth in vitro that would provide a viable alternative to counting
chlamydial inclusions by eye.
2. Investigation of the effects of ROvIFN-y on C. psittaci growth in ovine cells,
focusing on the mechanisms through which it restricts chlamydial growth and its
role in the induction and maintenance of persistence in vitro.
Quantifying chlamydial growth is often one of the major rate limiting steps in
experiments involving the study of anti-chlamydial pharmaceuticals or immune
effector mechanisms. Prior to the development of Inclusion Counter, an LPS-ELISA
[Graham et al, 1995] was routinely used to quantify C. psittaci growth in many of the
experiments detailed in this thesis (Chapters 5.0, 6.0, 7.0 and 8.0). Whilst the LPS-
ELISA provides a more rapid means of quantifying C. psittaci growth in vitro than
counting inclusion bodies by eye, there are a number of technical considerations. The
LPS-ELISA provides an indirect measure of chlamydial growth as a function of the
amount of LPS released into the extracellular milieu by infected cells in vitro and it
does not appear to be as sensitive as titration of culture supernatants for the
presence of infectious EB (Chapter 7.0). This is particularly true of cultures
maintained in the presence of ROvIFN-y where the sensitivity of the LPS-ELISA
appears to be reduced compared to cultures maintained in ROvIFN-y-free culture
medium (Figure 7.2). The reason for this is not clear, but it may be due to IFN-y
mediated changes in C. psittaci LPS levels similar to that describe for C. trachomatis
[Beatty, 1993]. RHuIEN-y-mediated C. trachomatis persistence in HeLa 229 cells is
associated with the formation of aberrant chlamydiae which exhibit reduced levels
of LPS, MOMP and the 60-kDa cysteine-rich OMP when compared to C. trachomatis
grown in HeLa 229 cells under control conditions. In contrast, chlamydial HSP60
production does not appear to be downregulated by chlamydiastatic concentrations
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of RHuIFN-y [Beatty, 1993; 1994c]. Similar changes in chlamydiae morphology and
antigen production have also be reported with chlamydiastatic concentrations of
penicillin, ampicillin and hydroxyurea [Cevenini et al, 1988; Rosenkranz et al, 1973;
Sardinia et al, 1988].
The possibility that chlamydial antigen expression may be modulated in response to
immunological and pharmaceutical stress has serious implications for the detection
and quantification of chlamydiae. Any technique based on the recognition of a single
chlamydial antigen or RNA sequence is likely to be open to misinterpretation if the
chosen antigen is preferentially upregulated or downregulated by chlamydiae as a
consequence of the hosfs immune response in vivo or in response to immune factors
or antibiotics in vitro. Consequently, monoclonal antibody and RT-PCR based
techniques may not be the best solution for quantifying chlamydial growth in vitro or
detecting chlamydiae in tissues ex vivo. This is particularly true of RT-PCR, where
there is little scope for direct verification of the results since both the host cells and
inclusion bodies are destroyed in the process of extracting RNA [Khan et al, 1996].
The use of monoclonal antibodies may adversely effect the interpretation of
immunohistochemistry and immunofluorescence. Inclusion bodies containing
aberrant C. trachomatis, which develop in HeLa 229 cells treated with
chlamydiastatic concentrations of RHuIFN-y, stain poorly with anti-MOMP
monoclonal antibodies compared to normal inclusion bodies from control cultures
[Beatty ei al, 1993]. Similarly, chlamydiastatic concentrations of ampicillin,
hydroxyurea and penicillin completely inhibit production of the cysteine-rich 60-
kDa C. trachomatis OMP but do not eradicate the pathogen from infected cultures
[Cevenini et al, 1988; Sardinia et al, 1988].
Differential downregulation of chlamydial antigens may explain why the anatomical
and cellular location of C. psittaci has has yet to be identified in the persistently
infected ewe. Monoclonal antibodies have been used to detect C. psittaci in tissue
sections derived from experimentally infected non-pregnant ewes with varying
degrees of success [Amin and Wilsmore, 1995; Buxton et al, 1996; Huang et al,
1990]. However, C. psittaci becomes increasingly difficult to detect in vivo with anti-
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LPS monoclonal antibodies 6 days after infection despite the continual presence of
C. psittaci DNA, as determined by PCR [Buxton et al, 1996]. Similarly, Amin and
Wilsmore (1995) were only able to detect C. psittaci during the first 6 days after
infection using monoclonal antibodies specific for a 57-kDa C. psittaci protein [Bollo
et al, 1992] and chlamydial-LPS. Recent attempts to detect C. psittaci in chronically
infected non-pregnant ewes which have previously aborted or experienced
fetopathology following experimental infection with C. psittaci have been more
successful [Papp et al, 1998]. Using a monoclonal antibody which is specific for
OEA strains of C. psittaci [Andersen, 1991], Papp et al (1998) were able to
demonstrate chlamydiae in cells collected from the cervix and vagina of 100% of
non-pregnant ewes that had experienced C. psittaci induced abortion three years
previously. Although the target antigen for the monoclonal antibody used by Papp
et al (1998) remains unspecified, it is reasonable to speculate that its ability to
detect chronic C. psittaci infection in non pregnant ewes where the Clearview test did
not is a result of differential antigen expression by C. psittaci in the chronically
infected ewe.
Diffuse staining of chlamydial inclusion bodies is particularly problematic for image
analysis since efficient segmentation of inclusion bodies from cellular background
not only depends on the specificity of the staining procedure employed, but also on
the intensity of stain taken up by the chlamydiae. This is especially true for
automated approaches to image analysis including Inclusion Counter. Consequently,
selection of a staining procedure which provides specific and uniformly intense
staining of inclusion bodies regardless of the developmental status of the
chlamydiae is of paramount importance. Polyclonal antibodies raised against live
chlamydiae offer the most straightforward solution to this problem. The chief
argument against using polyclonal antibodies is their potential to cross-react with
different species and strains of chlamydiae. Whilst this does not present a problem
under controlled in vitro conditions or in vivo experiments using specific pathogen
free animals, it has the potential to confound diagnosis of OEA because polyclonal
antibodies may also detect non-pathogenic stains of C. pecorum or polyarthritis
strains of C. psittaci. However, it is worth noting that anti-LPS monoclonal
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antibodies commonly used for diagnostic purposes such as Clearview and
IMAGEN™ (Celltech) are genus-specific rather than species-specific. Furthermore,
the anti-LPS monoclonal antibody 13/4 used by Huang et al (1990) and Buxton et al
(1996) not only recognises LPS from all four species of Chlamydia but also RE-strain
LPS from other bacteria including Salmonella Syp, which can also cause abortion in
ewes.
In situ DNA-hybridisation offers an attractive alternative to antibody based
technologies. It allows the use of strain specific oligonucleotides which can be
designed such that they only hybridise to DNA and are thus unlikely to be affected
by relative changes in chlamydial antigen expression. It also offers tighter regulation
of fluorochrome or substrate deposition than antibody-antigen based approaches.
Signal amplification can be achieved by using combinations of oligonucleotides
tagged with multiple moieties, direct biotin-streptavidin amplification, anti-moiety
biotinylated antibodies or biotinylated anti-Ig F(ab)2 fragments to enhance inclusion
body segmentation from cellular background. Alternatively, in situ PCR can be used
to amplify target DNA sequences prior to in situ hybridisation.
Whilst Inclusion Counter was designed and assessed using images of C. psittaci
inclusion bodies stained with MZN it has been developed to cope with the wide
diversity of staining procedures available for differentiating chlamydial inclusion
bodies from cellular background. This was initially achieved by generating 8-bit
greyscale images from combinations of the red, green and blue components of the
original 24-bit RGB colour images so as to maximise the contrast between inclusion
bodies and cellular background and thereby facilitate their segmentation (Chapter
3.0). In Inclusion Counter v2.0 (Chapter 4.0), a true 24-bit colour segmentation
system was developed using both the RGB and HSV colour models to allow
automated enumeration and measurement of inclusion bodies to be independent of
the colour of stain used. Inclusion Counter v2.0 can also be configured to ignore RGB
or HSV channels in which cellular background and inclusion bodies share similar
grey scale values. This feature is particularly effective at excluding particulate
background artefacts when used in conjunction with the HSV colour model (Chapter
4.0: Figure 4.6).
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The latest version of Inclusion Counter (v2.0) is not only highly accurate with regard
to counting inclusion bodies, but also provides accurate values for inclusion body
length, width, area, and total area/percentage of the field of view occupied by
inclusion bodies. These parameters are simply not available using flow cytometry
[Dessus-Babus et al, 1998] and are prohibitively time consuming to perform by eye
or by non-automated image analysis based approaches. Inclusion Counter
discriminates inclusion bodies from background using fixed threshold values and
size parameters for any given series of images, therefore the level of error inherent in
the system remains constant and is not open to operator bias. Furthermore, images
of control cultures can be used to determine the level of error inherent in the system,
a feature which is unavailable when counting inclusion bodies by eye. Further
measurement parameters such as morphological measurements like roundness or
width/length (aspect ration) can be added to Inclusion Counter v2.0 as required
without incurring significant development costs.
The range of measurement possible with Inclusion Counter should allow more
precise analysis of the effects of anti-chlamydial agents such as cytokines and
antibiotics than currently available techniques. Agents which target both
intracellular and extracellular chlamydiae are likely to affect inclusion body size and
frequency. Reductions in C. trachomatis inclusion body number and size have been
observed following pretreatment of murine McCoy or L-cells with IFN-y [Byrne and
Krueger, 1983; Mayer et al, 1993]. Treatment of HeLa 229 cells with RHuIFN-y six
hours after infection with C. trachomatis is associated with a significant reduction in
inclusion body size [Beatty et al, 1994b]. Agents which act exclusively on
chlamydial EB in the extracellular milieu or prevent internalised EB from escaping
phagolysosomal fusion would be expected to result in a reduction in the number of
inclusion bodies per field of view in the absence of significant changes in inclusion
body size or morphology. Consequently, Inclusion Counter may be useful in
determining whether novel pharmaceutical compounds penetrate infected cells and
act on established intracellular chlamydiae or simply inactivate extracellular EB.
The ability of Inclusion Counter to return accurate values for inclusion body size
may also be used to ensure that putative neutralising antibodies do not cause a
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significant reduction in inclusion body size that might otherwise indicate the
presence of contaminating cytokines such as IFN-y which influence inclusion body
size [Beatty et al, 1993; Byrne and Krueger, 1983; Mayer et al, 1993]. Conversely,
reduced inclusion body size in the absence of a reduction in inclusion body numbers
would be expected following treatment of infected cells with anti-chlamydial agents
which do not effect establishment of the inclusion body but restrict RB binary
fission. Agents which block the aggregation of endosomes containing chlamydiae in
cells infected with multiple EB, similar to that described for C. trachomatis in McCoy
and HeLa 229 cells after intracellular free Ca2+ depletion [Majeed et al, 1993; 1994],
should result in increased numbers of significantly smaller inclusion bodies
compared to controls. Future versions of Inclusion Counter will incorporate
roundness and aspect ratio measurements since significant changes in these
morphology parameters may indicate damage to inclusion body integrity in the later
stages of the chlamydial developmental cycle.
The same approach employed to segment inclusion bodies from cellular background
can also be used to calculate the area of the cell monolayer which was lysed due to
chlamydial growth. This allows the progression of the infectious process to be
measured after the first cycle of chlamydial growth and host cell lysis, providing
additional information about the effects of anti-chlamydial agents beyond the initial
phase of infection.
The major limitation of Inclusion Counter is that it has been designed primarily for
use with confluent monolayers of cells. It cannot, in its present format, be used for
applications such as determining the percentage of infected cells in primary
macrophage cultures or cytospins. However, an updated version of Inclusion
Counter v2.0 is under development which does address this requirement. In
addition to its designated application, Inclusion Counter has a number of other
potential uses. Inclusion Counter can be used to allow rapid and accurate
quantification of a wide variety of histological features both inside and outside
chlamydial biology, including cytokine expression, pathological changes and
infectious processes that would otherwise be difficult to quantify.
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The completed version of Inclusion Counter v2.0 (Chapter 4.0) is freely available in
the public domain and can be downloaded from the U.S. National Institute of
Health via the internet (ftp://codon.nih.gov/pub/nih-image/user-macros/).
However, Inclusion Counter is constantly evolving to accommodate new
applications and more recent versions of the software along with online instruction
manuals for Inclusion Counter v2.0 use can be downloaded from the Inclusion
Counter Home Page at (http:/ /www.image-analysis.co.uk).
Whilst clinical OEA appears to be restricted to fetopathology and abortion in the
ewe, the interaction between C. psittaci and the ovine immune system is highly
complex. Infection during pregnancy commonly results in abortion at or just before
the time of normal parturition [Buxton et al, 1990]. Non-pregnant ewes appear to be
able to control OEA strains of C. psittaci and do not develop demonstrable
pathology. However, many ewes infected in this manner fail to resolve the infection
or develop protective immunity, remain persistently infected for prolonged periods
and often go on to experience clinical disease during their next pregnancy [Wilsmore
et al, 1984], Furthermore, although ewes which experience OEA appear to develop
protective immunity to clinical disease in future pregnancies, the exact nature of this
immunity remains unclear.
Protective immunity to OEA may not to be synonymous with sterile immunity to C.
psittaci, since immune ewes may remain chronically infected for several years after
experiencing clinical OEA [Papp et al, 1994; 1998; Papp and Shewen, 1996b].
Delineation of the immune mechanisms involved in persistent infection in non¬
immune ewes and chronic infection of the vaginal and cervical epithelium of immune
ewes is likely to have major implications for OEA vaccine design.
ROvIFN-y restricts the growth of the S26/3 OEA strain of C. psittaci in a dose
dependent manner in ovine ST.6 cells and has a marked effect on chlamydial
inclusion body morphology in ovine BAL macrophages (Chapter 5.0). ROvIFN-y
appears to inhibit C. psittaci growth through both microbistatic and microbicidal
mechanisms in ST.6 cells. Concentrations of 1 to 25 U/ml of ROvIFN-y restrict but
do not completely inhibit C. psittaci growth in ST.6 cells. In contrast, C. psittaci
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growth is completely inhibited when infected ST.6 cells are maintained in the
presence of concentrations of 25 U/ml or more of ROvIFN-y. This effect appears to
become microbicidal when the concentration of ROvIFN-y is increased to 200 U/ml
or more (Chapters 6.0, 7.0 and 8.0).
Pretreatment of ST.6 cells with RBovIFN-a or synthetic double stranded RNA at
concentrations matched with ROvIFN-y in terms of anti-viral activity does not
significantly affect C. psittaci growth, suggesting that the mechanisms through which
ROvIFN-y restricts C. psittaci in ovine cells are independent from its anti-viral
activities (Chapter 5.0). ROvIFN-y does not induce the production of detectable
amounts of NO* in ST.6 cells or ovine BAL macrophages infected with the S26/3
OEA strain of C. psittaci. Indeed, direct comparison with the murine RAW 264.7
macrophage cell line strongly suggests that ovine BAL macrophages are incapable of
NO* synthesis, even when stimulated with combinations of IFN-y and LPS or C.
psittaci which induce maximal production of NO' in RAW 264.7 cultures. These
finding concur with previous data published by Bogdan et al (1997) which showed
that ovine BAL macrophages do not produce significant amounts of NO' in
response to live bacteria and supernatants from Corynebacterium pseudotuberculosis
and Pasteurella haemolytica cultures; purified E. coli or P. haemolytica LPS either alone
or in combination with IFN-y or lymphocyte conditioned medium; or ovine
lentivirus. Furthermore, whilst L-NMMA has been shown to reverse the anti-
chlamydial effects of IFN-y in murine RAW 264.7 and McCoy cells [Chen et al, 1996;
Mayer et al, 1993], it has no effect of the anti-chlamydial effects of ROvIFN-y in
ST.6 cells infected with C. psittaci (Chapter 5.0). Similarly, neither L-NMMA nor
depletion of L-arginine by the enzyme arginase reduce the capacity of human
peripheral blood monocyte derived macrophages stimulated with IFN-y in vitro or
monocytes from patients undergoing IFN-y therapy to restrict intracellular growth of
C. psittaci, T. gondii and L. donovani [Murray and Teitelbaum, 1992]. These findings
suggest that in contrast to the situation in mice and homologous to that in humans,
iNOS and NO* are unlikely to participate in the anti-chlamydial activities of IFN-y
in sheep.
Despite the body of evidence in support of the role of IFN-y mediated NO'
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production in restricting chlamydial growth in the mouse, several recent studies have
cast doubt on the relevance of iNOS/NO' in murine immunity to chlamydiae. Result
from experiments comparing the susceptibility of iNOS KO mice (iNOS -/- mice)
and normal control mice to MoPn suggest that NO' production is not required for
the resolution of chlamydial infections in vivo [Ramsey et al, 1998; Perry et al, 1998],
although iNOS -/- mice were marginally more susceptible to systemic infection
[Igietseme et al, 1998]. In addition, Ramsey et al (1998) demonstrated that
macrophages and primary cell lines (lung and urinary bladder cells) explanted from
iNOS -/- mice were not significantly different from cells derived from control mice
in terms of their ability to restrict C. trachomatis growth following treatment with
IFN-y in vitro. In light of these findings, IFN-y mediated NO' production may
accompany rather than mediate the anti-chlamydial effects of this cytokine in the
mouse. Moreover, the lack of evidence of a role for NO' production in IFN-y
mediated restriction of chlamydial growth in sheep or humans suggests that the
mouse model may have little value in this context.
In contrast to the apparent lack of involvement of NO' production, there is
considerable evidence to support a role for the induction of tryptophan catabolism
by in ROvIFN-y mediated inhibition of C. psittaci replication in ovine cells. In
agreement with previously published data [Graham et al, 1995], addition of
exogenous L-tryptophan to ROvIFN-y pretreated ST.6 cultures partially ablates
their ability to restrict the growth of the S26/3 OEA strain of C. psittaci (Chapter
5.0). Furthermore, regression analysis suggests that exogenous L-tryptophan reverses
the anti-chlamydial effects of ROvIFN-y rather than simply increasing C. psittaci
growth in a generalised manner (Chapter 5.0). These findings echo the results of
studies in human cells [Byrne et al, 1986; Mehta et al, 1998; Murray et al, 1989;
Summersgill et al, 1995; Thomas et al, 1993].
Tryptophan catabolism may not be the only anti-chlamydial mechanism induced by
ROvIFN-y in ovine cells. Long-term culture of C. psittaci infected ST.6 cells in the
presence of ROvIFN-y has allowed delineation of the microbistatic and microbicidal
activities of this cytokine (Chapter 7.0). Induction and maintenance of C. psittaci
persistence in ST.6 cells by microbistatic concentrations of ROvIFN-y is ablated
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when cultures are maintained in the presence of exogenous L-tryptophan. In
contrast, exogenous L-tryptophan does not rescue C. psittaci from the microbicidal
effects of concentrations of 200 U/ml or more of ROvIFN-y (Chapter 8.0). The
reason for this disparity is not clear, but it seems plausible that additional
microbicidal mechanisms may be induced when cells are maintained in the presence
of high concentrations of ROvIFN-y for prolonged periods of time. Ffowever, what is
clear is that further analysis is required in order to rule out the possibility the
microbicidal effects of ROvIFN-y are mediated by tryptophan catabolism alone.
Current opinion favours the down regulation of Thl-like immunity in favour of Th2-
like immunity during successful pregnancy [Raghupathy, 1997], A number of factors
are thought to contribute towards biasing the immune system away from Thl-like
immunity during pregnancy.Wegmann et al (1993) reported spontaneous production
of the Th2-like cytokines IL-4, IL-5 and IL-10 by murine decidual cells cultured ex
vivo throughout pregnancy. Progesterone biases antigen-specific human CD4 +ve T-
cell lines and clones towards Th2-like cytokine production [Piccinni et al, 1995],
Progesterone-induced blocking factor (PIBF) has a similar effect on murine spleen
cells [Szekeres-Bartho and Wegmann, 1996] and has been shown to suppress NK
cell cytotoxicity toward human embryonic fibroblast cells and TNF production
[Szekeres-Bartho et al, 1989], Suppressed PIBF production is also associated with
recurrent spontaneous abortion in women [Szekeres-Bartho et al, 1995].
Supernatants from human placental and trophoblast cells appear to have more
generalised immunoregulatory functions, including down regulation of murine and
human mixed lymphocyte reactions, mitogen induced T-cell proliferation, murine
graft-versus-host responses and CTL activity [Krishnan et al, 1991; 1995].
Constitutive expression of IDO by trophoblast cells has been proposed as a
potential mechanisms for preventing allogeneic fetal rejection. IDO activity increases
in human syncytiotrophoblast cells after 14 weeks gestation and is maintained at
high levels until shortly before parturition [Kamimura et al, 1991]. Munn et al (1998)
have recently described a similar pattern for IDO transcription in the murine
placenta. Furthermore, inhibition of IDO activity by the tryptophan analogue 1-
methyl-tryptophan induces abortion in pregnant mice carrying allogeneic concept!
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but has no effect on syngeneic pregnancies. In light of these findings and what is
know about the role of tryptophan catabolism in IFN-y mediated restriction of
chlamydial growth in human and ovine cells [Byrne et al, 1986; Graham et al, 1995;
Mehta et al, 1998; Murray et al, 1989; Summersgill et al, 1995; Thomas et al, 1993;
(Chapters 5.0 and 8.0)] it seems unlikely that trophoblast cells would support the
growth ofOEA strains of C. psittaci. However, C. psittaci inclusion bodies are readily
detectable in ovine trophoblast cells from approximately 90 days gestation onward
in vivo [Buxton et al, 1990], C. psittaci inclusion bodies have also been found in
murine trophoblast cells in vivo [Banks et al, 1982; Buendia et al, 1998] and in the
syncytiotrophoblast of pregnant women who have aborted as a consequence of
zoonotic infection with OEA strains of C. psittaci [Hyde and Benirschke, 1997].
The involvement of tryptophan deprivation in IFN-y mediated restriction of C.
psittaci growth in ovine cells does not exclude the possibility that it also plays a role
in preventing allogeneic fetal rejection in the ewe. Whilst the ability of C. psittaci to
infect cells in which the availability of tryptophan is likely to be heavily restricted
until the later stages of pregnancy is surprising, constitutive expression of IDO by
trophoblast cells may actually explain the delay between invasion of the placenta at
around day 60 of gestation and the onset of pathology after 90 days gestation in
OEA.
The finding that ROvIFN-y can mediate persistent C. psittaci infection in an ovine
cell line in vitro suggests that IFN-y may be involved in maintaining persistence in
vivo (Chapters 6.0, 7.0 and 8.0). It is therefore conceivable that down regulation of
Thl-like cytokines, including IFN-y, may be responsible the transition from
persistent to active C. psittaci infection during pregnancy, similar to the reduction in
resistance to L. major infection observed in C57BL mice during pregnancy [Krishnan
et al, 1996a]. Fetopathology may occur as a direct result of chlamydial replication in
the placenta. Alternatively, massive C. psittaci replication in the placenta may
induce a localised Thl-like response at the maternal-fetal interface and subsequent
allogeneic fetal rejection similar to that seen in pregnant mice injected with TNF-a,
IFN-y or IL-2 [Chaouat et al, 1990].
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Whilst downregulation of Thl-like cytokines provides an attractive hypothesis for
the reactivation of persistent C. psittaci during pregnancy, it does not explain why
ewes develop protective immunity to OEA after experiencing clinical disease.
However, the interaction between Plasmodium falciparum and the human immune
system during pregnancy may offer an explanation. Primary immunity to P.
falciparum infection in humans is thought to be mediated by CMI and is associated
with the production of Thl-like cytokines [Harpaz et al, 1992]. In contrast,
protective immunity to secondary infection is thought to be mediated by antibody
[Smith, 1996]. In highly endemic areas where acquired immunity is common, clinical
manifestations of malarial infection are not usually exacerbated during pregnancy.
In areas of low endemicity where acquired immunity is rare, pregnant women
infected with P. falciparum often suffer from exacerbated pathology during
pregnancy, possible as a result of suppressed Thl-like immunity [Smith, 1996].
Although it is not not clear whether protective immunity to OEA is predominantly
mediated by antibody or CMI, it is conceivable that immunity to OEA strains of C.
psittaci is regulated in a similar manner to that described for P. falciparum. Primary
infection in the non-pregnant ewe may be controlled by a Thl-like response, whereas
protective immunity to clinical OEA may be mediated by antibody. However, both
DTH and antibody responses to C. psittaci antigens are significantly enhanced in
immune ewes [Dawson et al, 1986].
Changes in the physiology of the ewe during pregnancy may induce C. psittaci to
express antigens which mediate its sequestration to the placenta. Protective
immunity may therefore be directed against an antigen which is only expressed by C.
psittaci during the pregnancy. Once again a parallel may be drawn between OEA
and P. falciparum infection in pregnant women. Malaria can cause complications
during pregnancy that arise as a result of P. falciparum infection of the placenta
leading to low birthweight babies and increased neonatal mortality [Steketee et al,
1996]. Sequestration of the parasite to the placenta is mediated by the adhesion of
parasitised erythrocytes to chondriotin sulphate A (CSA) expressed on the surface
of the syncytiotrophoblast [Fried and Duffy, 1996; 1998] where the parasite
appears induce a localised Thl-like response [Fried et al, 1998a]. However, such
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complications are most common in women during their first pregnancy and it
appears that women exposed to P. falciparum during pregnancy develop antibody
which specifically blocks the interaction of parasitised erythrocytes with CSA
expressed on the surface of the placenta [Fried et al, 1998b; Miller and Smith, 1998].
The existence of similar C. psittaci antigens may explain why immune ewes do not
experience clinical OEA despite the fact that they can remain chronically infected
with C. psittaci [Papp et al, 1994; 1998; Papp and Shewen, 1996b].
Broadly speaking, the interaction between the ovine immune system and OEA
strains of C. psittaci can be divided into three stages.
1. Persistent infection in the non-pregnant ewe in the absence of protective
immunity against abortion or pathology.
2. Active infection and invasion of the placenta with subsequent fetopathology
during pregnancy.
3. Persistent infection in the immune ewe in the absence of pathology outwith or
during subsequent pregnancies.
To be effective, the minimum requirement of an OEA vaccine would be the induction
of protective immunity to clinical OEA. In other words, the vaccine would be
required to induce an immune response that mimics naturally acquired immunity to
OEA but would not necessarily be required to induce sterile immunity to C. psittaci
itself. However, it is not clear which components of the acquire immune response to
OEA strains of C. psittaci are responsible for preventing fetopathology. Given the
complexity of the protective immune response to OEA, it seems unlikely that an
effective sub-component vaccine will be achieved by selecting target antigens merely
on the basis that they are expressed on the outer membrane of the EB and that they
are recognised by sera from immune ewes.
Whilst protective antigens must by definition be immunogenic, immunogenic antigens
are not necessarily protective. Recombinant MOMP is recognised by sera from
immune ewes and it is the major constituent of the C. psittaci EB outer membrane but
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it does not induce protective immunity to OEA [Herring et al, 1994, 1998]. Although
Herring et al (1998) suggest that the the reason for the lack of protection achieved
using experimental vaccines based on recombinant MOMP is due to its failure to
adopt native conformation, it may equally well be that immunologic recognition
MOMP is not required for protective immunity to OEA. Further work is required to
determine which C. psittaci antigens are involved in sequestration of the pathogen to
the placenta during pregnancy and whether their expression is modulated by
pregnancy. The identification of such an antigen might allow the development of a
vaccine which blocks C. psittaci invasion of the placenta similar to that envisaged by
Miller and Smith (1998) for preventing sequestration of P. falciparum infected
erythrocytes to the syncytiotrophoblast in pregnant women.
One of the major drawbacks of a vaccine which induces protective immunity to
clinical OEA rather that C. psittaci itself is that immunised ewes may still be
susceptible to persistent infection similar to that described in naturally immune
ewes [Papp et al, 1994; 1998; Papp and Shewen, 1996b], Although this type of
vaccine may reduce transmission at lambing by preventing abortion and the
subsequent shedding of large quantities of infectious C. psittaci into the local
environment, it is not clear whether it would prevent persistently infected immune
ewes from shedding C. psittaci during estrus. Consequently, OEA vaccines which
simulate natural immunity in the ewe are unlikely to be useful for wholesale
eradication of C. psittaci from infected flocks.
An alternative approach to OEA vaccine design would be to target persistent
infection in the non-immune ewe by boosting Thl-like immune responses to C.
psittaci. Under these circumstance, IFN-y production may be increased from
microbistatic to microbicidal levels and thus lead to eradication (Chapter 7.0) and
the induction of sterile immunity rather that persistence in the non-pregnant ewe.
Appropriate target antigens could be extrapolated from the in vitro model of C.
psittaci persistence in ovine ST.6 cells (Chapters 6.0, 7.0 and 8.0) by Western blot or
RT-PCR analysis. The possibility that persistently infected ovine cells present C.
psittaci antigens in the context of MHC that would make this approach feasible is
supported by the observation that IFN-y mediated persistent C. psittaci and C.
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trachomatis infected murine L-cells are efficiently recognised and killed by cytotoxic
CD8 +ve T cells [Rasmussen et al, 1996].
Although a vaccine which induces a strong Thl-like immune response might run the
risk of exacerbating fetopathology in ewes infected with C. psittaci during pregnancy,
it would be preferable to vaccines which mimic naturally acquired protective
immunity to OEA since it would in theory induce sterile immunity to C. psittaci. Such
a vaccine could be employed either prophylactically or curatively to eradicate C.
psittaci from infected flocks. The in vitro model of IFN-y-mediated C. psittaci
persistence in ovine cells may aid in the identification of putative target antigens for
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1.1 PBS (MRI scientific services)
• 900 ml deionised water
• 8 g NaCI (Sigma-Aldrich)
• 1.15 g N%HP04 (Sigma-Aldrich)
• 0.2 g KH2P04 (Sigma-Aldrich)
• 0.2 g KCL (Sigma-Aldrich)
• Adjusted to 1 L in volume at pH 7.4, autoclaved and stored at RT.
1.2 trypsin/versene
• 20% Trypsin solution (MRI scientific services)
• 40 g of NaCI (Sigma-Aldrich)
• 3.8 g of KCI (Sigma-Aldrich)
• 0.5 g of NajHPO,, (Sigma-Aldrich)
• 15 g of Tris (hydroxymethyl)methylamine (Sigma-Aldrich)
• 7.5 ml of 1% Phenol red solution (Sigma-Aldrich)
• 12.5 g Trypsin (Difco Laboratories, Surrey, UK)
• Made up to 5 L in deionised water pH 7.6.
• 80% Versene solution (MRI scientific services)
• 48.0 g of NaCI (Sigma-Aldrich)
• 1.2 g of KCI (Sigma-Aldrich)
• 6.9 g of Na2HP04(Sigma-Aldrich)
• 1.2 g of KH2P04 (Sigma-Aldrich)
• 1.2 g Versene (Ethylene Diamine Tetra acetic acid (Disodium salt: Dihydrate))
(Sigma-Aldrich)
• 9.0 ml of 1% Phenol red solution (Sigma-Aldrich)
• Made up to 6 L in deionised water pH 7.2.
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1.3 chlamydial transport medium (MRI scientific services)
• 373 g of Sucrose (Sigma-Aldrich)
• 2.560 g of KH2P04 (Sigma-Aldrich)
• 6.185 g of K2HP04 (Sigma-Aldrich)
• 3.605 g of L-glutamic acid (Sigma-Aldrich)
• Made up to 5 L in deionised water
• 20 ml 0.4% phenol red solution (Sigma-Aldrich) added
• 500 ml of FBS (GIBCO BRL) added
• 25 ml (1/4 vial) of gentacin (GIBCO BRL) added
• 0.5 g of streptomycin (GIBCO BRL) added
• Filtered and 25 ml 10 000 U/ml Nystatin suspension added
1.4 Carbonate coating buffer (pH 9.6 )
• 4.9 L of deionised water
• 10.6 g Na2C03(Sigma-Aldrich)
• 16.8 g NaHC03 (Sigma-Aldrich)
• Adjusted to 5 L in volume at (pH 9.6) aliquoted and stored at -20°C.
1.5 L-broth
• 900 ml of deionised water
• 10 g Tryptone (Difco Laboratories)
• 5 g Yeast Extract (Difco Laboratories)
• 5 g NaCI (Sigma-Aldrich)
• A /-li« H I i i-~i ir«A LJ "7 OX oi i+A^lrn/A/4 A
/-wjJUOiCu iu i i_ it i vuiuiiio cu i / auiwv^iavovj at iv-i otui cu ai ~t w.
1.6 L-agar
• 900 ml of deionised water
• 10 g Tryptone (Difco Laboratories)
• 5 g Yeast Extract (Difco Laboratories)
• 10 g NaCI (Sigma-Aldrich)
• 15 g Agar (Difco Laboratories)
• Adjusted to 1 L in volume (pH 7.2), autoclaved and cooled to 50°C before pouring under
class I flow bench. Set and stored upside down at 4°C.
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1.7 40 mM Phosphate buffer (pH 7.4)
• 162 ml of 0.2 M Na2HP04 (Sigma-Aldrich)
• 38 ml of 0.2 M NaH2P04 (Sigma-Aldrich)
• Autoclave and store at RT
• Diluted 1/5 in deionised water to yield 1 L of pH 7.4 40 mM Phosphate buffer prior to
use.
1.8 12% acrylamide resolving gel (10 ml)
• 4.0 ml acrylamide/Bis solution (30% acrylamide/0.8% N' N'-bis-methylene-acrylamide;
Severn Biotech LTD, Kidderminster, UK).
• 3.35 ml deionised water
• 2.5 ml 1.5 M (pH 8.8) Tris-HCL (Sigma-Aldrich)
• 0.1 ml 10% SDS in deionised water (Sigma-Aldrich)
• 100 /vl 10% ammonium persulfate (APS; BIO-RAD) and 10pl TEMED (BIO-RAD) were
added to catalyse polymerisation before to adding gel to the cast.
1.9 4% acrylamide stacking gel (5 ml)
• 1.15 ml acrylamide/Bis solution (30% acrylamide/0.8% N' N'-bis-methyiene-acrylamide;
Severn Biotech LTD, Kidderminster, UK).
• 3.09 ml deionised water
• 1.25 ml 0.5 M (pH 6.8) Tris-HCL (Sigma-Aldrich)
• 140 pi 10% SDS in deionised water (Sigma-Aldrich)
• 100 pi 10% ammonium persulfate (APS; BIO-RAD) and 10 pi TEMED (BIO-RAD) were
added to catalyse polymerisation before adding gel to the cast.
1.1 0 5x Electrode buffer (3 L)
• 45 g Tris base (Sigma-Aldrich)
• 216 g Glycine (Sigma-Aldrich)
• 15 g SDS (Sigma-Aldrich)
• Made up to 3 L in deionised water, diluted 1/5 in deionised water prior to use.
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1.11 Sample buffer (5 ml)
• 3.8 ml deionised water
• 1 ml 0.5 M (pH 6.8) Tris-HCL (Sigma-Aldrich)
• 0.8 ml Glycerol (Sigma-Aldrich)
• 1.6 ml 10% SDS in deionised water (Sigma-Aldrich)
• 0.4 ml 2-mercaptoethanol (ICN Biomedicals)
• 0.4 ml 0.05% bromophenol blue in deionised water (Sigma-Aldrich)
1.12 Acid-alcohol (Destain for Coomassie blue)
• 900 ml deionised water
• 500 ml absolute alcohol (Fisher Scientific)
• 200 ml acetic acid (Fisher Scientific)
1.13 Griess reagent
• Reagent A: 1% sulfanilamide (Sigma-Aldrich) in 5% phosphoric acid (Sigma-Aldrich),
stored in the dark at 4°C.
• Reagent B: 0.1% N -1-napthylethylenediamine dihydrochloride (Sigma-Aldrich) in
deionised water, stored in the dark at 4°C.
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